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Abbreviations 
 
 
ARCON: accelerated radiotherapy with carbogen and nicotinamide 
BrdUrd: bromodeoxyuridine 
CA-IX:   carbonic anhydrase IX 
CD-34: cluster of differentiation 34, endothelial marker 
EF-5:   2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide 
EGFR:  epidermal growth factor receptor 
9F1:  a rat monoclonal to mouse endothelium (CD-146) 
FITC:  fluorescein isothiocyanate 
Fldpimo:  fraction of IdUrd-labelled cells positive for pimonidazole 
Glut:  glucose transporter 
HF:   hypoxic fraction 
HIF-1:   hypoxia-inducible factor 1 
HNSCC: head and neck squamous cell carcinoma 
IdUrd:  iododeoxyuridine 
LI:  labelling index 
LIH:  labelling index in hypoxia 
MLD:  monoclonal liquid diluent 
PAL-E: pathologie anatomie Leiden-endotheel 
PBS:  phosphate buffered saline 
PCNA:  proliferating cell nuclear antigen 
PET:  positron emission tomography 
Pimonidazole: 1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride 
PLD:  polyclonal liquid diluent 
RVA:  relative vascular area 
TPZ:  tirapazamine (3-amino-1,2,4-benzotriazine 1,4-dioxide) 
VD:  vascular density 
VHL:  von Hippel Lindau 
TRITC: tetramethyl rhodamine isothiocyanate 
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Introduction 
 
Head and neck cancers are tumours originating from the lips, oral cavity, pharynx, 
nose and sinuses, larynx and the salivary glands. More than 500.000 new patients 
with head and neck squamous cell carcinomas are diagnosed each year 
worldwide.1  In the Netherlands the incidence is approximately 2300 per year and 
increasing with 3-4% per year. This is due to increasing effects of alcohol and 
nicotine abuse.2,3 Primary parotid gland malignant tumours are relatively rare and 
represent 1-3% of all head and neck malignancies.4 The treatment of head and 
neck carcinomas consists of surgical resection, radiation therapy, chemotherapy 
or a combination of these treatment modalities. During the past decade there has 
been a notable shift from surgery to organ preservation strategies. At the 
University Medical Centre St Radboud the number of patients with a T3-4 
laryngeal carcinoma treated by a surgical resection of the larynx has decreased 
from 50% (1988-1991) to less than 10% (2000-2003)3 in favour of radiotherapy. 
The consequence of laryngectomy is a permanent stoma, loss of the natural voice 
and sometimes impaired swallowing function, the latter in particular if 
laryngectomy is followed by postoperative radiotherapy. In addition, the tracheo-
stoma increases the risk of upper airway infections. The most important 
advantage of radiotherapy is that the larynx, and therefore also the natural 
speech, can be preserved. Good tumour control rates are obtained with primary 
radiotherapy, especially in early stage disease. For advanced tumours there is still 
a need to improve the effectiveness of radiotherapy. 
There has been much work attempting to understand the causes of radiotherapy 
failure. Important factors determining the treatment outcome of radiotherapy are 
hypoxia and proliferation. Many efforts have been made to overcome these 
problems in order to enhance the cure rate after radiotherapy for head and neck 
carcinomas. 
 
Hypoxia 
The relevance of blood flow for the outcome of radiation treatments was already 
described by Schwartz in 1909.5 He noticed that skin reactions were less severe 
when the radium applicator was firmly pressed to the skin. It was Cramer in 19356 
who gave the first suggestion of an “oxygen effect”. He suggested that the 
radiosensitive tumours had a better blood supply and, consequently, were better 
oxygenated. Later, Gray et al. established the importance of tumour oxygenation 
for radiotherapy.7 Clinically relevant hypoxia is detected in approximately 50% of 
all solid tumours irrespective of their size and histological features.8 Two types of 
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tumour hypoxia can be distinguished: perfusion-limited and diffusion-limited 
hypoxia. Perfusion-limited or acute hypoxia is often transient and may be due to 
severe structural and functional abnormalities of the tumour microvessels.9 These 
abnormalities cause disturbances in the blood supply leading to temporal 
shutdown of vessels, gradients of oxygen and nutrients and even reversal of blood 
flow.9-11 Hypoxia can also be caused by an increase in diffusion distances, 
resulting in diffusion-limited hypoxia, leaving cells chronically deprived of oxygen 
and other nutrients.9,12 In most tumours, both types co-exist and contribute to 
greater or lesser extent.  
Several methods have been developed over the years in an attempt to visualize 
and quantify hypoxia within a tumour. Initial evidence for hypoxia in human 
tumours came from work measuring oxygen status using polarographic 
electrodes.13 Unfortunately, the use of this invasive technique is limited to 
accessible tumours and careful needle positioning.  
Exogenous and endogenous hypoxia markers detectable by immunohisto-
chemistry require no additional intervention beyond the initial pre-treatment biopsy 
and may be suitable for widespread clinical use. Clinically relevant exogenous 
markers are the 2-nitroimidazoles pimonidazole and EF5 which require intra-
venous administration before tissue sampling.14,15 In viable cells with oxygen 
partial pressures ≤ 10 mm Hg the 2-nitroimidazoles are reductively activated and 
form protein adducts which can then be visualized by immunohistochemistry. 
Clinical experience with these compounds exists in head and neck carcinomas16, 
cervical cancer14, bladder cancer17, prostate cancer18 and soft tissue sarcoma.19  
Endogenous hypoxia-related markers include Hypoxia Inducible Factor-1α (HIF-
1α), Carbonic Anhydrase IX (CA-IX) and the glucose transporters (gluts).  
The transcription factor Hypoxia Inducible Factor consists of several subunits that 
include HIF-1α, HIF-2α and HIF-3α. Of the three HIF-α subunits HIF-1α functions 
as master regulator of oxygen homeostasis, HIF-2α is predominantly expressed in 
endothelial cells and iPAS, a variant of HIF-3 α, is expressed in the cornea, 
cerebellum and cerebrum.20 
Hypoxia leads to inactivation of the von Hippel-Lindau (VHL) gene which 
subsequently leads to stabilisation of the HIF-1α subunits and activation.21 Once 
activated, HIF-1α plays an important role in tumour growth, angiogenesis, pH 
regulation, cell proliferation and glucose metabolism.20,22-24  
CA-IX is up-regulated by HIF-1α in order to control acid-base homeostasis. 
Hypoxia increases glycolysis and lactate production, resulting in acidosis. CA-IX 
catalyzes the hydration of extracellular carbon dioxide to carbonic acid thereby 
maintaining a stable intracellular pH. Most studies, except in renal cancer show 
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that CA-IX upregulation is associated with tumour aggressiveness.25 In vitro 
studies indicate that CA-IX is upregulated from oxygen partial pressures of ≤20 
mm Hg and lower.26 
The glucose transporters are also controlled via de HIF-1 pathway. They mediate 
glucose uptake and facilitate anaerobic glycolysis. Glut-1 and Glut-3 have been 
examined in many tumour types including head and neck carcinomas. Glut-1 
expression is mainly found at a distance from perfused vessels, corresponding 
with areas of diffusion- limited hypoxia.22 
 
Non-invasive methods for detecting hypoxia include positron emission 
tomography (PET) and dynamic contrast-enhanced magnetic resonance imaging 
(DCE-MRI). Important advantages of these methods are that they visualize the 
whole tumour and because of their repetitive capacity they are ideally suited for 
treatment monitoring and early response assessment. PET tracers for hypoxia 
include [18F]-misonidazole (18F-MISO), [18F]-azomycin arabinoside (18F-AZA), 
60Cu (II)-diacetyl-bis(N4-methylthiosemicarbazone) (60Cu-ATSM), [18F]-fluoro-
erythronitroimidazole (18FETNIM), and [18F]-2-(2-nitroimidazol-1-yl)-N-(3,3,3-
trifluoropropyl)- acetamide (18F-EF3)   These radiopharmaceuticals differ in their 
kinetics and binding characteristics and it is not yet clear which is to be preferred 
for clinical use. Rischin et al. compared 18F-MISO-PET and 18F-AZA-PET in 
patients with head and neck squamous cell carcinomas and found a similar 
distribution of tumour hypoxia for both tracers. However, less background tracer 
accumulation occurred with 18F-AZA-PET.27 
DCE-MRI is used both experimentally and clinically to monitor the functionality of 
the tumour vasculature after administration of the contrast agent Gadolinium-
DTPA. Due to the high spatial resolution of MRI heterogeneities in blood flow, 
vascular volume and permeability of blood vessels within a tumour can be 
detected. Other magnetic resonance based methods include: blood oxygen level-
dependent magnetic resonance imaging (BOLD MRI); 19F MRI using 
perfluorocarbon probes; electron paramagnetic resonance imaging (EPRI) and 
proton-electron double resonance imaging (PEDRI). Finally, optical methods as 
near-infrared spectroscopy (NIRS) and phosphorescence imaging are used. The 
latter were reviewed with all their advantages and disadvantages by Vikram et 
al.28 
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Proliferation 
A second important cause for radiation treatment failure is cellular repopulation. 
Shortening the overall radiotherapy treatment time (accelerated fractionation) can 
counteract this phenomenon and improve outcome.29 
Different markers have been used for assessment of proliferation. These include 
the endogenous markers Ki-67, proliferating nuclear antigen (PCNA) and 
members of the cyclin group. Clinically available exogenous markers are the 
thymidine analogues bromodeoxyuridine (BrdUrd) and iododeoxyuridine (IdUrd) 
which need to be administered intravenously. The latter have a short half-life and 
are rapidly incorporated in the DNA, thus being specific S-phase markers.30 
Although not proliferation specific, EGFR signalling is an important stimulator of 
cell growth as well as other biological processes. EGFR overexpression is 
common in head and neck squamous cell carcinomas and is associated with poor 
locoregional control.31 Two clinical studies in head and neck cancer demonstrated 
improved locoregional control rates with a schedule of accelerated radiotherapy in 
tumours with high EGFR-expression levels but not in tumours with low EGFR-
expression.32,33 This strongly suggests that the EGFR-signalling pathway controls 
the proliferative response of tumours to fractionated radiotherapy.32 Additionally, 
the use of the anti-EGFR monoclonal antibody cetuximab in combination with 
radiotherapy has been shown to be superior to radiation alone.34 
 
Outline of the thesis 
The purpose of this investigation was to characterize human head and neck 
cancers in terms of their proliferative activity and oxygenation status using 
endogenous and exogenous immunohistochemical markers. A second aim was to 
analyze microenvironmental patterns of proliferation and hypoxia in relation to 
each other and to the tumour vasculature. The ultimate aim was to explore the 
potential of this immunohistochemistry-based characterization as a predictive tool 
that allows selection of patients for treatment strategies that counteract 
proliferation and hypoxic radioresistance. 
The biopsy material used for this investigation was obtained from patients with 
stage II-IV squamous cell carcinomas of the head and neck that were treated with 
primary radiotherapy. Part of these patients were treated by a new strategy that 
combines Accelerated fractionated Radiotherapy with administration of CarbOgen 
and Nicotinamide (ARCON). Accelerated radiotherapy counteracts radio-
resistance by tumour cell repopulation. Carbogen is a gas mixture composed of 
oxygen 95-98% and carbon dioxide 5-2% and reduces diffusion limited hypoxia 
whereas nicotinamide, a derivative of vitamin B3, reduces the intermittent closure 
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of blood vessels and thus acute hypoxia. We aimed to deliver proof of principle 
that microenvironmental profiling based on immunohistochemical markers can 
predict responsiveness to ARCON. In addition, a small cohort of patients who 
underwent surgery for a salivary gland tumour was studied as there was no 
previous knowledge on the clinical relevance of hypoxia in this tumour type. 
Chapter 2 describes the result of hypoxia and vasculature staining in 21 head and 
neck squamous cell carcinomas. We use the exogenous bioreductive marker 
pimonidazole which has been shown to be a robust marker of hypoxia. We 
demonstrate that we are able to visualize and quantify this marker noticing large 
intra- and intertumour variations. Also, we demonstrate that different architectural 
patterns of hypoxia exist with different spatial relationships with tumour 
vasculature. We make a first attempt to categorize tumours based on their hypoxic 
profile. 
In chapter 3 we compare outcome in patients treated with radiotherapy alone 
against patients treated with ARCON and associate this with measurements of 
hypoxic fraction and vascular density in the respective biopsies. Forty-three 
biopsies of head and neck carcinomas are stained for hypoxia by pimonidazole 
and CA-IX and for blood vessels. Staining patterns of pimonidazole and CA-IX are 
compared and co-localization is quantified. Hypoxic fraction, vascular density and 
relative vascular area are calculated and related to locoregional control and 
disease free survival.  
In chapter 4, we investigate the prognostic value of the endogenous hypoxia-
related markers CA-IX, Glut-1 and Glut-3 in biopsy material of 58 patients with 
head and neck carcinomas treated with ARCON. We study the expression 
patterns of these proteins using semi-quantitative scoring and relate this with 
clinical characteristics and outcome parameters such as locoregional control, 
freedom of distant metastasis and overall survival.  
Proliferation is another important biologic determinant for radiation outcome and 
may be of special interest if examined in conjunction with tumour hypoxia. In 
chapter 5 we study proliferation patterns in 50 head and neck tumours before and 
after transplantation in nude mice. The purpose is to quantitatively categorize 
human tumours according to proliferation patterns. A second aim is to examine 
whether these characteristics are retained after xeno-transplantation, an issue that 
is relevant when these tumour lines are used for preclinical studies. We stain both 
human tumour samples and xeno-transplanted tumours for the endogenous 
proliferation marker Ki-67 and for vasculature. We categorize the tumours 
according to distinct patterns of proliferation and quantify the number of vascular 
structures and proliferation and compare results of pre- and post-transplantation 
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samples. We also investigate if these parameters are predictive for the probability 
of growth after xeno-transplantation. 
As both hypoxia and proliferation are relevant for outcome after radiotherapy, 
there might be a subpopulation of tumour cells with particular relevance for 
radiotherapy responsiveness, i.e. cells that retain proliferative capacity under 
hypoxic conditions. In chapter 6 we investigate the magnitude of that cell 
population by dual staining for pimonidazole and the exogenous proliferation 
marker IdUrd. Thirty-nine biopsies of head and neck cancer patients are examined 
for co-localisation of these markers and associations with outcome parameters 
are sought.  
Finally, chapter 7 describes the results of multiple immunohistochemical analysis 
for hypoxia, proliferation and vasculature in salivary gland carcinomas. To 
investigate the potential relevance of hypoxia in this tumour type we perform 
immunohistochemistry for a panel of hypoxia-related markers including 
pimonidazole, CA-IX, Glut-1, Glut-3 and HIF1-α in 8 salivary gland carcinomas. In 
addition, staining is done for IdUrd and the epidermal growth factor receptor 
(EGFR). 
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Abstract 
 
Tumour oxygenation and vasculature are determinants for radiation treatment 
outcome and prognosis in patients with squamous cell carcinomas of the head 
and neck. In this study we visualized and quantified these factors which may 
provide a predictive tool for new treatments.  
 
Twenty-one patients with stage III-IV squamous cell carcinomas of the head and 
neck were intravenously injected with pimonidazole, a bioreductive hypoxic 
marker. Tumour biopsies were taken 2 h later. Frozen tissue sections were 
stained for vessels and hypoxia by fluorescent immunohistochemistry. Twenty-two 
sections of biopsies of different head and neck sites were scanned and analyzed 
with a computerized image analysis system.  
 
The hypoxic fractions varied from 0.02 to 0.29 and were independent from T- and 
N-classification, localization and differentiation grade. No significant correlation 
between hypoxic fraction and vascular density was observed. As a first attempt to 
categorize tumours based on their hypoxic profile, three different hypoxia patterns 
are described. The first category comprised tumours with large hypoxic, but 
viable, areas at distances even greater than 200 µm from the vessels. The second 
category showed a typical band-like distribution of hypoxia at an intermediate 
distance (50-200 µm) from the vessels with necrosis at greater distances. The 
third category demonstrated hypoxia already within 50 µm from the vessels, 
suggestive for acute hypoxia.  
 
This method of multiparameter analysis proved to be clinically feasible. The 
information on architectural patterns and the differences that exist between 
tumours can improve our understanding of the tumour micro-environment and 
may in the future be of assistance with the selection of (oxygenation modifying) 
treatment strategies. 
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Introduction  
 
The relevance of blood flow for the outcome of radiation treatments was already 
described by Schwartz in 1909.1 He noticed that skin reactions were less severe 
when the radium applicator was firmly pressed to the skin. It was Cramer in 19352 
who gave the first suggestion of an “oxygen effect”. He found that mouse 
mammary tumours with a well developed stroma and vascular network were more 
radiosensitive than tumours with a more delicate stromal component. He 
suggested that the radiosensitive tumours had a better blood supply and, 
consequently, were better oxygenated. Later, Gray et al.3 established the 
importance of tumour oxygenation for radiotherapy.  
 
The tumour micro-environment is a key factor in tumour biology and has great 
impact on clinical radiotherapy as well as other cancer treatments. Single 
parameters such as polarographic pO2 measurements and microvascular density 
have been demonstrated to be prognostic indicators in a variety of tumour types, 
including carcinomas of the head and neck.4-9 However, considering the 
complexity of the micro-environmental system, it is unlikely that a single 
parameter can reliably predict treatment outcome on an individual basis. Multiple 
parameter analysis will be necessary to acquire a better understanding of the 
tumour micro-environment and to obtain a “predictive profile” which can guide the 
clinician in the selection of patients for new treatment strategies. 
A computerized image analysis system for multi-parameter analysis has been 
developed in our institute.10 The method involves computer controlled microscopic 
scanning of immunohistochemically stained tissue sections. It allows quantitative 
and simultaneous analysis of vascular parameters, oxygenation status and 
proliferation parameters. We have recently published our experience with this 
method in xenografted human tumours.11,12  
We now apply this method also to tumour biopsies from patients with squamous 
cell carcinomas of the head and neck. Before a biopsy was taken, the patients 
were injected with Hypoxyprobe-1 (pimonidazole hydrochloride) as a hypoxia 
marker. Pimonidazole can easily be dissolved in saline, has a low toxicity, and an 
efficient tumour uptake. So far pimonidazole has proven to be an effective hypoxia 
marker for human tumours of the cervix and head and neck.13-15 
In the present study we report the results of the analysis of biopsy material from 
21 patients with squamous cell carcinoma of the head and neck. 
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Materials and Methods 
 
Patients 
Patients with primary laryngeal, oropharyngeal (stage III-IV) or hypopharyngeal 
(stage II-IV) squamous cell carcinomas were entered. Accrual was restricted to 
patients who were also eligible for our ongoing phase II ARCON-study 
(Accelerated Radiotherapy with Carbogen and Nicotinamide).16 Inclusion criteria 
were: age over 18 years, WHO performance status of 0-2, no severe heart or lung 
disease, no severe liver or kidney dysfunction, no severe stridor, no distant 
metastases, and written informed consent. In the period from May 1998 to 
December 1998, 21 patients were included. Approval from the local ethics 
committee was obtained. 
 
Markers of hypoxia and proliferation 
As hypoxia marker we used pimonidazole hydrochloride (Hypoxyprobe-1, Natural 
Pharmacia International Inc.). Pimonidazole is a bioreductive chemical probe with an 
immuno-recognizable side chain. The addition of the first electron in bio- reductive 
activation is reversibly inhibited by oxygen with a half maximal pO2 of inhibition of 3 
mm Hg and almost complete inhibition at about 10 mm Hg.17 Pimonidazole (0.5g/m2) 
was dissolved in 100cc NaCl 0.9% and was administered intravenously over 20 
minutes, two hours before biopsy (range 1h35 min - 4h05 min, median 1h59 min). A 
maximum dose of one gram was given to patients with a body surface > 2 m2. After 
biopsy the tissue was directly frozen in liquid nitrogen. Sections of 5 µm were cut and 
mounted on poly-L-lysine coated slides and stored at -80o C until staining. 
 
Immunohistochemical staining 
Prior to the staining procedure, sections were fixed in acetone of 4o C for 10 min. 
Then the sections were rehydrated in phosphate buffered saline (PBS). Next, 
sections were incubated overnight at 4o C with both anti-pimonidazole (rabbit 
polyclonal)18 diluted 1:200 in PBS and PAL-E diluted 1:5 in PBS (Department of 
Pathology, University Hospital Nijmegen, The Netherlands). The monoclonal 
antibody PAL-E is a marker for human endothelium, especially useful in frozen 
tissue sections.19 After rinsing three times in PBS the staining procedure was 
followed by a pooled incubation for 1 h at room temperature with fluorescein 
isothiocyanate (FITC)-conjugated donkey anti-rabbit antibody (Jackson Immuno 
Research Laboratories, West Grove, PA, USA) 1:100 in PBS for the hypoxia 
signal, combined with tetramethyl rhodamine isothiocyanate (TRITC)-conjugated 
goat anti-mouse antibody (Jackson Immuno Research Laboratories, West Grove, 
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PA, USA) diluted 1:100 in PBS to visualize the vessels. After rinsing in PBS for 
three times the sections had another pooled incubation for 1 h with the same 
FITC-conjugated antibody, but now combined with TRITC-conjugated donkey anti-
goat antibody (Jackson Immuno Research Laboratories) diluted 1:100 in PBS to 
amplify the blood vessel signal. Slides were then rinsed and mounted in PBS for 
scanning of the hypoxia and vessel signals. 
 
Scanning of tumour sections and image processing 
For quantitative analysis, the slides were scanned by a computerized image 
processing system using a high-resolution intensified solid-state video camera on 
a fluorescence microscope (Zeiss Axioskop). The fluorescence signals were 
recorded by the camera and subsequently digitized to a binary image on a 
Macintosh computer. For the vessels (TRITC-signal, 510-560 nm excitation) a 590 
nm emission filter was used and for hypoxia (FITC-signal, 450-490 nm excitation) 
a 520 nm emission filter was used. In order to move a tissue section automatically 
a motorized scanning stage, coupled to a stage controller, was interfaced with the 
computer. Each tumour section was scanned two times at 100x magnification. In 
the first scan only the vascular structures were detected, in the second scan the 
hypoxic marker was detected. Each scan consisted of 16, 25 or 36 fields (4x4, 5x5 
or 6x6, field size 1.22 mm2) depending on the size of the biopsy. Processing all 
fields of one scanning procedure resulted in a composite binary image. After the 
scanning procedure the two composite binary images, one showing vascular 
structures and the other showing hypoxic areas, were superimposed. A detailed 
description of the scanning method has been given by Rijken et al.10 With the use 
of a haematoxylin-eosin staining of a consecutive section the tumour area was 
delineated. This area was used as a mask in further image analysis excluding 
non-tumour tissue and large necrotic areas from the analysis. Necrosis can 
produce an aspecific red stain in the fluorescent images. It is therefore important 
that these areas be excluded such that they do not disturb the analysis of vascular 
parameters. Small necrotic areas were not excluded because this could cause 
loss of information of the directly surrounding viable tissue. The delineation of the 
tumour area was supervised by a pathologist (P.C.M. de Wilde). 
 
Analysis of hypoxic and vascular parameters 
The vascular density was calculated as the number of vascular structures per 
mm2. The relative vascular volume was defined as the PAL-E positive surface 
divided by the total tumour surface. The hypoxic fraction was defined as the 
pimonidazole positive surface divided by the total tumour surface. These 
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parameters were calculated for the complete tumour surface, but also in arbitrary 
subareas of 0.3 mm2 for analysis of the intra-tumour variability.  
In order to quantitate the distribution of hypoxia in relation to the vasculature, 
zones were chosen arbitrarily at increasing distance from the surface of the 
nearest vessel (0-50 µm, 50-100 µm, 100-150 µm, 150-200 µm, 200-250 µm, and 
>250 µm). The hypoxic fraction in a zone was calculated as the pimonidazole-
stained surface in a zone divided by the tumour surface in that zone.  
 
Statistics 
Mean values were compared by the student-t-test. Correlations between various 
parameters were tested by linear least-squares regression analysis. The statistical 
analyses were done on a Macintosh computer using Statistica 4.0 software. 
 
 
Results 
 
Patients  
Twenty-three patients entered the study. Two biopsies were not included in the 
analysis, one biopsy contained no tumour tissue and one patient had a 
mucoepidermoid carcinoma. Thus biopsies from 21 patients with confirmed 
squamous cell carcinoma were the subject of this study. The median age of the 
patients was 58 years (range 47-75). There were 17 men and 4 women. Tumours 
were localized in the oropharynx (2), in the larynx (9) and in the hypopharynx (9). 
One patient suffered from two primary tumours, an oropharyngeal and a 
hypopharyngeal tumour which were both biopsied. Thirteen tumours were 
moderately differentiated and nine were poorly differentiated. Classification of the 
tumours according to the TNM staging system (as defined by the UICC, 1997) is 
shown in Table 1.  
None of the patients had any adverse reaction to the pimonidazole administration.  
 
Table 1. TNM-classification of the 22 biopsied tumours 
 
 N0 N1 N2 N3 Total 
T1 - 1 1 - 2 
T2 1 1 3 * 2 7 
T3 2 1 5 * - 8 
T4 - 2 3 - 5 
Total 3 5 12 2 22 
 * Biopsies from one patient with two primary tumours. 
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Hypoxia and vessel staining 
The hypoxic staining gave a reproducible and bright green fluorescent signal in all 
tissue sections. At increasing distance from the vessels an increasing intensity of 
the hypoxic staining was found. There was no or very little background staining 
(Figure 1). At the edges of some tumour sections we observed a strong staining. 
This so called “edge-effect” was sometimes substantial and, if included in the 
analysis, could influence the outcome significantly. Three different causative 
phenomena were identified. First, freezing artefacts occur sometimes at the tissue 
edges which are caused by the formation of ice crystals with subsequent tissue 
damage. These freezing artefacts are known to give non-specific staining with 
immunohistochemical techniques. Secondly, the edges of tissue sections can 
become pleated while being cut, which enhances the background staining. The 
third reason is the presence of normal epithelium covering the surface of a biopsy. 
The differentiated squamous layers can demonstrate considerable hypoxia. The 
latter is obviously not an artefact but was excluded from the analysis as non-
tumour tissue. In the majority of the biopsies no or very little normal epithelium 
was identified. 
 
 
 
Figure 1. Fluorescence microscopic image of a tumour section (200x magnification) after 
staining for hypoxia with pimonidazole (green) and vessels with PAL-E (red). Typical 
tumour cords can be recognized with well oxygenated areas directly adjacent to vessels 
and hypoxia at greater distance. At even greater distances there is necrosis (white arrow, 
confirmed in H&E stain). 
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The red fluorescent vessel staining gave a strong signal in all tumours with hardly 
any background staining. Some aspecific staining was observed in areas of 
necrosis, which also can contain remnants of bloodvessels (Figure 1). 
 
Staining patterns 
Based on the vascular architecture and the pattern of hypoxic staining we have 
tried to categorize the tumours into three groups. Category A (N=8) showed 
increasing amounts of hypoxia with increasing distance from the vessels and large 
areas of hypoxia at distances greater than 200 µm. They had almost no hypoxia 
close to the vessels (Figure 2a). Category B (N=4) tumours had a typical band-like 
pattern of hypoxia at shorter distances from the vessels (between 50 and 200 µm) 
(Figure 2b). In this category of tumours we found small areas of necrosis at 
distances > 150-200 µm. This was confirmed in the haematoxylin-eosin staining 
but these areas were too small to be excluded from the analysis. Category C 
demonstrated a more diffuse hypoxic pattern with significant amounts of hypoxia 
in the zones closest to the vessels. The relation to the vasculature was less 
obvious in this category (N=4) (Figure 2c). Even tumours with similar hypoxic 
fractions could vary in their hypoxic patterns. Six tumours had small hypoxic 
fractions of less than 5% and, therefore, could not be properly classified (Figure 
2d). 
 
Quantitative analysis  
Vascular parameters 
The vascular density (VD) of the 22 tumours ranged from 11 mm-2 to 67 mm-2 with 
a median value of 42 mm-2. The vascular density was also calculated in arbitrary 
subareas of 0.3 mm-2. The highest values of these subareas were a factor of 1.5 
to 6 higher than the overall values of the various tumours.  
The relative vascular volume varied from 1.9 % to 9.0 %, with a median of 3.8 %. 
There was no correlation between the vascular parameters and tumour site, T- 
and N-stage or histological grade. 
 
Hypoxia 
Figure 3 presents the hypoxic fractions of the tumours as a cumulative plot. The 
lowest and highest values were 0.02 and 0.29, respectively, with a median of 
0.09. There was an indication that pharyngeal tumours had a higher hypoxic 
fraction (median 0.10) as compared to the larynx tumours (median 0.05). 
However, these differences were not statistically significant (p=0.21, t-test). There 
was also no correlation between T- and N-stage or histological grade and the 
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hypoxic fraction. Hypoxic fractions were also calculated for the subareas in each 
tumour and cumulative plots were constructed. Figure 4 shows these plots for the 
three tumours of which the corresponding images are shown in figure 2. The 
steepest curve with the lowest median value (=0.03) corresponds with the tumour 
that demonstrates hypoxia mainly at large distances from vessels (category A). 
The plot for the tumour with the more diffuse hypoxic pattern (category C) is less 
steep with a much higher median value (=0.26). 
 
 
 
Figure 2. Composite binary images of four different tumours; sccNij50 (A), sccNij70 (B), 
sccNij49 (C) and sccNij69 (D) showing hypoxia (green) and vessels (red). The tumours 
represent examples of different hypoxic patterns. Large necrotic areas have been 
excluded from these binary images. Only in tumour sccNij70 there were areas of necrosis 
that were too small to be excluded (arrows). 
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Figure 3. Cumulative plot of hypoxic fractions of 22 tumours originating in three head and 
neck sites. 
 
 
 
Figure 4. Cumulative plot of the hypoxic fractions of arbitrary subareas in three tumours 
(sccNij50, sccNij70, sccNij49). 
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Relation between vasculature and hypoxia 
We sought for further correlations between vascular density, relative vascular 
volume, and hypoxic fraction. There was a significant correlation between relative 
vascular volume and vascular density (r=0.56, p<0.01).  There was only a weak 
and non-significant inverse correlation between vascular density and hypoxic 
fraction (r=-0.34, p=0.13) (Figure 5).  
In all tumours there was an increase of hypoxia with increasing distance from the 
vessels. As an example, figure 6 shows how the arbitrary zones chosen at 
increasing distances from the vessels are projected over the binary image of 
vessels and hypoxia in tumour sccNij50. Figure 7 shows the relative distribution of 
hypoxia over these zones for the tumours of figure 2A-C. 
 
 
Discussion 
 
Methods 
With the quantitative analysis method used here we successfully visualized and 
quantitated multiple parameters while maintaining the tissue architecture.10-12 To 
obtain a strong signal with lower background staining we used fluorescent labelled 
antibodies on frozen sections. A disadvantage of the immunohistochemical 
staining is that only specific structures are stained, i.e. the complete tissue 
architecture is not visualized. Therefore we used haematoxylin-eosin staining of 
consecutive sections to contour the tumour area, excluding non-tumour tissue and 
areas of necrosis. Both the hypoxia and the vessel stainings gave strong signals 
with very low background staining in all slides. Edge artefacts were easily 
recognized with the aid of the haematoxylin-eosin stained sections and were 
excluded from the analysis. 
 
Vascular parameters 
There is an abundance of literature on morphometric vascular tumour parameters, 
in particular microvascular density, and their prognostic value. For squamous cell 
carcinomas of the head and neck, as for other tumour types such as carcinoma of 
the breast, conflicting results have been reported. Some investigators found a 
correlation between vascular density and metastatic potential20-23, whereas others 
did not.5,6,24-28 In this study no correlation was found between vascular density and 
N-stage, even when the 75th percentile value or the highest value of the subareas 
was used. The latter analysis was done to approximate the so called “hot spot 
counting” method which is often used by others.20,22-24,27  
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Figure 5. Vascular density (mm-2) versus hypoxic fraction in 22 tumours of three head and 
neck sites. 
 
 
 
 
 
Figure 6. Binary image of vessels (red) and hypoxia (green) in tumour sccNij50 with the 
zones at increasing distances from the vessels superimposed. 
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Figure 7. Relative hypoxic fractions in 50 µm zones at increasing distance from vessels. 
Example of three tumours (sccNij50, sccNij70, sccNij49). 
 
 
Two investigators found an association between vascular density and local tumour 
control after radiation treatment.7,29 Unfortunately, the relationship was opposite in 
the two studies, one study7 demonstrating increased risk of local recurrence with 
low vascular density but the other29 with high vascular density. The current study 
is being continued and patient numbers and follow-up will be increased to allow 
meaningful correlations between the micro-environmental parameters and 
treatment outcome. 
Absolute values of vascular density are difficult to compare between studies, 
mainly because of methodological differences, in particular the type of endothelial 
marker used and the counting technique. Our values are in the lower range 
compared with other studies. This can be explained by the fact that in most 
studies vessels were counted in selected, highly vascularized areas (“hotspots”), 
whereas in the present analysis figures are based on the counting of an entire 
biopsy section. Indeed, the highest values obtained from the arbitrary subareas 
correspond better with values reported in literature. We found only a weak and 
non-significant correlation between the overall vascular density and hypoxic 
fraction. This indicates that a global assessment of vascularity is probably not a 
good parameter for tumour oxygenation, due to the heterogeneity in vasculature 
and oxygenation in tumours. Lyng et al.30 also demonstrated that there are large 
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regional differences in vascularity and oxygenation in carcinomas of the uterine 
cervix. At the microregional level they did however observe a correlation between 
low pO2 readings by the polarographic method (Eppendorf Histograph) and 
vascularity. 
 
Hypoxia 
Various methods have been described to measure tumour tissue oxygenation 
including polarographic oxygen electrodes, magnetic resonance spectroscopy, 
haemoglobin saturation assays, radionuclide assays, and, as used in the present 
study, by immunohistochemical markers. Methods for assessing the radio-
biological hypoxic fraction include the classical paired survival curve assay and, 
more recently, the comet assay.31 Most clinical data have been obtained with the 
oxygen micro-electrodes. The low water solubility of the earlier immunohisto-
chemical hypoxia markers prohibited their introduction in the clinic. Pimonidazole 
hydrochloride however has a high water solubility and can be easily administered 
intravenously in a small volume of aqueous solution. It distributes rapidly into the 
tissues where concentrations threefold of that in plasma are reached. These 
properties and the absence of any significant adverse effects with the amount 
required make this agent attractive for clinical use.  
Raleigh et al.17 compared pimonidazole binding with micro-electrode 
measurements and with measurements of the radiobiologically hypoxic fraction in 
the C3H mouse mammary carcinoma. The oxygenation of these tumours was 
manipulated by the breathing of air, hyperoxic gases, injection of hydralazine and 
tumour clamping. They showed that pimonidazole binding was well correlated with 
both micro-electrode measurements and the radiobiological hypoxic fraction. A 
good correlation was found between pimonidazole binding and percentage of 
micro-electrode measurements ≤ 10 mm Hg. This is consistent with the 
intracellular binding properties of pimonidazole, rising steeply at pO2 < 10 mm Hg. 
However, it was also clear from their data that the micro-electrodes systematically 
overestimate the extent of hypoxia at the cellular level. Under well-oxygenated 
circumstances where pimonidazole binding was almost negligible, the micro-
electrodes still recorded a significant number of readings ≤ 10 mm Hg (36%). One 
of the explanations given was the presence of necrosis which produces low 
readings with the micro-electrodes while there is no pimonidazole binding in these 
areas.  
Also when our results of hypoxic fraction assessed by pimonidazole binding 
(median 0.09) are compared with studies of micro-electrode measurements in 
head and neck cancer patients, the latter report substantially higher values.4,8,9 In 
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these studies the median of the fraction of pO2 readings < 5 mm Hg varied from 
0.29 to 0.41. The fraction of pO2 values < 10 mm Hg was generally not reported. 
These measurements were mostly taken from metastatic neck nodes in contrast 
to our biopsy material which originated from the primary tumours in all cases. 
Central necrosis is often observed in cross-sectional CT-imaging of nodal 
metastasis, and this may be one explanation for the discrepancy between our 
results and those of the polarographic studies.  
Initial studies on the clinical use of pimonidazole as a hypoxia marker came from 
the group from the University of North Carolina.13-15 Raleigh et al.14 reported on 18 
patients with carcinomas of the uterine cervix and head and neck. The area 
fraction labelled with pimonidazole varied from almost zero to approximately 0.25 
with a median of 0.02. Varia et al.15 reported on 10 patients with carcinoma of the 
uterine cervix. Values for pimonidazole binding were below 0.1 in 9 of the 10 
patients. It is difficult to compare the results from these two studies with the 
current study because of the differences in tumour sites and the relatively small 
sample sizes. Also, different methodologies were used for assessment of the 
hypoxic fraction.  
Another bioreductive compound of the nitroimidazole group is “EF5”, a 
pentafluorinated derivate of etanidazole. This recently developed immuno-
histochemically detectable hypoxic marker has been tested in animal tumours and 
xenografted human tumours.32 Very recently, Evans et al.33 reported the first 
clinical application of this marker. 
 
Patterns of hypoxia 
As demonstrated various patterns of hypoxia can be recognized (Figure 2). 
Differences between these patterns can be quantified by calculating the hypoxic 
fractions of arbitrary subareas (Figure 4) and, maybe more interesting, by 
quantifying hypoxia as a function of distance from the vessels (Figures 6 and 7). 
The categorization of the tumours was based on the visual aspect of the hypoxia 
staining combined with the quantitative analysis of the hypoxia distribution over 
the vascular zones. The tumours shown in figures 1 and 2b are typical examples 
of the classical “cord-like” tumour model described by Thomlinson and Gray.34 
Diffusion limited hypoxia was the predominant feature of all the tumours we 
analysed. However, the spatial relationship to the vessels was not always the 
same.  
In the tumour of category A hypoxia was virtually absent within 100 µm of vascular 
structures. Hypoxia was predominantly present at large (150 µm to 250 µm) 
distances from the vessels. In this tumour all necrotic areas could be excluded 
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from the analysis, i.e. figures 2A and 6 depict only viable tumour tissue. Thus, 
significant amounts of viable tumour tissue, both hypoxic and non-hypoxic (e.g. six 
o’clock position in Figure 6) were observed at large (> 250 µm) distances from 
blood vessels. It can, however, not be excluded that these areas might have had 
oxygen and nutritional supply from vessels above or below the section examined. 
The analysis system used provides only a two-dimensional image of the tumour 
which obviously is a limitation. On the other hand, there is no good reason to 
assume that the vascular architecture will be any different in the third dimension. 
Since this category A tumour demonstrates large intervascular distances, it is 
most likely that vascular structures are sparse, also above and below the plane of 
the section analysed. 
The category B tumour showed already some hypoxia in the first 50 µm zone 
(hypoxic fraction 0.09) and a gradual increase of the hypoxic fraction in the 
second and the third zones. However, at distances > 150 µm hypoxia seemed to 
decrease again. The explanation for this unexpected phenomenon is a 
“contamination” by small areas of necrosis at these greater distances (see arrows 
in Figure 2B). This was confirmed in the haematoxylin-eosin staining. These 
necrotic areas were too small however to be excluded from the analysis and 
because they were not labelled by pimonidazole, in the computer calculations they 
were falsely considered as “viable non-hypoxic tumour tissue”. Thus, in this 
particular tumour, the hypoxic fractions at distances > 150 µm were 
underestimated. 
Nevertheless, it is an interesting observation that, while in one category of 
tumours (A) there are significant amounts of viable tissue at distances > 250 µm, 
in other tumours there is already necrosis at 150-200 µm (category B). These 
differences suggest that the balance between oxygen delivery and oxygen 
consumption may vary among tumours of the same histology resulting in different 
distributions of chronic hypoxia and necrosis.  
The tumour of category C demonstrated a considerable amount of hypoxia within 
100 µm from the vessels with a hypoxic fraction of 0.20 at 0-50 µm. This suggests 
impaired functioning of particular vessels, either permanently or temporarily 
(“acute hypoxia”). This may also be the case, but to a lesser extent, in the 
category B tumour. In xenografted tumours we demonstrated that after 10 min of 
exposure to pimonidazole there is a weak binding in the hypoxic cells which 
increases between 10 and 30 min of exposure (unpublished data). This indicates 
that, with this assay, acute hypoxia probably will only be recognized if cells are 
hypoxic for at least 10 min. 
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Together with single parameters such as vascular density and hypoxic fraction, 
the pattern of hypoxic staining may give additional prognostic information and may 
help to select appropriate treatment modalities. We have previously demonstrated 
that carbogen can very efficiently reduce diffusion limited hypoxia in human 
squamous cell carcinoma xenografts.12 However, preliminary data from our 
laboratory suggest that it is difficult to eradicate all the hypoxia at greater distance 
from the vessels. This may also be the case in the category A tumours. At the 
same time there seems to be limited value in adding vasoactive agents such as 
nicotinamide to the treatment of such tumours since they exhibit no or only very 
little acute hypoxia. Our clinical attempt to categorize tumours based on hypoxic 
patterns must be validated with a larger number of patients. This is the subject of 
ongoing investigations. 
 
 
Conclusion 
 
We have presented a quantitative method for multiparameter analysis of 
vascularity and hypoxia in head and neck tumours which is clinically feasible. 
These measurements can be of prognostic relevance. Moreover, this method 
yields information on architectural patterns which may improve our understanding 
of the tumour micro-environment and may in the future be of assistance with the 
selection of treatment strategies. 
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Abstract 
 
Hypoxia is associated with tumour aggressiveness and is an important cause of 
resistance to radiation treatment. Assays of tumour hypoxia could provide 
selection tools for hypoxia modifying treatments. This study correlated the 
exogenous 2-nitroimidazole hypoxia marker 1-[(2-hydroxy-3-piperidinyl)propyl]-2-
nitroimidazole hydrochloride (pimonidazole) with the endogenous hypoxia-related 
marker carbonic anhydrase IX (CA-IX) and with vascular parameters using 
immunohistochemical techniques and a computerized image analysis system. 
 
Tumour biopsies were obtained from patients with head and neck carcinomas that 
were potential candidates for a phase II trial with accelerated radiotherapy 
combined with carbogen and nicotinamide (ARCON). If, after completion of the 
diagnostic workup, the eligibility criteria were met and informed consent was 
obtained, patients were treated with ARCON. Those patients that were not eligible 
or refused ARCON were treated with radiotherapy, surgery or a combined 
modality. Forty-three biopsies were analyzed and the results were related with 
treatment outcome. The distribution patterns of pimonidazole and CA-IX were 
similar although the CA-IX signal was generally observed already at shorter 
distances from blood vessels. There was a weak but significant correlation 
between the relative tumour areas positive for pimonidazole binding and areas 
with CA-IX expression. Locoregional tumour control was significantly lower for 
patients who had hypoxic tumours or tumours with low vascular density. The 2-
year control rates were 48% versus 87% for tumours with high and low 
pimonidazole binding levels (stratified by median, p = 0.01) and 48% and 88% for 
tumours with low and high vascular density (stratified by median, p = 0.01). These 
associations disappeared in the subgroup of patients treated with ARCON. There 
was no relationship between the level of CA-IX expression and treatment 
outcome. 
 
It is concluded that pimonidazole binding and vascular density can predict 
treatment outcome in head and neck cancer and may be useful as selection tools 
for hypoxia modifying treatments. Pimonidazole and CA-IX demonstrate 
concordant staining patterns but the latter is a less specific marker for hypoxia. 
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Introduction 
 
In almost all solid tumours there is to some extent an imbalance between oxygen 
delivery and oxygen consumption resulting in hypoxia.1 Hypoxia is a powerful 
trigger for changes in gene expression and associated changes in the micromilieu. 
The altered genetic expression profile and the changed microenvironment 
stimulate clonal selection within the tumour cell population for cells with increased 
adaptation to hypoxia and drive the tumour towards a more malignant phenotype 
with increased resistance to anticancer treatments.2,3 Methods that identify 
hypoxic tumours could therefore provide a powerful selection tool for oxygenation 
modifying treatments. 
Clinical studies using oxygen microelectrodes in carcinomas of the head and neck 
and uterine cervix have demonstrated a correlation between measurements of low 
tumour pO2 and poor outcome after radiation treatment.2,4-6 In soft tissue 
sarcomas and in carcinomas of the uterine cervix, hypoxia was also related with 
outcome after surgical treatment.2,7,8 A limitation of the oxygen microelectrodes is 
the invasive nature of the procedure and their use is restricted to accessible 
tumours. 
Exogenous and endogenous hypoxia markers detectable by immunohisto-
chemistry require no additional intervention beyond the initial pretreatment biopsy 
and may be very suitable for widespread clinical use. They also provide a more 
sensitive and high resolution assay of the distribution of hypoxia at the micro-
regional level. Clinically relevant exogenous markers are the 2-nitroimidazoles, 
pimonidazole3 hydrochloride and [2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-penta-
fluoropropyl)acetamide] (EF-5).9,10 Hypoxic fraction estimated by pimonidazole 
binding agreed well with the hypoxic fraction measured using the comet assay in a 
number of animal and human tumours indicating that pimonidazole labelling can 
give a reliable estimate of radiobiologically relevant hypoxia.11 Pimonidazole has 
proven to be an effective and nontoxic hypoxia marker for human squamous cell 
carcinomas of the cervix and head and neck.9,12-14 A disadvantage of the 
nitroimidazole markers is that they require i.v. injection before biopsy taking. 
In addition to the well-known angiogenic factor, vascular endothelial growth factor, 
more recently, new and possibly more specific endogenous hypoxia-associated 
molecular markers have been described. Most promising at present is CA-IX 
which is regulated via the von Hippel-Lindau and HIF-1 pathway. Carbonic 
anhydrases are transmembranic enzymes catalyzing the reversible hydration of 
carbon dioxide to carbonic acid and are involved in respiration and acid-base 
balance.15 Immunohistochemistry revealed high-to-moderate expression of CA-IX 
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in normal adult tissues but mainly in highly specialized cells.16 High levels of 
expression were found in a large sample of cancer cell lines and fresh and 
archived tumour tissues.16 CA-IX had the greatest magnitude of induction among 
12 hypoxia-overexpressed genes including vascular endothelial growth factor and 
was induced in many tumour cell lines.17 CA-IX-positive cells from cervical 
carcinoma xenografts were found to be clonogenic, resistant to killing by ionizing 
radiation, and preferentially able to bind pimonidazole.18 Immunohistochemical 
patterns of CA-IX expression are typically described as “perinecrotic”, consistent 
with the distribution of diffusion-limited hypoxia. Retrospective clinical studies 
support the notion that CA-IX represents tumour aggressiveness. High CA-IX 
expression predicted poor survival in carcinoma of the head and neck, lung, 
uterine cervix and breast.19-22 
In this study we relate pimonidazole binding and CA-IX expression in biopsy 
material of human squamous cell carcinomas of the head and neck. We 
demonstrate that the distribution pattern of the two markers relative to the 
vasculature is similar with increasing signal at greater distance from the blood 
vessels. CA-IX expression was often observed at shorter distances from the 
vessels, suggesting that CA-IX upregulation occurs at pO2 levels higher than 
those required for pimonidazole binding. Although the patterns were concordant, 
there was only a weak correlation between the overall pimonidazole and CA-IX 
positive tumour areas. In patients with head and neck cancer, pimonidazole 
binding and vascularity were predictors of outcome but CA-IX expression was not. 
The poor outcome of hypoxic tumours could be corrected with hypoxia-modifying 
treatment with disappearance of the discriminative power of pimonidazole binding 
and vascularity. Our findings strongly support the notion that nitroimidazole 
markers together with vascular parameters can provide powerful selection tools 
for hypoxia-modifying treatment on an individual patient basis. Since CA-IX is 
upregulated at intermediate levels of oxygenation, its specificity and sensitivity as 
a hypoxia marker needs additional investigation. 
 
 
Materials and methods 
 
Patients 
At the Department of Radiation Oncology of the University Medical Center 
Nijmegen, a Phase II clinical trial of ARCON in advanced squamous cell 
carcinomas of the head and neck has recently been completed.23 ARCON 
combines accelerated radiotherapy with carbogen breathing and nicotinamide to 
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reduce diffusion-limited and perfusion-limited hypoxia. Eligibility criteria for this 
study were: (a) stage III or IV squamous cell carcinoma of the oral cavity, 
oropharynx, hypopharynx or larynx and stage II hypopharynx carcinomas with a 
greatest dimension of the primary tumour >2 cm; (b) age over 18 years; (c) WHO 
performance status of 0-2; (d) no distant metastases; (e) no severe heart or lung 
disease; (f) no severe liver or kidney function impairments; (g) no severe stridor; 
(h) no concurrent treatment for other malignant disease outside the upper aero-
digestive tract. 
Patients that were potential candidates for this trial were asked to participate in 
the current hypoxia marker study. After giving consent, the patients received a 20 
min i.v. infusion of 500 mg/m2 Hypoxyprobe-1 (pimonidazole hydrochloride, NPI, 
Inc., Belmont, MA). Approximately 2 h later tumour biopsies were taken under 
general anesthesia. Biopsies were taken for routine diagnostic purposes and 
additional biopsies were taken for hypoxia marker analysis. The latter were snap 
frozen and stored in liquid nitrogen until immunohistochemical processing. The 
diagnostic workup further included physical examination, chest X-ray, computed 
tomography scan, and/or magnetic resonance imaging scan of the head and neck 
area. If, after completion of the diagnostic workup, the eligibility criteria were met 
and informed consent was obtained, patients were treated with ARCON. Patients 
that were not eligible or refused inclusion in the trial were treated with 
radiotherapy, surgery or a combined modality. The ARCON-trial and the hypoxia 
marker study were approved by the ethics committee of the University Medical 
Center Nijmegen. 
 
Immunohistochemistry 
From the biopsy material, frozen sections of 5 µm were cut and mounted on poly-
L-lysine coated slides and stored at –80°C until staining. Before staining, sections 
were fixed for 10 min in acetone of 4°C and rehydrated in phosphate buffered 
saline. Between all consecutive steps of the staining procedure, sections were 
rinsed three times for 2 min in PBS.  
The sections were incubated for 30 min at 37°C with mouse anti-CA-IX antibody 
(Egbert Oosterwijk, Department of Urology, UMC Nijmegen, The Netherlands) 
diluted 1:100 in PLD (DPC Breda Diagnostic Products, The Netherlands) and 
pimonidazole polyclonal rabbit antibody (J.A. Raleigh24) diluted 1:200 in PLD. The 
second incubation was for 30 min at 37°C with goat-anti-mouse(Fab)Cy3 antibody 
(Jackson Immuno Research Laboratories, West Grove, PA) 1:300 in PLD and 
donkey-anti-rabbit-AlexaA488 antibody (Molecular Probes, Leiden, The 
Netherlands) 1:200 in PLD. This was then followed by 30 min incubation with 
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donkey-anti-goatF(ab’)2 tetra-methyl rhodamine isothiocyanate (Jackson Immuno 
Research Laboratories) 1:200 in PLD at 37°C to block the first mouse monoclonal. 
Next, to stain the vessels, the sections were incubated with the mouse antibody 
PAL-E (Department Pathology, University Medical Center Nijmegen) 1:6 in PLD 
for 30 min at 37°C, followed by 30 min incubation at 37°C with chicken-anti-
mouse-AlexaA647 (Molecular Probes) 1:200 in PLD. The monoclonal antibody 
PAL-E is a marker for human endothelium, especially useful in frozen tissue 
sections.25 After the staining procedure, the sections were mounted in fluorostab 
(ICN Pharmaceuticals, Zoetermeer, The Netherlands). 
 
Image acquisition and analysis 
The sections were scanned on a 8-bit digital image analysis system with a high-
resolution intensified solid-state camera on a fluorescence microscope (Axioskop, 
Zeiss, Göttingen, Germany) and a computer controlled motorized stepping stage. 
The signals captured by the camera were converted to binary images using the 
digital image application TCL-image (TNO, Delft, The Netherlands) on a 
Macintosh computer as described previously.26,27 Thresholds for the fluorescent 
signals were interactively set above the background staining for each individual 
marker. For each marker a composite binary image was obtained from the 
complete biopsy. In conference with a pathologist and guided by a haematoxylin-
eosin staining of a consecutive section, the tumour area was delineated. This area 
was used as a mask in further analysis excluding nontumour tissue, large necrotic 
areas and artefacts. One section per biopsy was analyzed. 
The VD was calculated as the number of vascular structures per mm2. The RVA 
was defined as the PAL-E positive area divided by the total tumour area. HFpimo 
and HFCA-IX were defined as the tumour area positive for pimonidazole and CA-
IX respectively, relative to the total tumour area. To quantitate the distribution 
patterns of pimonidazole and CA-IX relative to the vasculature, zones were 
chosen at increasing distance from the nearest vessel (0-25 µm, 25-50 µm, 50-
100 µm and >100 µm). The area positive for pimonidazole or CA-IX in a particular 
zone divided by the total pimonidazole or CA-IX positive tumour area gave the 
proportion of marker distributed over that particular zone, HFpimo-distribution and 
HFCA-IX-distribution, respectively. The details of this analysis were described 
previously.27 
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Statistics 
Statistical analyses were done on a Macintosh computer using the Statistica 
software package. Correlations between ordinal variables were assessed using 
linear regression analysis. For differences in ordinal variables in relation to 
categorical tumour characteristics (site, T-stage, N-stage, histopathological grade) 
the Kruskall Wallis test was used. Cumulative control and survival rates were 
calculated from the date of pathologic diagnosis using the Kaplan-Meier method 
and the log-rank test was used to test for differences. Patients who never reached 
complete remission after treatment (as assessed by clinical examination) were 
considered as having locoregional failure from time zero. Cox regression analysis 
was used to analyze the associations between patient and tumour variables and 
locoregional tumour control and disease-free survival. P < 0.05 was considered 
significant. 
 
Table 1. Clinical characteristics of 43 squamous cell carcinomas analyzed (UICC 1997). 
 
 Treatment 
 ARCON Non-ARCONa Palliative 
Site 
larynx 
hypopharynx 
oropharynx 
oral cavity 
 
8 
7 
7 
1 
 
4 
5 
6 
2 
 
2 
-- 
-- 
1 
T-stage 
T1 
T2 
T3 
T4 
 
2 
3 
13 
5 
 
1 
7 
6 
3 
 
-- 
-- 
1 
2 
N-stage 
N0 
N1 
N2 
N3 
 
4 
7 
11 
1 
 
6 
3 
7 
1 
 
-- 
-- 
3 
-- 
Total 23 tumours 
23 patients 
17 tumours 
16 patients 
3 tumours 
3 patients 
aReasons for non-ARCON: 
Oral cavity/oropharynx tumours smaller than anticipated and still resectable: surgery with 
postoperative radiotherapy (N = 5); One larynx and one hypopharynx tumour larger than 
anticipated with extensive cartilage destruction: surgery with postoperative radiotherapy (N = 2); 
Larynx carcinomas smaller than anticipated and not eligible for ARCON: radiotherapy only (N = 2); 
Included in trial with neo-adjuvant chemotherapy and radiotherapy (N = 2);and refused 
participation in ARCON trial, radiotherapy only (N = 6, includes one patient with two primary 
tumours). 
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Results 
 
Patients and treatment 
Between May 1998 and February 2001, Hypoxyprobe-1 was administered to 55 
patients before biopsy taking. Seven were women and 48 were men and age 
ranged from 37 to 85 years with a median of 59 years. Two patients had two 
synchronous primary head and neck tumours that were both biopsied. None of the 
patients had adverse reactions to Hypoxyprobe-1. Fourteen biopsies were 
excluded from additional analysis, 6 because they contained no or only very little 
invasive carcinoma, 6 because of poor quality attributable to mechanical damage 
during the biopsy procedure, and 2 because the histological diagnosis was not 
squamous cell carcinoma. Thus, 43 squamous cell carcinomas were analyzed. 
The clinical characteristics of these tumours are listed in Table 1. After completion 
of the diagnostic workup, 23 patients were eligible and gave consent for inclusion 
in the ARCON-trial. Sixteen patients were not included for various reasons and 
received other treatment as indicated in Table 1. One patient in this group had two 
primary tumours and was excluded from the analysis for locoregional control and 
disease-free survival. Also the 3 patients that were treated palliatively were 
excluded from outcome analysis. Overall, the ARCON patients had more 
advanced disease. Figure 1 summarizes the patient selection for the outcome 
analysis. 
Patients in the ARCON trial received 64-68 Gy to the primary tumour and involved 
neck nodes and 44 Gy to electively treated areas. The dose per fraction was 2 Gy 
and two fractions per day were given during the last 1.5 weeks of the treatment 
with an overall treatment time of 36-38 days. During the irradiations, patients 
breathed carbogen, and they received nicotinamide, 60 mg/kg p.o., 1 h before the 
start of irradiations. This protocol has been described previously, and we refer to 
this publication for details of the treatment and compliance.23 Patients who 
underwent surgery with postoperative radiotherapy received 50 Gy in fractions of 
2 Gy to the surgical bed and 64 Gy to areas at high risk for recurrence using a 
conventional schedule of once daily fractionation. The other patients were treated 
with primary radiotherapy, 3 with a conventional schedule (66–70 Gy) and 6 with 
an accelerated schedule to 68 Gy as described above. Of the latter, 2 patients 
received neo-adjuvant chemotherapy with 5-fluorouracil and cisplatin. The median 
duration of follow-up was 18 months. 
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Figure 1. Diagram summarizing patient selection for treatment outcome analysis. 
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Figure 2. Fluorescent microscopic images of four head and neck carcinomas stained by 
triple immunofluorescence as described in the text. Blue: vessels; green: pimonidazole; 
red: CA-IX. Overlap of pimonidazole and CA-IX signal results in bright orange. SCCNij19 
is a negative control, i.e. biopsy material from a patient that was not infused with 
pimonidazole; apart from a few very small artefacts this tumour shows no green 
fluorescence. N indicates necrosis with nonspecific staining. 
 
 
Pimonidazole binding and CA-IX expression 
The triple staining for vessels, pimonidazole and CA-IX gave bright fluorescent 
signals with very little background except in areas of necrosis and occasionally in 
the stromal components of the tumour (Figure 2). CA-IX staining was typically 
confined to the cell membrane although a weaker cytoplasmic stain was 
occasionally observed as well. Both pimonidazole and CA-IX positivity generally 
increased with distance from the vessels with considerable overlap of the two 
signals. CA-IX immunoreactivity was usually observed already at shorter 
distances from blood vessels compared to pimonidazole (Figure 3). There were 
also areas of mismatch where CA-IX was found but no pimonidazole and vice 
versa (Figure 4). All but 1 of the 43 biopsies showed good quality of the triple 
staining. One biopsy demonstrated significant artefacts in the CA-IX staining and 
was excluded from the comparison between CA-IX and pimonidazole. Mean and 
median values and range for HFpimo, HFCA-IX, VD and RVA in the biopsy 
material are given in Table 2.  
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Figure 3. Fluorescent microscopic image of an oropharynx carcinoma. Blue: vessels; 
green: pimonidazole; red: CA-IX; N indicates necrosis. 
 
 
Figure 4. Composite binary images of four head and neck carcinomas: blue: vessels; 
green: pimonidazole; red: CA-IX; yellow: areas of pimonidazole and CA-IX overlap. 
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Table 2. Values for HFpimo, HFCA-IX, VD and RVA in biopsies of 43 squamous cell 
carcinomas of the head and neck. 
  
 HFpimo (%) HFCA-IX (%) VD (mm-2) RVA (%) 
Mean 
Median 
Range 
SD 
6.0 
5.6 
0.3 – 17.2 
4.6 
6.4  
3.5 
0.6 – 29.4 
6.8 
20.9 
16.5 
6.2 – 58.2 
11.7 
1.8 
1.5 
0.5 – 4.2 
1.0 
 
 
Figure 5. Comparison between the fraction of the tumour area that binds CA-IX antibody 
(HFCA-IX) with the fraction of the tumour area that binds pimonidazole antibody (HFpimo) 
in 42 squamous cell carcinomas of the head and neck. The linear best fit is shown. 
 
HFpimo, HFCA-IX, VD and RVA were independent of site, T-stage, N-stage and 
histopathological grading. No correlations were found between HFpimo or HFCA-
IX and the vascular parameters. Linear regression analysis showed a significant 
but weak correlation between HFpimo and HFCA-IX (Figure 5). The distribution 
pattern of the two markers relative to the vasculature was similar however, with 
increasing signal intensity at greater distance from vessels (Figure 6). CA-IX 
positivity was greater in the zones 25-50 µm and 51-100 µm from vessels relative 
to pimonidazole positivity which was more pronounced at distances >100 µm. The 
first zone (0-25 µm) directly adjacent to vessels included mainly stromal cells and 
extracellular matrix in the majority of the tumour samples. Only very small tumour 
areas were generally found in this zone. This zone was therefore excluded from 
the analysis because it represents mainly nontumour tissue. 
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Figure 6. Comparison between the area that binds CA-IX antibody (HFCA-IX-distribution) 
with the area that binds pimonidazole antibody (HFpimo-distribution) in distinct zones 
divided by the total positive tumour area for the respective markers in 42 squamous cell 
carcinomas of the head and neck. The linear best fit is shown. 
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Correlations of patient and tumour characteristics with treatment outcome 
Univariate Cox regression analysis demonstrated no associations between tumour 
site, T-stage, N-stage, or histopathological grade and locoregional control or 
disease-free survival (Table 3). HFpimo, HFCA-IX, VD and RVA were tested both 
as continuous variables and as dichotomous variables (stratification by median 
values; Table 3). When entered in the model as continuous variables, only VD 
showed a significant association with locoregional control. As dichotomous 
variables both HFpimo and VD demonstrated significant associations with 
locoregional control. Patients with high HFpimo or low VD did worse. Figure 7 
shows Kaplan-Meier estimates for locoregional control and disease-free survival 
stratified by the median of HFpimo. Locoregional tumour control at 2 years was 
48% for patients with hypoxic tumours versus 87% for patients with less hypoxic 
tumours (p = 0.01). Disease-free survival was 38% and 70% respectively (p = 
0.04). When analyzed by treatment, ARCON versus non-ARCON, the difference 
in outcome between low and high HFpimo was mainly found in the non-ARCON 
group. The same phenomenon was observed for VD with 48% locoregional 
control for tumours with low vascularity and 88% for tumours with high vascularity 
(p = 0.01, Figure 8). 
 
Table 3. Correlations of tumour characteristics with treatment outcome (univariate Cox 
regression analysis). HFpimo, HFCA-IX, VD and RVA analyzed as continuous and as 
dichotomous variables (stratification by median values). 
 
 Association with outcome 
Variables Locoregional 
control 
Disease-free 
survival 
Site 
T-stage 
N-stage 
Grade 
HFpimo 
continuous 
dichotomous 
HFCA-IX 
continuous 
dichotomous 
VD 
continuous 
dichotomous 
RVA 
continuous 
dichotomous 
n.s.a 
n.s. 
n.s. 
n.s. 
 
p = 0.09 
p = 0.02 
 
n.s. 
n.s. 
 
p = 0.02 
p = 0.02 
 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
 
n.s. 
p = 0.09 
 
n.s. 
n.s. 
 
n.s. 
n.s. 
 
n.s. 
n.s. 
an.s., not significant. 
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Figure 7. Kaplan-Meier estimates of locoregional control (A, B) and disease-free survival 
(C, D). Stratification is by the median of HFpimo. Comparison by log-rank test. Panels B 
and D show results by treatment group (ARCON versus non-ARCON). 
 
 
 
Figure 8. Kaplan-Meier estimates of locoregional control (A, B) and disease-free survival 
(C, D). Stratification is by the median of VD. Comparison by log-rank test. Panels B and D 
show results by treatment group (ARCON versus non-ARCON). 
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Discussion 
 
CA-IX expression and hypoxia  
Induction of the CA-IX protein by hypoxia has been observed in a number of cell 
lines including cell lines derived from squamous cell carcinomas of the head and 
neck.16,28,29 The time course of gene expression in response to hypoxia in a panel 
of human tumour lines was measured by real-time polymerase chain reaction.17 
CA-IX had the greatest magnitude of induction among 12 hypoxia-overexpressed 
genes and was induced in the greatest number of tumour cell lines. Western blot 
analysis, using an antibody to CA-IX, showed that under hypoxia protein levels 
steeply increased from 4 to 24 h, which was similar to the transcript level time 
course. Experiments with graded hypoxia in one cell line demonstrated CA-IX 
induction from pO2 levels of approximately 20 mmHg and downward.28 In the 
present study, there was concordance between CA-IX expression and 
pimonidazole binding with increasing positivity at greater distance from the blood 
vessels. CA-IX expression was often observed at shorter distances from the 
vessels suggesting that CA-IX upregulation occurs at pO2 levels higher than 
required for pimonidazole binding. In earlier work we demonstrated that, at a 
certain distance from the blood vessels, there is a rapid increase from background 
to maximum level of the fluorescent pimonidazole signal.27 This is consistent with 
data from other studies, showing a steep rise in binding of the 2-nitroimidazole, 
misonidazole, at pO2 values below 10 mmHg in multicellular spheroids30, and 
comparable Km and binding patterns of pimonidazole.31 Olive et al.18 
demonstrated that in spheroids from human cervical cancer cells (SiHa) only 0.5% 
of the cells were sufficiently hypoxic to bind pimonidazole, yet 12% of the cells 
bound CA-IX antibodies. In tumour biopsies of patients with cervical cancer, the 
percentage of the tumour area with CA-IX immunostaining was twofold the area 
that was stained for pimonidazole.18 This indicates that CA-IX expression 
identifies low tissue oxygenation levels as well as intermediate levels. 
With double hypoxia marker experiments in xenografted head and neck tumours, 
although with higher pimonidazole doses, we demonstrated that the presence of 
pimonidazole for a period of 30 min is sufficient to stain all hypoxic areas.32 
Tumour regions that were only temporarily hypoxic may stain for pimonidazole but 
not for CA-IX because upregulation of CA-IX requires at least several hours. This 
can explain, at least partly, the pimonidazole positive but CA-IX negative areas. 
Other reasons for mismatch can be additional positive or negative non-hypoxic 
stimuli influencing CA-IX expression or defective expression of CA-IX in some 
tumours. CA-IX is involved in intra- and extracellular pH homeostasis of tumour 
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cells. CA-IX is localized normally on differentiated cells specialized in acid/base 
regulation (collecting ducts of the kidney, gastrointestinal gland cells) suggesting a 
role for CA-IX in maintaining extracellular acidity in tumours.16 Thus, changes in 
the acid/base balance may provide additional stimuli for CA-IX expression. In 
bladder and skin carcinomas Wykoff et al. observed pimonidazole staining 
extending beyond CA-IX immunoreactivity, the latter being more tightly limited to 
perinecrotic regions.28 This is in contrast to the results of the current study and 
those of Olive et al.18 Whether this truly represents differences between tumours 
of different origin and histology or if this should be explained by differences in 
immunohistochemical techniques is yet unclear. In the skin and bladder 
carcinomas no overall correlation between the percentage of tumour stained for 
pimonidazole and CA-IX was found. 
 
It can be concluded that, although CA-IX is indicative for hypoxia, it is less specific 
compared to pimonidazole which can explain the weak correlation between 
relative pimonidazole and CA-IX positive areas in this study (Figure 5). 
The transmembrane carbonic anhydrases are regulated by HIF-1 which is 
considered to be a master regulator integrating physiological responses to 
hypoxia. HIF-1 itself is also gaining interest as an intrinsic hypoxia marker. 
Immunohistochemical detection of HIF-1α demonstrated patterns similar to those 
of its target gene products with typical perinecrotic staining.33,34 However, more 
diffuse expression patterns with staining in proximity of blood vessels are also 
reported.33,34 In cervical cancer xenografts maximal HIF-1α expression generally 
occurred at shorter distances from blood vessels than the maxima of EF-5 
binding.33 This suggest that HIF-1 upregulation occurs at higher pO2 levels than 
required for nitroimidazole binding, similar to what we observed for CA-IX. HIF-1α 
expression was inversely correlated with local failure-free survival, disease-free 
survival and overall survival in squamous cell carcinomas of the oropharynx 
treated with radiotherapy.34 
 
Prognostic value of tumour vascularity and hypoxia related markers 
In this study there was a significant association between VD and locoregional 
tumour control. With our automated image processing system we analyzed 
complete tissue sections and the average number of vascular structures was 
calculated per mm2 tumour area. This is different from hot-spot counting where 
vessel counting is restricted to selected areas of high vascularity yielding what is 
generally referred to as “microvascular density” (MVD). Three studies in head and 
neck carcinomas found an association between MVD and local tumour control 
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after radiation treatment.35-37 One study demonstrated an increased risk of local 
recurrence with low MVD in larynx carcinomas but another showed the opposite in 
oropharynx tumours. The largest study on head and neck tumours thus far 
published found a “U-shaped” relationship between MVD and survival after 
combined radiotherapy and chemotherapy.37 An intermediate MVD defined a 
better survival, while both low MVD and high MVD were linked to poor outcome. 
This observation was explained by a poor treatment response due to insufficient 
oxygen and drug availability in the poorly vascularized cases and an increased 
metastatic potential in the highly vascularized tumours. The association between 
low VD and poor oxygenation and consequently unfavorable outcome after 
radiotherapy is compatible with the results of the current study. The suggestion is 
strengthened by the fact that the outcome of poorly vascularized tumours 
improved with ARCON. A weakness in this hypothesis is, however, the absence of 
a correlation between VD and HFpimo in the current material. 
Retrospective clinical studies support the notion that CA-IX represents tumour 
aggressiveness. High CA-IX expression predicted poor survival in carcinoma of 
the head and neck, lung, uterine cervix and breast.19-22 One older study, however, 
showed the reverse in early cervical cancers.38 The association of CA-IX 
expression with local tumour response is still equivocal. One retrospective study in 
patients with head and neck carcinomas treated with concurrent chemoradio-
therapy did show a correlation with local control rate whereas a study in patients 
with cervical carcinomas treated with radiotherapy did not.19,22 In this study, we 
found no correlation with locoregional control nor with disease-free survival. 
Although not consistently so, the available data are supportive of a role for CA-IX 
as a predictor of tumour aggressiveness reflected in patient survival. Whether CA-
IX can serve as a reliable marker of tumour hypoxia and predictor of local 
outcome remains unclear to date. 
To our knowledge, this is the first report presenting data on the predictive value of 
pimonidazole. Direct measurements of hypoxia with oxygen microelectrodes have 
been associated with treatment outcome in squamous cell carcinomas of the head 
and neck and uterine cervix.2,4-6 Likewise, the pimonidazole binding assay being 
also a direct indicator of tumour hypoxia demonstrated a significant association 
with locoregional control and disease-free survival in the current study. Patients 
with hypoxic tumours showed a worse initial response to the treatment and more 
locoregional recurrences within the first 15 months of follow-up (Figure 7A). After 
this initial period there was no further divergence of the course of the locoregional 
control or disease-free survival curves (Figures 7A,C). This suggests that the 
worse outcome of hypoxic tumours is mainly determined by early locoregional 
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failures and not so much by later events such as distant metastases. Follow-up is 
still short however, and distant metastases may occur later than 2 years. The 
observation that the association with locoregional control exists mainly in the non-
ARCON treatment group but hardly in the ARCON treatment group (Figure 7B) is 
a strong indication that pimonidazole binding indeed reflects hypoxic radiation 
resistance. This also indicates that the nitroimidazole binding assay together with 
vascular parameters may provide a selection tool for hypoxia modifying 
treatments on an individual patient basis. 
 
An important limitation of this study is the relatively small sample size and the 
heterogeneity of the patient selection with regard to tumour site and stage. This 
could partly explain why no correlations were found between these classical 
clinical parameters and outcome. However, also in a larger series of 215 ARCON-
treated patients, T-stage was no longer a prognostic indicator which may well be 
the result of the very high local control rates with this treatment.23 Furthermore, 
treatment assignment was not randomized and various treatment modalities were 
used in the non-ARCON group and follow-up is still short. This precludes firm 
conclusions to be based on this material and verification of the results is needed 
in a larger patient cohort. A recently started randomized trial comparing ARCON 
with accelerated radiotherapy in laryngeal cancer with a projected accrual of 344 
patients will provide sufficient material to validate the conclusions of this study. 
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Abstract 
 
Background and Purpose  
Hypoxic radioresistance is an important cause for treatment failure in a number of 
tumour types including head and neck cancers. Recent studies suggest that 
outcome can be improved by oxygenation modifying treatments such as ARCON. 
A robust endogenous marker of hypoxia might be a valuable aid to select patients 
for such treatments. The aim of this investigation was to study associations 
between the putative endogenous hypoxia markers CA-IX, Glut-1 and Glut-3 and 
clinical tumour and patient characteristics and to evaluate the prognostic value of 
these markers. 
 
Material and Methods 
Tumour biopsies from 58 patients treated with ARCON in a phase II trial were 
included. Tumour sections were immunohistochemically stained for CA-IX, Glut-1 
and Glut-3. Sections were scored for relative tumour area stained by the markers 
(CA-IX and Glut-3) and for intensity of staining (Glut-1 and Glut-3). Further, 
sections were stained for CD34, an endothelial marker to assess microvascular 
density. 
 
Results 
Staining of CA-IX and Glut-3 was observed at some distance from vessels and 
adjacent to necrosis. Glut-1 staining was generally very diffuse. The distribution of 
clinical characteristics was equal between tumours with high and low marker 
expression. Significant differences were found for locoregional control (p=0.04) 
and for freedom of distant metastases (p=0.02) in favour of patients with high CA-
IX positivity (>25% of tumour area). High Glut-3 expression was associated with a 
better locoregional control (p=0.04). Higher Glut-1 intensity was associated with 
an increased rate of distant metastases (p=0.0005) and a worse overall survival 
(p=0.001). 
 
Conclusions 
The inconsistent associations with outcome of CA-IX and the glucose transporters 
indicate that different factors play a role in upregulation of these markers. 
Compared to studies with conventional treatment, the correlation between CA-IX 
expression and Glut-3 expression and outcome was reversed after treatment with 
ARCON. This does not support the potential of any of these proteins as very 
specific and robust hypoxia markers. 
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Introduction 
 
Oxygenation status is an important factor in the radiation response of solid 
tumours. Hypoxia is associated with malignant tumour progression and is a cause 
of resistance to ionizing radiation. Tools increasingly used to study hypoxia are 
the exogenous nitro-imidazole markers, which are detectable by immunohisto-
chemistry. Pimonidazole and etanidazole (EF-5) have been proven to be sensitive 
markers in experimental studies and are being evaluated in the clinical setting for 
assessment of tumour hypoxia.1-6 A disadvantage of these markers is that they 
have to be injected intravenously prior to biopsy taking. An intrinsic marker of 
hypoxia, which does not require additional interventions beyond the initial 
pretreatment biopsy, is therefore attractive. In addition, studies can then be done 
retrospectively on archival biopsies. Several endogenous markers have been 
suggested as hypoxia or hypoxia-related markers, like HIF-1, CA-IX, Glut-1 and -3 
(glucose transporter), VEGF and osteopontin.7-18 Carbonic anhydrase IX (CA-IX) 
is under transcriptional control by the hypoxia-inducible-factor 1 (HIF-1).12,17 It is a 
transmembrane glycoprotein often expressed in perinecrotic areas and a weak 
relationship with pimonidazole binding has been reported.3,17,19 Carbonic 
anhydrases are involved in energy metabolism and acid-base balance and 
catalyze the reversible hydration of CO2 to HCO3- .20 CA-IX has been described as 
being upregulated in head and neck squamous cell carcinomas.19 Expression of 
CA-IX has been shown to be associated with a more aggressive tumour behavior 
and a worse prognosis in some tumour types.9,13,19 Other studies, however, show 
no or reverse associations.3,10,21-23 Variable results are reported regarding the 
association with tumour vascularity.3,9,19  
The switch from oxidative phosphorylation to anaerobic glycolysis in hypoxic 
tumour cells is accompanied by an increase in glucose requirements and 
transport. Glucose transporters (Gluts) are upregulated in cells of many different 
tumours and mediate passive glucose uptake. They are induced by hypoxia and 
decreased oxidative phosphorylation, via HIF-1.18 Glut-1 is almost always 
expressed in head and neck squamous cell tumours while Glut-3 shows greater 
inter-tumour variability.24 Few studies have explored the association between 
hypoxia and expression of glucose transporters in human tumours with equivocal 
results.8,14 
There is interest in measurements of vascularity as a reflection of oxygenation 
status but few clinical studies have addressed this issue and the results are 
inconclusive.3,9,25 Another indistinct point is the association between vascular 
density or other vascular parameters and prognosis. In the past decade, many 
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studies have been performed without really clarifying this relationship. Some 
investigators found a higher vascular density to be associated with an increased 
rate of distant metastases and a shorter overall survival,26,27 whereas others did 
not find any correlation.28,29 
In this study, we investigated the putative endogenous hypoxia markers CA-IX, 
Glut-3 and Glut-1 in a series of head and neck squamous cell carcinomas treated 
with primary radiotherapy. Correlations between the expression of the different 
markers and between marker expression and clinical tumour and patient 
characteristics were studied. In addition, we investigated the prognostic value of 
CA-IX, Glut-3 and -1 and microvascular density (MVD) in relation to locoregional 
control, freedom of distant metastases and overall survival after radiotherapy with 
hypoxic modification. We hypothesized that expression of these markers in 
tumour cells would predict an increased risk of distant metastases and a worse 
overall survival, because hypoxia is known to be associated with increased 
metastatic potential and a poor overall survival.30-32 We anticipated that a potential 
association with locoregional control might be negated by the hypoxia modifying 
components of the treatment. 
 
 
Materials and methods 
 
Patients and treatment 
At the Department of Radiation Oncology of the Radboud University Nijmegen 
Medical Centre, a phase II clinical trial of ARCON (accelerated radiotherapy with 
carbogen and nicotinamide) in advanced squamous cell carcinomas of the head 
and neck has recently been completed.33 ARCON combines accelerated 
radiotherapy with carbogen breathing and nicotinamide to reduce diffusion-limited 
and perfusion-limited hypoxia, respectively. Eligibility criteria for this study were: 
(a) stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, 
hypopharynx or larynx and stage II hypopharynx carcinomas with a greatest 
dimension of the primary tumour > 2 cm34; (b) age over 18 years; (c) WHO 
performance status of 0-2; (d) no distant metastases; (e) no severe heart or lung 
disease; (f) no liver or kidney function impairments; (g) no severe stridor; (h) no 
concurrent treatment for other malignant disease outside the upper aero-digestive 
tract. 
Biopsy material was obtained from patients that satisfied the eligibility criteria 
between January 1993 and September 2000. Further criteria were availability of 
biopsies and sufficient material in the biopsy. Biopsies were taken for routine 
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diagnostic purposes and were retrieved from the Department of Pathology in our 
hospital. All patients underwent a diagnostic workup, which included physical 
examination, blood cell count, blood chemistry, chest X-ray, CT-scan and/or MRI-
scan of the head and neck area and examination under anaesthesia. 
All patients were treated with ARCON as described previously.33 They received 
64-68 Gy to the primary tumour and involved neck nodes and 44 Gy to electively 
treated areas. The dose per fraction was 2 Gy and two fractions per day were 
given during the last 1.5 weeks of the treatment with an overall treatment time of 
36-38 days. During the irradiations patients breathed carbogen and they received 
nicotinamide, 60-80 mg/kg orally, 1-1.5 h prior to the start of irradiations. 
 
Immunohistochemistry 
Staining for CA-IX and CD34 
For vessel staining, 5 µm sections were incubated for 60 min with mouse 
monoclonal antihuman CD34, followed by 30 min with horse-antimouse antibody, 
and next with avidin-biotin complex for 30 min. Biotinyl-tyramide (Department of 
Pathology, Radboud University Nijmegen Medical Centre, The Netherlands) was 
applied for 5 min for subsequent amplification. After incubation with streptavidin β-
galactosidase for 30 min, colour development was established with β-galacto-
sidase (Department of Pathology, Radboud University Nijmegen Medical Centre, 
The Netherlands). For epitope retrieval of CA-IX, sections were boiled for 13 min 
in 10 mM citratebuffer of pH 6.0. Then sections were incubated with mouse anti-
CA-IX antibody (Egbert Oosterwijk, Department of Urology, Radboud University 
Nijmegen Medical Centre) for 60 min, horse-antimouse antibody for 30 min, and 
ABC reagent for 30 min. Peroxidase activity was detected with di-amino benzidine 
(DAB). Finally, sections were counterstained with haematoxylin and mounted with 
Permount. 
 
Staining for Glut-3 and CD34 
The slides were incubated at 4°C overnight with mouse monoclonal antihuman 
CD34 and goat antihuman Glut-3. After rinsing with PBS, endogenous peroxidase 
was blocked with 3% H2O2 in methanol. Then, sections were incubated for 1 h 
with a mixture of secondary antibodies: alkaline-phosphatase conjugated donkey-
anti-mouse and biotin conjugated donkey-anti-goatF(ab’)2. Sections were then 
incubated with fast red substrate solution for 25 min to develop an intense red 
vascular stain. After this, sections were incubated for 30 min with ABC-reagent. 
Peroxidase activity was detected with DAB. Finally, sections were counterstained 
with haematoxylin for 30 sec and mounted with Fluorostab. 
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For negative controls, instead of the primary antibodies, slides were incubated 
with MLD. 
 
Staining for Glut-1 and CD34 
The staining protocol for Glut-1 was similar to that of Glut-3. Instead of goat-
antihuman Glut-3, rabbit-antihuman Glut-1 was used and biotin conjugated 
donkey-anti-rabbit was used as the secondary antibody. 
 
Scoring 
Scoring of CA-IX 
We used a semi-quantitative method for scoring CA-IX positive areas as 
described and validated for pimonidazole staining by Raleigh et al.35, with some 
modifications. The complete tumour area was scored with a light microscope 
using an objective of 25x and ocular of 12.5x magnification and the same light 
intensity for all tumours. The classes 0-5%, 5-15%, 15-30%, 30-50% and >50% 
CA-IX positive area per field of the tumour area were assigned semi-quantitative 
scores of 0, 1, 2, 3 and 4, respectively. Areas of stroma, necrosis, acellularity or 
keratinisation were not included as tumour area. A median value for each tumour 
was computed correcting for range width, using the formula:  
  
 
 
(Xll, lower limit of class containing median of field scores; Xul, upper limit of class 
containing median; fc, frequency of class containing median; Fc-1, cumulative 
frequency of class under class containing median and n, total number of 
observations). When more than one biopsy per tumour was available both 
biopsies were pooled for analyses. All scoring was done without knowing patient 
outcome. 
 
Scoring of Glut-3 and Glut-1 
The same scoring system for staining area was used for Glut-3. There was a large 
variability in the intensity of the Glut-3 staining. We therefore also scored the 
staining intensity as described by Airley et al.7 Sections were viewed at a 
magnification of 50x and given a score for staining intensity (0, no staining; 1, 
weak staining; 2, medium staining; 3, heavy staining).  
It was not possible to quantify the Glut-1 positive area because staining of the 
tumour was diffuse in most biopsies so Glut-1 was scored for intensity only. 
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Microvascular density 
Microvascular density (MVD) was assessed as described often in literature. At low 
magnification three fields of vision of high vascularization per tumour were 
chosen. Microvessel counting was performed with an objective of 25x and ocular 
of 12.5x magnification. MVD was the mean value of the three appraised fields of 
vision. 
 
Statistics 
All statistical analyses were done on a personal computer using the SPSS 12.0.1® 
statistical package. 
Correlations between numerical variables were obtained using Spearman's rank 
correlation. Survival analysis was performed by the Kaplan-Meier product limit 
method, and survival rates were compared using the logrank statistic. Cox 
regression analysis was used for confounder analysis. All time-dependent 
outcomes were calculated from time of pathological diagnosis, and patient data 
were censored when a disease event had not occurred at the last follow-up. For 
the endpoint “locoregional control” an event was recurrence at the primary tumour 
site or in the regional lymph nodes. Patients without locoregional recurrence were 
censored at the date of last follow-up. For the endpoint “freedom of distant 
metastases” an event was occurrence of hematogenous metastases. Patients 
without distant metastases were censored at the date of last follow-up. For overall 
survival, all deaths were analyzed as event and patients still alive were censored 
at the date of last follow-up. P-values below 0.05 were considered significant. 
  
 
Results 
 
Patients and clinical tumour characteristics 
Biopsy material was obtained from 71 patients. Thirteen biopsies were excluded, 
12 because the sample contained only little or no invasive carcinoma and one 
patient was diagnosed with two primary tumours. So, 58 patients with squamous 
cell carcinomas were included. Of those, 43 were men and 15 were women. 
Median age at the time of diagnosis was 58 years (range 41-87). Mean pre-
treatment hemoglobin concentration was 14.2 g/dl (range 9.2-16.8). Two patients 
had a hemoglobin concentration under 11.3 g/dl (7.0 mmol/l). Primary tumours 
were localized in the larynx (42), oral cavity (5), hypopharynx (8) and oropharynx 
(3). Differentiation grade was distributed as follows: 2 tumours grade 1, 38 grade 
2, 17 grade 3 and 1 grade 4. All patients were treated with ARCON. One patient 
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had to discontinue nicotinamide because of side effects and another patient 
refused carbogen and nicotinamide after a week and continued treatment with 
radiotherapy alone. Median follow-up time for patients alive at the time of analysis 
was 5.1 years. Patient and tumour characteristics and associations with marker 
expression are summarized in table 1.  
 
Table 1. Patient and tumour characteristics of 58 head and neck cancer patients (UICC 
1992)34 
 
The distribution of clinical characteristics was equal between tumours with high 
and low marker expression. None of the clinical characteristics demonstrated a 
correlation with locoregional control or survival. 
 
Staining of CA-IX and glucose-transporters 
The median of CA-IX staining amongst all tumours was 6.0% of the tumour area. 
Many tumours demonstrated little or no CA-IX expression (Figure 1A). Staining 
was mostly limited to tumour cell membranes, but a weak cytoplasmatic staining 
was also observed. Positive staining, when present, was observed at some 
distance from vessels and around necrosis (Figures 2A and D). 
 All CA-IX area Glut-3 area Glut-1 intensity 
score 
MVD 
  <med >med <med >med 0-1 2-3 <med >med 
Age 
mean 
range 
 
60.0 
41-87 
 
59.5 
41-87 
 
60.4 
46-82 
 
59.6 
41-82 
 
60.4 
46-87 
 
60.2
41-87 
 
59.0 
47-76 
 
57.0 
41-82 
 
62.4 
47-87 
Gender 
male 
female 
 
43 
15 
 
20 
9 
 
23 
6 
 
21 
8 
 
22 
7 
 
36 
13 
 
7 
2 
 
22 
7 
 
21 
8 
Tumour site 
larynx 
hypopharynx 
oropharynx 
oral cavity 
 
42 
8 
3 
5 
 
22 
5 
0 
2 
 
20 
3 
3 
3 
 
18 
4 
2 
5 
 
24 
4 
1 
0 
 
34 
8 
2 
5 
 
8 
0 
1 
0 
 
21 
5 
1 
2 
 
21 
3 
2 
3 
T-stage 
 T1 
 T2 
 T3 
 T4 
 
4 
16 
27 
11 
 
2 
12 
12 
3 
 
2 
4 
15 
8 
 
1 
9 
11 
8 
 
3 
7 
16 
3 
 
2 
15 
22 
10 
 
2 
1 
5 
1 
 
2 
10 
12 
5 
 
2 
6 
15 
6 
N-stage 
 N0 
 N1 
 N2 
 
25 
16 
17 
 
11 
6 
12 
 
14 
10 
5 
 
10 
10 
9 
 
15 
6 
8 
 
22 
13 
14 
 
3 
3 
3 
 
14 
6 
9 
 
11 
10 
8 
Hemoglobin 
 mean 
 range 
 
14.2 
9.2-
16.8 
 
14.0 
9.8-
16.8 
 
14.0 
9.2-
16.3 
 
14.2 
12.3-
16.3 
 
14.0 
9.2-
16.8 
 
14.2 
9.2-
16.8 
 
13.7 
9.8-
15.5 
 
14.4 
12.3-
16.3 
 
14.0 
9.2-
16.8 
Diff. Grade 
 1 
 2 
 3 
 4 
 
2 
38 
17 
1 
 
0 
18 
10 
1 
 
2 
20 
7 
0 
 
1 
19 
9 
0 
 
1 
19 
8 
1 
 
1 
34 
13 
1 
 
1 
4 
4 
0 
 
1 
18 
10 
0 
 
1 
20 
7 
1 
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A B 
 
Figure 1. Distribution of median CA-IX expression (A) and Glut-3 expression (B). 
 
Overall, Glut-3 expression was more pronounced than CA-IX, with a median 
staining area of all tumours of 25.1% of the total tumour area and larger hetero-
geneity between tumours (Figure 1B). Glut-3 expression was often observed at a 
distance from vessels (Figures 2B and E), but more diffuse staining patterns with 
Glut-3 in areas close to vessels were also observed. Glut-3 expression occurred 
in the cytoplasm of tumour cells and stromal areas. Between the Glut-3 positive 
area and the overall intensity of Glut-3 there was a significant correlation with rS = 
0.71 (p < 0.01). 
For Glut-1, a very diffuse staining of the entire tumour area was generally 
observed (Figure 2C). Therefore, scoring of relative tumour area stained by Glut-1 
was not possible and only intensity of staining was scored. The overall intensity of 
Glut-1 was weak in most cases (score 1), but the majority of the tumours (75%) 
also contained focal areas with higher staining intensity (Figure 2F). 
 
Correlations between CA-IX, Glut-3 and microvascular density 
Staining of CD34 was very intense and vessels were easy to identify (Figure 2). 
The median microvascular density (MVD) of all tumours was 38 per microscopic 
field (range 7-132). A very weak but significant negative correlation was found 
between MVD and CA-IX expression: rS = -0.27 (p = 0.04). No correlation was 
found between MVD and Glut-expression. 
Also, no correlations were found between CA-IX expression and Glut-expression, 
neither for relative marker positive tumour area nor for intensity of staining. 
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Figure 2. Different staining patterns and scores of CA-IX, Glut-3 and Glut-1 in consecutive 
sections of two different tumours (A-C and D-F). There is co-localization but also 
significant mismatch of the three markers. A) CA-IX, score 4; B) Glut-3, score 3; C) Glut-
1, intensity score 3; D) CA-IX, score 0; E) Glut-3, score 4; F) Glut-1, intensity score 1, 
focal areas with intensity score 3. Bar represents 0.1 mm. 
B 
C 
D
E
F
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Table 2. Logrank analysis of outcome dichotomized by hypoxia-related marker 
expression and MVD.NS: not significant, significant at p ≤ 0.05. ¶In favour of patients with 
high CA-IX or Glut-3 expression. $In favour of patients with low Glut-1 expression 
 
Parameter Overall survival Locoregional 
control 
Freedom from 
distant 
metastases 
CA-IX area 
median 
NS NS NS 
CA-IX area 
80th percentile 
NS 0.04¶ 0.02 
Glut-3 area median NS NS NS 
Glut-3 intensity 0,1 vs 2,3 NS 0.04¶ NS 
Glut-1 intensity 0,1 vs 2,3 0.001$ NS 0.0005$ 
MVD median NS NS NS 
 
 
Correlations with outcome 
Results of Kaplan-Meier estimates and logrank analyses are summarized in table 
2. 
 
CA-IX 
When dichotomized by the median of relative tumour area staining positive for 
CA-IX, no correlations were found between CA-IX expression and outcome. 
Because of the skewed distribution and many low percentages of CA-IX positive 
areas (Figure 1A), an additional analysis was done after stratification by the 80th 
percentile resulting in a group with no to medium CA-IX expression (CA-IX 
staining area ≤ 25%, n = 46) and a group with high CA-IX expression (CA-IX 
staining area > 25%, n = 12). This analysis demonstrated a significant association 
with outcome with better locoregional control (p = 0.04) and freedom of distant 
metastases (p = 0.02) for patients with high CA-IX expression (Figures 3A and B). 
Of the patients with tumours showing high CA-IX expression levels, none 
developed local or distant recurrences. CA-IX expression and the conventional 
prognostic factors T-stage, N-stage, site of tumour, differentiation, age and gender 
were included in a univariate Cox regression analysis. None of these factors 
except CA-IX expression had an effect on prognosis for any of the outcome 
parameters. Multivariate Cox regression analyses were then carried out to 
examine the prognostic significance of CA-IX, Glut-1 and -3 expression after 
allowing for age, gender, pre-treatment hemoglobin concentration, T- and N-
stage, differentiation grade and tumour site. The adjusted relative risk of high CA-
IX expression increased compared to the univariate analysis indicating that none 
of these factors acted as a confounder.  
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Glut-3 
After stratification of the tumours by the median of Glut-3 relative staining area, no 
differences were found between the two groups for any of the endpoints. When 
stratifying for overall intensity of Glut-3 between no or weak staining (score 0 or 1) 
and medium to heavy staining (score 2 or 3), a significant difference was found for 
locoregional control (p = 0.04), no or weak staining having a worse prognosis than 
medium or heavy staining (Fig 3C). 
 
Glut-1 
For Glut-1, only intensity of staining was scored. Patients with a higher intensity 
score (score 2 and 3) had a higher distant metastases rate (p = 0.0005) and a 
worse overall survival (p = 0.001) compared with patients with low scores of 
overall intensity (score 0 and 1) (Figure 3D). 
 
MVD 
For MVD, no significant correlations with any of the endpoints were found.  
 
 
Discussion 
 
In this study we investigated the value of the putative endogenous hypoxia 
markers CA-IX, Glut-3 and Glut-1. Associations between the expression of the 
different markers and between marker expression and clinical tumour and patient 
characteristics were investigated. Further, the prognostic value of these hypoxia 
markers and MVD was studied in a series of patients with head and neck 
squamous cell carcinomas treated with ARCON. 
 
Clinical parameters 
In head and neck cancer important prognostic indicators for locoregional control 
and freedom from distant metastases are T-stage and N-stage. In this study we 
could not demonstrate any prognostic significance of these clinical parameters. 
This is consistent with a previous analysis of a larger series of head and neck 
cancer patients treated with ARCON and suggests that the more advanced 
tumours benefit most from oxygenation modifying treatment.3 With the 
disappearance of these major clinical parameters, biologic factors may become 
the more important predictors for treatment outcome. Also, in the current study, 
there was no association between tumour site and outcome but this can be 
explained by the fact that most of the patients had larynx tumours and only a 
minority (28%) had tumours at other head and neck sites. 
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No correlations were found between patient characteristics and clinical tumour 
parameters and expression of any of the hypoxia-related markers or MVD. This 
suggests that the expression of these molecular markers is relatively independent 
of host factors and tumour stage. Two other studies did find correlations between 
CA-IX expression and age and tumour stage in cervix carcinoma but the results 
were contradictory.13,22 The literature is more consistent with respect to the 
relationship with histological grade: in poorly differentiated tumours decreased 
CA-IX expression but increased expression of Glut-1 and Glut-3 has been 
described.20,22,36,37 This opposite relationship with differentiation grade could not 
be confirmed in the current material but it indicates that expression of CA-IX and 
the glucose transporters, although both HIF-1 and thus hypoxia-dependent, do not 
necessarily behave in a coherent fashion. 
 
CA-IX 
CA-IX is under transcriptional control by HIF-1α and has been shown to be 
increasingly upregulated after exposure to decreasing oxygen tensions.12,17,38 This 
dependency and the observation that CA-IX is expressed in a variety of tumour 
types has led to the suggestion that it might be a useful endogenous marker of 
tumour hypoxia and a potential indicator of tumour aggressiveness and poor 
outcome. This hypothesis is supported by the study in head and neck cancers by 
Koukourakis et al. which demonstrated that patients with CA-IX-expressing 
tumours had significantly poorer local relapse-free survival and overall survival.20 
Assuming that ARCON counteracts hypoxic radiation resistance resulting in 
improvement of locoregional tumour control primarily in the patients with the more 
hypoxic tumours, we hypothesized that the predictive potential of CA-IX 
expression for locoregional control would decrease or disappear in the current 
material. A correlation with occurrence of distant metastases might still be found 
however, because the treatment is not expected to affect metastatic potential. 
Unexpectedly, patients with tumours showing a higher CA-IX staining area had a 
better locoregional control and freedom from distant metastases after treatment 
with ARCON. No confounders were found for this association. Although the group 
showing a high CA-IX staining was fairly small (n = 12), the difference between 
survival parameters for the two groups was considerable and consistent for the 
two endpoints. A previous study from our institute, also on a series of patients with 
head and neck tumours receiving different treatments, showed no correlation 
between CA-IX expression and outcome.19 However, a subgroup (n = 24) that 
was treated with ARCON showed a non-significant trend for better outcome with 
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high CA-IX expression as well. Whether this unexpected result can be attributed 
to the hypoxia-modifying components of the treatment is a question that cannot be 
resolved with the current material. An ongoing randomized trial with ARCON in 
larynx carcinoma may address this issue. There is one other study that has 
correlated CA-IX and Glut-1 expression with outcome after treatment with 
ARCON. This study by Hoskin et al. in 64 patients with bladder cancer showed 
that the two markers were highly correlated with each other and were independent 
predictors for overall and cause-specific survival but not for local control or distant 
metastases rate.11 
Studies exploring the prognostic relevance of CA-IX in other tumour types 
produced ambiguous results, some confirming the anticipated association with 
adverse outcome but others showing no or even the reverse association.9,10,13,22-24 
Several studies showed to some degree a co-localization of pimonidazole binding 
and CA-IX expression but the correlation is often weak.11,15,17,19,39 These clinical 
investigations indicate that the role of CA-IX as an intrinsic marker of hypoxia and 
a prognosticator of outcome remains equivocal. Combination with assays that 
assess other aspects of the tumour microenvironment as for example vascularity, 
proliferation and apoptosis, may provide a panel of markers and a more powerful 
approach towards development of predictive tools.20,40,41 
 
Glut-3 
Compared to CA-IX, Glut-3 expression generally involved larger tumour areas. 
Like CA-IX, Glut-3 was often observed around necrotic areas but more diffuse 
staining near vessels was also observed. Further, the intensity of Glut-3 staining 
showed a larger variability. For this reason, both the relative positive area and the 
intensity of staining were scored. No correlations were found between Glut-3 and 
CA-IX positivity. 
The relative Glut-3 staining area was not associated with outcome. Low overall 
intensity score of Glut-3 was correlated with worse locoregional control but there 
were no significant correlations with occurrence of distant metastases or overall 
survival. Only a few studies have related Glut-3 expression to outcome. A high 
Glut-3 expression was associated with a worse survival in laryngeal carcinoma 
and non-small cell lung carcinoma.36,37 Our observation is not in concordance with 
these reports, but is consistent with the reverse relationship also found for CA-IX 
in this material. 
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C D 
Figure 3. Locoregional control (A) and freedom from distant mestases (B) after 
stratification by the 80th percentile of CA-IX staining surface. Locoregional control 
stratified for overall intensity of Glut-3 staining (C) and freedom from distant metastases 
stratified for overall intensity of Glut-1 staining (D). Small vertical lines on plots indicate 
censored cases. 
 
 
Glut-1 
The expression of Glut-1 was weak and very diffuse in most biopsies. The Glut-1 
isoform is expressed at some level in many cell types.42 Previous studies 
demonstrated that Glut-1 mRNA or the Glut-1 protein was elevated in almost all 
head and neck tumours,25,36,43,44 expression occurring early in the development of 
these tumours.25 However, only one of these studies reported this diffuse 
expression of Glut-1.25 For cervix carcinomas, diffuse staining was described as 
well.7 Whether these different observations must be explained by different staining 
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techniques, different antibodies or by organ-specific differences in expression is 
unclear. It does however indicate that results must be interpreted cautiously, 
especially when studies are compared that use different antibodies. 
Patients with a higher overall intensity of Glut-1 staining had an increased rate of 
distant metastases and a worse overall survival compared with patients with low 
intensity scores but there was no difference in locoregional control. In particular 
the correlation with metastatic rate was highly significant. In contrast to our results 
for CA-IX and Glut-3 expression, this was in concordance with our hypothesis 
that, if the enhanced expression of glucose transporters represents hypoxia, no 
difference was expected for locoregional control, since ARCON counteracts 
hypoxic radioresistance responsible for the worse locoregional outcome. Glut-1 
has been studied more extensively than Glut-3. Its prognostic value has been 
investigated for squamous cell carcinoma of the oral cavity, larynx, hypopharynx 
and oesophagus, and in breast, gastric, colorectal, bladder, cervix and non-small 
cell lung carcinomas, and was shown to be indicative of poor prognosis in most 
studies.7,36,37,43-49 
There was no correlation between CA-IX and Glut-1 expression. Both markers 
have been related to hypoxia, but there are some differences. The Glut-1 
response to hypoxia exhibits an early and late phase. During the early phase of 
the response (0-2 h) Glut-1 proteins already present on the cell membrane are 
probably activated and their affinity increased, and Glut-1 proteins present in the 
cell are translocated to the cell membrane, resulting in a strongly enhanced 
glucose transport rate. The late phase (8-24 h) is characterized by a further 
enhancement of glucose transport associated with increments in cellular Glut-1 
and Glut-1 mRNA content.49 So Glut-1 might reflect both chronic and (sub-)acute 
hypoxia, since Glut-1 is constitutively present in the cell and can be activated 
almost immediately, in contrast to CA-IX that needs a longer time course to be 
upregulated. Secondly, Glut-1 expression is also a consequence of glucose 
starvation and reflects high, though inefficient, glucose metabolism, in contrast to 
CA-IX.50 Thirdly, ARCON therapy might be a factor accounting for the inconsistent 
effects of the Glut’s and CA-IX on survival endpoints, since both markers are 
associated with a worse outcome in studies employing conventional therapies. 
With ARCON, CA-IX and Glut-3 seem to be associated with a better outcome. 
Carbogen and nicotinamide can counteract hypoxia, but their effects on glucose 
availability are largely unknown. This might also explain why CA-IX and the Glut’s 
predict differently for outcome after ARCON treatment. 
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MVD 
No association between MVD and the various endpoints was found. Patients were 
also stratified by tertiles to investigate the ‘U-shaped’ association between death 
rate and MVD, as described by Koukourakis et al.51 These authors observed that 
tumours with very low MVD and very high MVD had poor outcome whereas 
tumours in the intermediate group did better. This association was not confirmed 
in the current material. There was a very weak but significant negative correlation 
between MVD and CA-IX area staining. This might indicate consistence with the 
significance of CA-IX as a marker of (chronic) hypoxia. No association was found 
between MVD and the other markers studied. 
 
 
Conclusion 
 
This study indicates that dissimilarities exist between the glucose transporters and 
CA-IX regarding their significance as clinically relevant hypoxia-related markers. 
There was no correlation between CA-IX staining area and Glut-3 or Glut-1 area 
or intensity and neither of the markers demonstrated any correlations with clinical 
patient and tumour characteristics. Further, their associations with outcome 
parameters were inconsistent indicating that other factors are also responsible for 
upregulating the different markers. This does not support the potential of any of 
these proteins as very specific and robust hypoxia markers. A limitation of this 
study is the relatively small sample size and the heterogeneity of the material. 
This precludes firm conclusions and verification of the results is needed in a larger 
patient cohort. An ongoing randomized trial comparing ARCON with accelerated 
radiotherapy in laryngeal cancer will provide sufficient material to validate the 
conclusions of the current study. 
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Abstract 
 
Purpose 
The predictive potential of tumour cell kinetic parameters may be improved when 
they are studied in relation to other microenvironmental parameters.The purpose 
of this investigation was to quantitatively categorize human tumour samples 
according to proliferation patterns. Second, it was examined whether these 
characteristics are retained after xeno-transplantation. 
 
Materials and methods 
Fifty tumour samples from head and neck cancer patients were immuno-
histochemically stained for Ki-67 and vessels. Also, parts of the samples were 
transplanted into nude mice. Tumours were categorized according to previously 
described patterns of proliferation. Vascular and proliferation patterns were 
analyzed using an image processing system. 
 
Results 
The 50 tumours were categorized into four patterns of proliferation by visual 
assessment: marginal (6), intermediate (10), random (21) and mixed (12). One 
tumour could not be classified. These patterns were quantified by calculating the 
Ki-67 labelling index in distinct zones at increasing distance from vessels yielding 
good discrimination and significant differences between patterns.  
The probability of growth after xenotransplantation was significantly higher for 
tumours with a labelling index and vascular density above the median value 
compared to tumours with both parameters below the median (82% vs. 35%). Fifty 
percent of the tumours retained their proliferation patterns after xeno-
transplantation. 
 
Conclusion 
The categorization by proliferation pattern previously described by others was 
reproduced quantitatively and spatially related to the vascular network using a 
computerized image processing system. The combination of quantitative and 
architectural information of multiple microenvironmental parameters adds a new 
dimension to the study of treatment resistance mechanisms. Tumour models 
representative of the various patterns can be used to further investigate the 
relevance of these architectural patterns. 
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Introduction  
 
In various studies, the value of proliferation markers as predictors for treatment 
outcome in patients with head and neck tumours has been examined.1-4 The 
results are conflicting, with some studies showing positive association with 
outcome while others do not. This might be explained by differences in patient 
categories and treatment modalities, low patient numbers, and by differences in 
the methodologies used for the analyses. Most studies rely on endogenous 
markers for proliferation such as Ki-67, proliferating cell nuclear antigen (PCNA) 
and markers of the cyclin group, or on the incorporation of thymidine analogues 
such as iododeoxyuridine and bromodeoxyuridine (IdUrd, BrdUrd) in the DNA of 
S-phase cells. 
A multicenter analysis including IdUrd- or BrdUrd- labelled biopsies from 467 
patients receiving radiotherapy alone demonstrated that labelling index (LI) 
assessed by flow cytometry was a weak predictor of outcome.5 It was suggested 
by the authors and by other investigators5,6 that the predictive potential of cell 
kinetic parameters might be improved by relating these parameters with other 
biological parameters and with the microregional architecture of tumours. Bennett 
et al.7 and Wilson et al.6 described four different histologic patterns of proliferation 
and found that the pattern of proliferation was the more important predictor for 
outcome over LI.  
In this study we have categorized tumour samples of patients with head and neck 
carcinomas according to the proliferation patterns described by Bennett et al.7 and 
Wilson et al.6 In an attempt to develop this approach further, we have quantified 
these patterns in relation to the vasculature using a computerized image analysis 
system. In addition, we have examined whether individual tumours retain these 
proliferation characteristics after transplantation into nude mice. This would then 
provide tumour models that can be instrumental to further investigate the 
relevance of these architectural patterns. 
 
 
Materials and Methods 
  
Collection and processing of tumour material 
Between February 1995 and April 1997, surgical resection specimen of 28 
patients with squamous cell carcinoma of the head and neck were collected. The 
fresh resected tumour specimen of each patient was brought to the pathology 
department. In agreement with the pathologist, a sample (0.25 - 0.5 cm3) of viable 
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tumour tissue was cut from the macroscopically identified tumour. One-half of this 
sample was put in L15 culture medium (Life Technology, Breda, The Netherlands) 
with penicillin and gentamycin, and transported to the animal laboratory where 1 
mm3 pieces of viable tumour were transplanted subcutaneously in the flank of five 
nude mice (Balb/c nu/nu mouse). The other half of the sample was immediately 
frozen into isopentane cooled by liquid nitrogen and stored at -190 oC until frozen 
sections were cut and stained.  
 
During a second period between May 1998 and December 1998, multiple biopsies 
were taken under general anesthesia from 21 patients, who were planned to be 
treated by radiotherapy. Apart from the biopsy for routine histopathologic 
examination we obtained two additional biopsies from each patient. One sample 
was immediately frozen in liquid nitrogen, the other was put in L15 medium and 
was transplanted in five nude mice afterwards as described above. 
After growing in the nude mice, tumours were passaged when they reached a 
diameter of 1 cm. For the purpose of this investigation the ability of a tumour to 
grow as a xenograft was defined as growth of tumour in the mice in at least the 
first and the subsequent passage. 
Approval from the local ethics committee was obtained for this study. 
  
Immunohistochemical staining of the human resection and biopsy material 
Before the staining procedure, frozen sections were fixed in acetone of 4o C for 10 
min. Then the sections were rehydrated in phosphate buffered saline (PBS). 
Between all the consecutive steps of the staining procedure, the sections were 
rinsed three times for 2 min in PBS. All antibodies were diluted in PBS. The DNA 
in the tissue sections was denatured by incubation with hydrochloric acid 2 N for 
10 min. To neutralize the pH, sections were rinsed in 0.1 M borax for 10 min. The 
sections were then incubated overnight at 4o C with undiluted Ki-67 antibody 
(mouse monoclonal, clone 7B11, Zymed, San Francisco, CA). This was followed 
by incubation for 1 h at room temperature (RT) with fluorescein isothiocyanate 
(FITC)-conjugated rabbit anti-mouse antibody (Jackson Immuno Research 
Laboratories, West Grove, PA, USA) 1:100. To enhance the signal, this step was 
followed by incubation for 1 h at RT with FITC-conjugated donkey anti-rabbit 
antibody (Jackson Immuno Research Laboratories) 1:100. 
Next, the vessels were stained by an incubation at RT for 1 h with PAL-E 
(Department of Pathology, University Medical Center St. Radboud, The 
Netherlands) 1:5. The mouse monoclonal antibody PAL-E is a marker for human 
endothelium, especially useful in frozen tissue sections.8 The staining procedure 
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was followed by 1 h incubation at RT with tetramethyl rhodamine isothiocyanate 
(TRITC)-conjugated goat anti-mouse antibody (Jackson Immuno Research 
Laboratories) 1:100. To enhance the signal, this was followed by incubation for 1 
h with TRITC-conjugated donkey anti-goat antibody (Jackson Immuno Research 
Laboratories) 1:100.  
Finally, all nuclei were stained with fast blue (Sigma-Aldrich Chemie BV, 
Zwijndrecht, The Netherlands) 1:1000 in PBS for 15 min at RT. Slides were then 
rinsed and mounted in PBS for quantitative imaging of the proliferation, 
vasculature and all nuclei. 
 
Immunohistochemical staining of the xenograft material 
The first part of the staining procedure of the xenograft material was identical to 
that of the human material, including the incubation with the Ki-67 antibody. Next, 
the staining procedure was continued by incubation for 1 h at RT with biotin-
conjugated donkey anti-mouse antibody (Jackson Immuno Research 
Laboratories) 1:100. This was followed by incubation for 1 h at RT with 
streptavidin Alexa Fluor 488 (Molecular Probes, Eugene, Oregon) 1:100 in PBS.  
Next the sections were incubated overnight at 4o C with undiluted 9F1 (rat 
monoclonal antibody to mouse endothelium, Department of Pathology, University 
Medical Center St. Radboud, The Netherlands), followed by 1 h incubation at RT 
with TRITC-conjugated goat anti-rat antibody (Jackson Immuno Research 
Laboratories) 1:100, to visualize the vessels. The vessel signal was enhanced by 
incubation for 1 h with donkey anti-goat Alexa Fluor 546 conjugated antibody 
(Molecular Probes) 1:100. Finally, all nuclei were stained with fast blue (Sigma-
Aldrich Chemie) 1:1000 in PBS for 15 min at RT. Slides were then rinsed and 
mounted in PBS for quantitative imaging of the proliferation, vasculature and all 
nuclei. 
 
Scanning of tumour sections and image processing 
For quantitative analysis, the slides were scanned by a computerized digital image 
processing system using a high-resolution intensified solid-state camera on a 
fluorescence microscope (Zeiss Axioskop) with a computer-controlled motorized 
stepping stage. The scanning method has been described in detail by Rijken et 
al.9 and has been previously used to visualize and quantify vessels, kinetic 
parameters10 and hypoxic markers11.  
 
Each tumour section was scanned three times at 200x magnification. After each 
scan, which consisted of 64 fields (8x8, field size 0.31 mm2), a composite binary 
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image was reconstructed from these fields. For the vessels (TRITC-signal, Alexa 
Fluor 546, 510-560 nm excitation) a 690 nm emission filter was used and for Ki-67 
labelled nuclei (FITC-signal, Alexa Fluor 488, 450-490 nm excitation) a 520 nm 
emission filter was used. For the nuclei (fast blue, 365 nm excitation) a 420 nm 
emission filter was used. After the scanning procedure, the three composite binary 
images of the vascular structures, the proliferating nuclei, and all nuclei were 
superimposed. The tumour area was delineated using a hematoxylin-eosin 
staining of a consecutive tumour section. This area was used as a mask in further 
image analysis excluding nontumour tissue and large necrotic areas from the 
analysis. A pathologist supervised the delineation of the tumour area. 
 
Analysis of proliferation and vascular parameters 
The composite binary images were used for computerized calculations of various 
parameters. The vascular density (VD) was calculated as the number of vascular 
structures per mm2. The relative vascular volume was defined as the PAL-E or 
9F1 positive surface divided by the total tumour surface. The LI was defined as 
the ratio of the Ki-67-labelled area to the total nuclear area.  
To quantitate the distribution of proliferation in relation to the vasculature, zones 
were chosen arbitrarily at increasing distance from the surface of the nearest 
vessel (0-15 µm, 15-30 µm, 30-70 µm and >70 µm). In each zone the LI was 
calculated as the Ki-67-stained surface in a zone divided by the total nuclear 
surface in that zone. 
 
Patterns of proliferation 
We categorized the tumours into four different groups according to the visual 
proliferation staining patterns that were previously described by Bennett et al.7 
The marginal pattern shows proliferating cells only in the basal or suprabasal cell 
layers. The second, intermediate pattern shows proliferating cells in the basal and 
suprabasal layers, but also in more distant layers. The random pattern shows a 
diffuse distribution of proliferation without obvious organization. Finally, the mixed 
pattern shows a combination of the above mentioned patterns. Two observers 
categorized the tumours independently according to these criteria. 
 
Statistics 
Mean values of VD and LI of subgroups of tumours were compared by the 
Student’s-t-test. Correlations between vascular and kinetic parameters were 
tested by linear least-squares regression analysis. Fisher’s exact test was used to 
compare growing and non-growing xenografted tumours in relation to VD and LI. 
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The statistical analyses were done on a Macintosh computer using Statistica 4.0 
software. 
 
 
Results 
 
Patients  
Of the 28 patients undergoing surgery, 1 patient was diagnozed with two different 
primary tumours (laryngeal and oral cavity) which were both analyzed. Thus, 29 
resection specimen were collected with tumours originating from larynx (13), 
hypopharynx (5), oral cavity (7), oropharynx (3) and nasal cavity (1). In six cases 
the specimens were derived from a local recurrence after previous radiotherapy. 
Of the 21 patients from whom only biopsies were obtained, 1 patient presented 
with two synchronous primaries (oropharynx and hypopharynx). Tumour sites 
from which biopsies were collected were: larynx (9), hypopharynx (10) and 
oropharynx (3). In one case the biopsy material was insufficient for xenografting. 
Thus, we obtained tumour samples of 51 head and neck squamous cell 
carcinomas, of which 50 were transplanted in nude mice, which were the subject 
of the study. One tumour was well differentiated, 3 tumours were well to 
moderately differentiated, 30 were moderately differentiated, and 16 were poorly 
differentiated.  
 
Proliferation 
A strong fluorescent green staining of Ki-67 positive nuclei was seen with little 
background staining (Figure 1). The Ki-67 LI varied from 0.01 to 0.32, with a 
median of 0.07 (Figure 2). There was no correlation between the LI and the 
differentiation grade or the primary tumour site. The tumours were classified into 
four categories according to their proliferation patterns as described by Bennett et 
al.7 Examples are shown in figure 3.  
The proliferation pattern was classified as marginal in 6 tumours, intermediate in 
10, random in 21 and mixed in 12. One tumour contained only few proliferating 
nuclei and could not be classified. The tumours in the intermediate category had a 
higher mean overall LI compared to the tumours in the other categories: 0.15 (SD 
0.11) vs. 0.08 (SD 0.07) (t-test: p = 0.01). There was no correlation between the 
different proliferation patterns and the pathological grading of the tumours.  
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Figure 1. Fluorescence microscopic image of a xenografted tumour section (200x 
magnification) after staining for proliferation with Ki-67 (yellow) and vessels with 9F1 
(red). The proliferation pattern is typical for the intermediate classification showing 
multiple layers of proliferating nuclei close to the vessels. 
 
 
Figure 2. Cumulative plot of labelling indices of 50 tumours showing different proliferation 
patterns. 
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Figure 3. Composite binary images of four different patterns of proliferation in primary 
human tumours; marginal (SccNij30), intermediate (SccNij37), random (SccNij13) and 
mixed (SccNij43). Ki-67 stained green, vessels (Pal-E) stained red. Proliferating cells in 
close proximity to vessels produce a yellow color. 
 
 
Figure 4 shows the distribution of the proliferative activity as a function of distance 
from the nearest vessel. The tumours are grouped according to their proliferation 
pattern and the figure shows median values of the Ki-67 labelling index in distinct 
vascular zones (0-15 µm, 15-30 µm, 30-70 µm and > 70 µm) for the four groups. 
The tumours with marginal proliferation patterns demonstrated proliferative activity 
almost exclusively within a 1-2 cell layer thick zone directly adjacent to vessels. 
The intermediate type tumours had even more active proliferation in this first zone 
but there was also activity in the more distant zones. The tumours with random 
proliferation patterns showed a more homogeneous distribution of proliferating 
cells although there was still a gradient in relation to the vasculature. The mixed 
type showed histologic features of the three other types, but in quantitative aspect 
is most similar to the random type. 
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Figure 4. Median labelling indices at increasing distance from the vessels. Tumours are 
categorized into four groups according to proliferation patterns. 
 
 
Figure 5. Labelling index vs. vascular density in 50 different human tumours. Circles 
represent tumours not growing in nude mice, squares represent tumours growing in nude 
mice. Median of LI and VD is indicated by horizontal and vertical lines. Regression line is 
shown (r = 0.58, p < 0.0001). 
 
 
Vasculature 
The vessels showed a bright red stain without any background staining (Figure 1). 
The VD varied from 41 mm-2 to 305 mm-2 with a median of 106 mm-2 (Figure 5). 
The relative vascular volume varied from 0.6 to 8.4%, with a median of 2.2%. No 
correlation was found between the vascular parameters and differentiation grade 
or primary tumour site. There was a weak (r = 0.58) but highly significant (p < 
0.0001) correlation between VD and LI (Figure 5). The tumours with marginal and 
intermediate proliferation patterns had a higher mean VD (144 mm-2, SD 74) than 
the other categories (116 mm-2, SD 63) but the difference was not statistically 
significant (p = 0.17). 
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Figure 6. Labelling indices at increasing distance from vessels comparing human tumours 
and corresponding xenografts. Panel A shows 5 pairs demonstrating good resemblance 
both visually and quantitatively. Panel B shows 2 tumours with good resemblance visually 
but not quantitatively. Panel C shows 3 tumours with no resemblance visually nor 
quantitatively. 
 
 
Xenografted tumours 
Of the 50 transplanted tumours, 33 (66%) demonstrated growth as a xenograft in 
at least the first and subsequent passage. Figure 5 shows that tumours are more 
likely to grow as a xenograft when they have either a LI which is higher than the 
median (0.07) (Fisher exact: p = 0.04), or a VD higher than the median (106 mm-2) 
(Fisher exact: p = 0.008). When tumours with a LI greater than median and a VD 
greater than median are compared with tumours having both parameters below 
the median there is a highly significant difference (Fisher exact: p = 0.001) in the 
probability that tumours will grow in mice (82% vs. 35%). 
Early passages of 10 xenografted tumours were stained for vessels and 
proliferation and were compared with the resected tumour tissue from which they 
originated. In seven tumours there was a good resemblance of the visually 
assessed proliferation staining pattern between the xenograft and the original 
human tumour. In five of these seven tumour sets the correspondence of the 
visually assessed proliferation patterns was supported by the quantitative analysis 
(Figure 6A). In two of the seven tumour sets the quantitative analysis did not 
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support the visual correlation (Figure 6B). Three of the xenografted tumours did 
not show any resemblance with the original human material, nor by visual 
comparison or by quantitative analysis (Figure 6C).  
 
 
Discussion 
 
The use of fluorescence immunohistochemistry together with computerized image 
analysis to quantify multiple parameters in one tumour section was earlier 
described by our group.9-11 The quantification of proliferation markers by this 
method has been validated.10 There was a good correlation between the LI based 
on computerized surface analysis and the manual counting technique and flow 
cytometry. The advantage of this method over flow cytometry is that the tissue 
architecture is preserved. This enabled us to visualize and quantify architectural 
patterns of proliferation, in close relation to other structures such as vasculature. 
The VD observed in this material (median 106 mm-2) is considerably higher than 
reported in a previous paper involving a comparable group of patients (median 42 
mm-2) .11 This can be explained by different magnification factors used, 200x and 
100x respectively. We could confirm this by scanning a number of sections 
repeated at both magnification factors. At the larger magnification many small 
vessels were identified which remained undetected with the 100x scan. Also when 
VD was determined in hot spot areas, Aebersold et al.12 found higher values of 54 
– 282 vessels per optical field (median 104) in squamous cell carcinomas of the 
oropharynx. These differences show the dependence of vascular parameters on 
the methods used for vessel counting as we discussed in our previous paper.11 
 
There are many studies on the prognostic relevance of proliferation markers in 
human tumours, including carcinomas of the head and neck area.1-5,13-15 We used 
the endogenous marker Ki-67, a nuclear antigen that is expressed in all phases of 
the cell cycle except G0.16 Other commonly used proliferation markers include 
PCNA, the cyclins and the thymidine analogues BrdUrd and IdUrd. Because of the 
different expression profiles of these markers and differences in methods for 
analysis, direct comparison between studies is difficult. Nevertheless, when LI of 
these various markers is related with treatment outcome of head and neck 
cancers, conflicting results are reported. 
 
There is increasing recognition that a combination of factors can be responsible 
for treatment failure. It is also becoming clear that radiation response cannot be 
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accurately predicted by the value of a single parameter such as LI or potential 
doubling time. It was suggested that the predictive potential might be increased 
when cell kinetic parameters are studied in relation to the microenvironment and 
combined with other biological parameters.5,17 Wilson et al.6 studied BrdUrd 
labelled tumour biopsies from 115 head and neck cancer patients by flow 
cytometry and immunohistochemistry. In a multivariate analysis the proliferation 
pattern appeared to be the predominant predictor for outcome after accelerated 
radiotherapy. In the present study we were able to reproduce the proliferation 
patterns described by Wilson et al.6 (Figure 3). In addition we could relate these 
patterns to the vascular architecture of tumours and quantify them by automated 
image analysis. When ranking the proliferation patterns by local control rates, 
Wilson et al.6 found the best local control for tumours with proliferation patterns of 
the marginal type while outcome was progressively worse for the intermediate, 
mixed and random patterns. The authors gave some suggestions to explain this, 
including possible differences in proliferative organization, growth fraction, cell 
cycle time and cell loss rate. An alternative explanation comes from our 
quantitative analysis of the patterns in relation to the vasculature. Figure 4 shows 
that, in the same order from the marginal to the random type, there is an increase 
in the relative number of proliferating tumour cells at distances greater than 70 µm 
from vessels. It is likely that at such distances from vessels oxygenation is poor 
and at least conditions of intermediate hypoxia can be expected. This suggests a 
viable, actively proliferating and relatively hypoxic cell population which may well 
be the resistant subpopulation of the tumour and which apparently is more 
prominent in some tumours than in others. This is only a hypothetical explanation 
but it clearly illustrates the importance of multiparameter analysis to better 
understand tumour biology and therapy resistance mechanisms. This may 
ultimately result in better selection for new treatments, based on architectural 
characteristics. We are currently expanding our technique of computerized 
multiparameter analysis by introducing both exogenous and endogenous markers 
of hypoxia and analyzing these in conjunction with vascularity and proliferation 
patterns. 
 
Since the discovery of the nude mouse mutant by Flanagan18, various human 
tumour lines were xenografted in these athymic nude mice. These tumours are 
widely used as a model to study human tumour biology and to test cytotoxic drugs 
and radiation treatments. Nearly all tumour types have been xenografted with 
varying degrees of success. Take rates partly depend on the histological type and 
site of the primary tumour. Different success rates (26% - 77%) were reported for 
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squamous cell carcinomas of the head and neck.19-21 In the present study 66% of 
the transplanted tumours demonstrated growth in at least the first two passages. 
An important finding from this study was the dependence of take rate on LI and 
VD. Tumours with a high LI or a high VD, or both, had a significantly higher 
probability of growth compared to tumours with both low LI and VD, which has not 
been reported in the literature so far. It has been reported though that the 
macroscopic growth curve of first passage xenografts significantly predicts the 
chances of establishment of a xeno-transplantation line after serial 
subpassagings.22 Thus, clearly, selection of model systems occurs favoring well 
vascularized and actively proliferating tumours. 
Another observation concerned the retention of proliferation characteristics after 
xeno-transplantation. Of the 10 xenografted tumours, 5 demonstrated good 
resemblance with the proliferation pattern of the original tumour both by visual and 
quantitative computerized assessment. We are currently examining whether other 
microenvironmental characteristics such as patterns of hypoxia are retained as 
well both in early and in later passages. It has been demonstrated that human 
malignant tumours can retain the cytological and histological appearance of the 
inoculated human material after long-term serial transplantation over many 
years.23 Half of the transplanted tumours in our material did retain the 
characteristics of the primary tumours, expressing similar patterns of vascularity 
and proliferation. We will use these tumour lines to study the interrelationships of 
the microenvironmental parameters, including oxygenation, in greater detail. 
Furthermore, they can be used to test various treatment modifications comparing 
the responses of tumours with different microenvironmental characteristics. 
 
In conclusion, the computerized simultaneous analysis of multiple micro-
environmental parameters allows objective and quantitative categorization of 
tumours and can improve our understanding of treatment resistance mechanisms. 
Tumour lines derived from xenotransplantation can be used to further explore 
these mechanisms and test subsequent treatment modifications. 
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Abstract 
 
Purpose 
Two mechanisms of radiotherapy resistance of major importance in head and 
neck cancer are tumour cell repopulation and hypoxia. Hypoxic tumour cells that 
retain their clonogenic potential can survive radiation treatment and lead to local 
recurrences. The aim of this study was to quantify this cellular population in a 
cohort of human head and neck carcinomas and to investigate the prognostic 
significance. 
 
Materials and Methods 
The proliferation marker iododeoxyuridine (IdUrd) and the hypoxia marker 
pimonidazole were administered intravenously prior to biopsy taking in patients 
with stage II-IV squamous cell carcinoma of the head and neck. Triple 
immunohistochemical staining of blood vessels, IdUrd and pimonidazole was 
performed and co-localization of IdUrd and pimonidazole was quantitatively 
assessed by computerized image analysis. The results were related with 
treatment outcome. 
 
Results 
Thirty-nine biopsies were analyzed. Tumours exhibited different patterns of 
proliferation and hypoxia but generally the IdUrd signal was found in proximity to 
blood vessels whereas pimonidazole binding was predominantly at a distance 
from vessels. Overall, no correlations were found between proliferative activity 
and oxygenation status. The fraction of IdUrd-labelled cells positive for 
pimonidazole ranged from 0% to 16.7% with a mean of 2.4% indicating that 
proliferative activity was low in hypoxic areas and occurring mainly in the well-
oxygenated tumour compartments. IdUrd positive cells in hypoxic areas made up 
only 0.09% of the total viable tumour cell mass. There were no associations 
between the magnitude of this cell population and local tumour control or survival. 
 
Conclusions 
Co-localization between proliferating cells and hypoxia in head and neck 
carcinomas was quantified using an immunohistochemical triple staining 
technique combined with a computerized simultaneous analysis of multiple 
parameters. The proportion of cells proliferating under hypoxic conditions was 
small and no correlation with treatment outcome could be found.  
 
Chapter 6 
 
100 
 
Introduction 
 
Radiotherapy is one of the prime treatment modalities in the management of 
squamous cell carcinoma of the head and neck area. Early stages are often 
treated with radiotherapy alone whereas combinations with surgery or 
chemotherapy are generally used for the more advanced cases. Clinically relevant 
factors determining the response of squamous cell carcinomas to radiation 
treatment include tumour cell repopulation and hypoxia.1-3 
The concept of accelerated fractionation is based on the assumption that a 
reduction of the overall treatment time will restrict the opportunity for repopulation 
by clonogenic tumour cells. Clinical studies have proven the benefit of accelerated 
radiotherapy but at the cost of increased toxicity.4,5 Selection of patients that are 
most likely to benefit from accelerated fractionation based on reliable predictive 
assays is therefore desirable. However, the prognostic and predictive value of 
assays that measure the proliferative activity of the tumour prior to the start of the 
treatment remains controversial.6-12 Different markers have been used for 
assessment of proliferation. These include endogenous markers such as Ki-67, 
proliferating nuclear antigen (PCNA) and members of the cyclin group, or the 
intravenous administration of the thymidine analogues bromodeoxyuridine 
(BrdUrd) and iododeoxyuridine (IdUrd).7,10 The latter have a short half-life and are 
rapidly incorporated in the DNA of S-phase cells. The parameter that is mostly 
used to quantify these markers is the proportion of tumour cells identified as 
positive for a certain marker, the labelling index (LI). Knowledge of the time 
elapsed between administration of the thymidine analogues and biopsy taking and 
analysis by flow cytometry can also provide information on S-phase time (Ts) and 
potential doubling time (Tpot). However, neither of these parameters have 
consistently shown strong associations with treatment outcome.7,8,12 
Methods that measure tumour oxygenation have shown to be more promising as 
prognostic indicators of treatment outcome. Studies using oxygen microelectrodes 
consistently show significant correlations between low tumour pO2 and poor 
response to radiation treatment.13,14 A limitation is the invasive nature of the 
procedure and their use is restricted to accessible tumours. Endogenous hypoxia-
related markers that are detectable by immunohistochemistry offer an attractive 
alternative because they require no additional intervention beyond the initial pre-
treatment biopsy and may be very suitable for widespread clinical use. Examples 
are HIF-1α, CA-IX and the glucose transporters –1 and –3. Expression of these 
markers has been associated with poor outcome although the data are not 
unequivocal.15-22 Also, there are reservations as to whether they are very robust 
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markers of hypoxia because only weak correlations are found with microelectrode 
readings and nitroimidazole-marker binding.22-24 Clinically relevant exogenous 
markers are the 2-nitroimidazoles pimonidazole hydrochloride and EF-5.22,25.  
In a previous study we demonstrated a significant association between the 
pimonidazole binding assay and loco-regional control and disease-free survival in 
patients with head and neck carcinomas.22 A disadvantage of the nitroimidazole 
markers is that they require intravenous injection before biopsy taking. 
Clinical studies that have used measurements of proliferation and hypoxia in a 
combined assay are sparse. Co-registration of hypoxia and proliferative activity 
may identify an important cellular subpopulation in the tumour that may be 
responsible for treatment resistance and tumour progression. In the current study 
we have used exogenous markers of hypoxia (pimonidazole) and proliferation 
(IdUrd) to investigate the magnitude of this subpopulation in a cohort of patients 
with squamous cell carcinomas of the head and neck. 
 
 
Materials and methods 
 
Patients 
Patients with a primary stage III or IV squamous cell carcinoma of the oral cavity, 
oropharynx or larynx, or a stage II-IV carcinoma of the hypopharynx were entered 
in this study. These were patients that were also potential candidates for a phase 
II trial combining accelerated radiotherapy with carbogen breathing and 
nicotinamide (ARCON).26 The hyperoxic gas carbogen (95-98% O2 + 2-5% CO2) 
and the vasoactive agent nicotinamide are added to counteract diffusion-limited 
and perfusion-limited hypoxia, respectively. Other inclusion criteria were: age over 
18 years, WHO performance status of 0-2, no severe heart or lung disease, no 
severe liver or kidney dysfunction, no severe stridor, no distant metastases, no 
concurrent treatment for other malignant disease outside the upper aerodigestive 
tract, and written informed consent. Approval was obtained from the Institutional 
Review Board of the Radboud University Medical Centre Nijmegen. 
Approximately 2 h before biopsies were taken, the patients received a 20 min. i.v. 
infusion of 500 mg/m2 of the hypoxia marker pimonidazole ((1-((2-hydroxy-3-
piperidinyl)propyl)-2-nitroimidazole hydrochloride, Hypoxyprobe-1; Natural 
Pharmacia International, Belmont, MA) dissolved in 100 ml NaCl 0.9%. 
Pimonidazole is a bio reductive chemical probe with an immunorecognizable side 
chain. Necrotic areas are not stained by pimonidazole because the probe binds 
only in viable cells as a result of hypoxia-dependent bio reduction by cellular 
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nitroreductases. The S-phase marker 2’-deoxy-5-iodouridine (Iododeoxy-
uridine/IdUrd; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland) 
was injected i.v. in 5 min in a dose of 200mg, 20 min before biopsy. IdUrd is a 
thymidine analogue with a short half-life and is rapidly incorporated into the DNA 
of S-phase cells. Under general anaesthesia, biopsies were taken for routine 
diagnostic purposes and additional biopsies were collected for hypoxia and 
proliferation marker analysis. The latter were snap frozen and stored in liquid 
nitrogen until immunohistochemical processing. The diagnostic workup further 
included physical examination, chest X-ray, CT-scan and/or MRI-scan of the head 
and neck area. After completion of the diagnostic workup, the patients were 
treated with ARCON. Patients that were not eligible or refused ARCON were 
treated with radiotherapy alone, surgery or a combined modality. 
 
Immunohistochemistry 
From the biopsy material, sections of 5 μm were cut and mounted on poly-l-lysine 
coated slides and stored at -80oC. Prior to staining the sections were fixed in 
acetone of 4oC for 10 min and rehydrated in phosphate buffered saline (PBS) 
twice for 2 min. Between all consecutive steps of the staining procedure, sections 
were rinsed in PBS three times for 5 min. DNA was denaturated during 10 min 
with 2N HCL followed by 10 min in 0.1 M Borax to neutralize the pH. Then during 
30 min a pooled incubation was done at 37 oC with mouse-anti-PAL-E 
(Department of Pathology, Radboud University Medical Centre Nijmegen, The 
Netherlands) 1:6 and with rabbit-anti-pimonidazole polyclonal rabbit antibody (J.A. 
Raleigh, Department of Radiation Oncology and Toxicology, University of North 
Carolina, Chapel Hill, North Carolina) 1: 400 in polyclonal liquid diluent (PLD, DPC 
Breda Diagnostic Products, Breda, The Netherlands). The monoclonal antibody 
PAL-E is a marker for human endothelium especially useful in frozen tissue 
sections.27 This was followed by a second pooled incubation with goat-anti-mouse 
(Fab)Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) 1:100 
and donkey-anti-rabbit-Alexa488 (Molecular Probes, Leiden, The Netherlands) 
1:400 in PLD during 60 min at 37 oC. Next the sections were incubated with 
donkey-anti-goat (Fab)2 tetra-methyl rhodamine isothiocyanate (TRITC, Jackson 
ImmunoResearch Laboratories) 1:200 during 45 min at 37 oC. Then the sections 
were incubated overnight with mouse-anti-IdUrd (Caltag laboratories, Burlingame, 
CA, USA) 1:1000 in monoclonal liquid diluent (MLD, Euro-DPC, Breda, The 
Netherlands) at 4 oC. The next morning the sections were incubated during 30 min 
in donkey-anti-mouse BIOTIN (Jackson ImmunoResearch Laboratories) 1:400 in 
PLD at 37 oC, followed by an incubation with STREP-ALEXA350 (Molecular 
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Probes, Leiden, The Netherlands) 1:200 in PLD during 30 min at 37 oC. After the 
staining procedure, the sections were mounted in fluorostab (ICN 
Pharmaceuticals, Zoetermeer, The Netherlands). 
After image acquisition of the IdUrd, pimonidazole and vessels signals (see 
below), all nuclei were stained with Fast Blue (Sigma-Aldrich Chemie BV, 
Zwijndrecht, The Netherlands) 1:1000 in PBS during 5 min at room temperature. 
Slides were then rinsed and mounted in PBS for quantitative imaging of all nuclei. 
 
Image acquisition 
The sections were scanned by a computerized image processing system using a 
high-resolution intensified solid-state camera on a fluorescence microscope 
(Axioskop, Zeiss, Göttingen, Germany).28 Each tumour section was scanned four 
times at 200x magnification; starting with the IdUrd staining (blue) followed by the 
pimonidazole signal (green), next the vessels (red) and finally the fast blue signal 
for the nuclei (blue). For the IdUrd signal (Alexa350) and all nuclei (Fast Blue) 
(blue signals, 365 nm excitation) a 420 nm emission filter was used. For the 
hypoxia signal (Alexa488, green, 450-490 nm excitation) a 520 nm emission filter 
was used. For the vessels (TRITC, red signal, 510-560 nm excitation) a 590 nm 
emission filter was used.  
Thresholds were interactively set above the background staining resulting in a 
composite binary image for each individual marker. After completion of the 
scanning procedure the four composite images showing IdUrd, pimonidazole, 
PAL-E and Fast-Blue were superimposed as previously described by Rijken et 
al.28 The scanning procedure was followed by a delineation of the tumour area 
excluding necrosis, artefacts, and non-tumour tissue. This delineation was done 
with use of a haematoxylin-eosin staining of a consecutive tumour section and 
was supervised by a pathologist. 
 
Image analysis 
Computerized image analysis was performed for the entire delineated tumour 
section, but also for predefined areas within certain distances from the vessels. 
The hypoxic fraction (HF pimo) was defined as the pimonidazole positive surface 
divided by the total tumour surface. The vascular density (VD) was defined as the 
number of vascular structures per mm2 of tumour surface. The labelling index 
(IdUrd LI) was determined as the area of IdUrd positively stained nuclei relative to 
the total area of nuclei (Fast Blue). In order to quantitate the distribution of hypoxia 
and proliferation in relation to the vasculature, zones were chosen arbitrarily at 
increasing distance from the surface of the nearest vessel (0-50 µm, 50-100 µm, 
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100-150 µm, 150-200 µm, 200-250 µm, >250 µm). Both IdUrd LI and HF pimo 
were also calculated within these vascular zones. The labelling index in hypoxia 
(IdUrd LIH) was defined as the surface positive for both IdUrd and pimonidazole 
divided by the total nuclear surface (Fast Blue). The fraction of IdUrd-labelled cells 
positive for pimonidazole (FId[pimo]) was defined as the area that stained positive 
for both pimonidazole and IdUrd divided by the total IdUrd-positive area. 
 
Statistics 
The statistical analyses were done with the SPSS 12.0.1 software package. 
Correlations between the biological parameters (HF pimo, IdUrd LI, IdUrd LIH, 
FId[pimo], VD) were assessed using the two-tailed Spearman test. For differences 
in biological parameters in relation to categorical tumour characteristics (site, 
stage, histopathological grade) the Kruskal Wallis test was used. Associations 
between the proliferation parameters and treatment outcome were examined by 
Cox regression analysis. 
 
 
Results 
 
Patients and treatment 
In the period from May 1998 to February 2001, 55 patients were injected with 
pimonidazole and IdUrd before biopsy taking. Sixteen biopsies were excluded 
from further analysis, 6 because they contained no or only very little invasive 
carcinoma, 7 because of poor quality due to mechanical damage during the 
biopsy procedure or poor staining quality and 3 because the histological diagnosis 
was not squamous cell carcinoma.  
There were 32 men and 7 women with age ranging from 40 to 85 years and a 
median of 60 years. The tumour characteristics and treatment are summarized in 
Table 1. None of the patients reported any adverse reaction after either 
pimonidazole or IdUrd administration. The duration of follow-up for surviving 
patients ranged from 42 to 84 months with a median of 73 months. 
 
Staining patterns 
The triple staining for vessels, pimonidazole and IdUrd produced bright 
fluorescent signals with very little background except in areas of necrosis and 
occasionally in the stromal components of the tumour (Figure 1). The 
pimonidazole staining was cytoplasmatic whereas IdUrd was confined to the 
nuclei. Generally, the IdUrd signal was mostly found in proximity to the blood 
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vessels but with variations between tumours, some with IdUrd labelling also at 
somewhat larger distance from vessels and others showing a more random 
pattern of proliferation. Pimonidazole binding was predominantly at a distance 
from vessels but also the hypoxia patterns differed between tumours. Some 
tumours are characterized by hypoxic zones of only few cell layers wide while 
others exhibit larger areas of hypoxia, often but not always with necrosis. Figure 2 
shows examples of different hypoxic and proliferation patterns. At visual 
assessment in most tumours no or only little overlap is observed between 
pimonidazole and IdUrd positivity. Only very few tumour biopsies clearly 
demonstrated significant amounts of IdUrd labelled nuclei in hypoxic areas. One 
such exceptional case is shown in Figure 3. 
 
 
Table 1. Characteristics of 39 squamous cell carcinomas analyzed (UICC 1997). 
 
 No. of patients 
Site 
larynx 
hypopharynx 
oropharynx 
oral cavity 
 
14 
11 
12 
2 
T-stage 
T1 
T2 
T3 
T4 
 
3 
8 
19 
9 
N-stage 
N0 
N1 
N2 
N3 
 
9 
9 
19 
2 
Differentiation grade 
well 
moderate 
poor 
 
1 
23 
15 
Treatment 
none 
ARCON 
radiotherapy alone 
surgery and radiotherapy 
chemotherapy and radiotherapy 
 
1 
19 
9 
6 
4 
Total 39 
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Figure 1. Fluorescent microscopic image of a hypopharynx carcinoma. Red: vessels; 
blue: IdUrd, nuclear stain; green: pimonidazole, cytoplasmic stain. 
 
 
Quantitative analysis 
Mean and median values and range for HF Pimo, IdUrd LI, IdUrd LIH, Fid [Pimo] 
and VD for the 39 tumour biopsies are given in Table 2. None of these parameters 
correlated with clinical tumour characteristics such as tumour site, T-stage, N-
stage or histopathological grade. There was a significant (p < 0.001) albeit weak (r 
= 0.57) negative correlation between VD and HF pimo (Figure 4). No correlations 
were found between HF pimo or VD and the proliferation parameters. FId[pimo] 
ranged from 0% to 16.7% with a mean of 2.4% indicating that proliferative activity 
was low in hypoxic areas and occurred mainly in the well-oxygenated tumour 
compartments. IdUrd positive cells in hypoxic areas made up 0.09% (mean) of the 
total viable tumour cell mass (IdUrd LIH). 
Relative to the vasculature, IdUrd and pimonidazole binding demonstrated 
opposite distribution patterns (Figure 5). The pimonidazole signal increased with 
increasing distance from vessels and was most pronounced at distances >150 
μm. IdUrd labelling decreased with distance from vessels although IdUrd labelled 
cells could still be found at distances >200 μm. However, also at these larger 
distances, IdUrd labelling was predominantly in well-oxygenated tumour areas.  
The fraction of dual labelled cells (IdUrd and pimonidazole) was slightly higher at 
greater distance but IdUrd LIH was well below 0.3% in all zones. 
Proliferation and hypoxia in head and neck cancer 
 
107 
 
No associations were found between the proliferation parameters (IdUrd LI, IdUrd 
LIH, FId[pimo]) and the treatment outcome endpoints local control, metastasis-free 
survival, disease-free survival and overall survival. 
 
Figure 2. Fluorescent microscopic images of six different head and neck carcinomas. 
Red: vessels; blue: IdUrd; green: pimonidazole. Note differences in patterns of hypoxia 
and proliferation and relation to blood vessels. 
7 N
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Figure 3. Fluorescent microscopic image of an oropharynx carcinoma. Red: vessels; blue: 
IdUrd; green: pimonidazole. IdUrd labelling in pimonidazole positive areas indicating 
active DNA-synthesis under hypoxic conditions. 
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Figure 4. Comparison between the fraction of the tumour area that binds pimonidazole 
(HF pimo) and vascular density (VD). The linear best fit is shown. 
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Figure 5. Relative hypoxic fraction (HF pimo), IdUrd labelling index (IdUrd LI) and area 
positive for both IdUrd and pimonidazole relative to total nuclear area (IdUrd LIH) as a 
function of distance to nearest vessels. Plots show average values of 39 tumours. 
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Discussion 
 
Malignant tumours tend to outgrow their vascular supply which leads to 
deficiencies in nutrients and oxygen. This is further enhanced by the chaotic 
organization of the vascular bed and inefficient transport function. As a 
consequence of these gradients of oxygen and nutrient availability, functionally 
and kinetically distinct populations of cells exist within a tumour. Heterogeneities 
in oxygenation and proliferative activity within a tumour reflect the dynamic nature 
of evolving and regressing subpopulations of cells. It is likely that certain specific 
cellular subpopulations will have a greater impact on tumour aggressiveness and 
treatment response than others.29 
Under sustained hypoxic conditions, tumour cells undergo a variety of biological 
responses including activation of several signalling pathways for the regulation of 
proliferation, angiogenesis and apoptosis.30,31 These adaptation mechanisms 
allow clonogenic tumour cells to survive and even proliferate under hypoxic 
conditions. Because hypoxia protects against radiation damage, these cells may 
survive radiation treatment and eventually lead to local recurrences. This study 
aimed to identify and quantify this cell population by using a triple marker assay 
for vasculature, hypoxia and proliferation. 
 
Patterns of hypoxia and proliferation 
Different patterns of hypoxia and proliferation are observed between tumours. A 
detailed description of these patterns was the subject of previous studies.32,33 
Characterization of these patterns was based on the spatial relationship with the 
vasculature. Some tumours exhibit large hypoxic areas with viable cells even at 
great distance from vessels (Figure 2C) whereas other tumours have hypoxic 
zones of only few cell layers wide with necrosis at slightly greater distance 
(Figures 2D,F). In addition, inter-tumour variations of distances from vessels to the 
“hypoxic front” were described.32 Similarly, different patterns of proliferation have 
been described varying from proliferation restricted to only few cell layers around 
vessels (Figures 2B,C) to random proliferative activity throughout the tumour 
(Figure 2E) and intermediate patterns (Figure 2F).33,34 These phenotypic patterns 
are the reflection of a dynamic system and depend on the metabolic and kinetic 
activity of the tumour cells. 
 
Tumour cell proliferation under hypoxic conditions 
Proliferative activity was mainly found in the well oxygenated compartments of the 
tumour and decreased in hypoxic areas more distant from the vasculature. This 
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does not necessarily mean that the overall proliferative activity is less in hypoxic 
tumours or vice versa. The current study showed a weak inverse correlation 
between hypoxic fraction (HF pimo) and VD indicating that there is a trend for 
poorly vascularized tumours to be more hypoxic. However, the overall proliferative 
activity was independent of tumour vascularity and overall oxygenation status. 
This is consistent with results from other studies that have used combined assays 
of proliferation and hypoxia.35-45  
 
A limitation when comparing these studies is that a variety of endogenous and 
exogenous markers were used for assessment of hypoxia and proliferation. Also 
the methods of analysis differed and included quantitative and semi-quantitative 
immunohistochemistry, flow cytometry and microelectrode pO2 measurements.  
Nevertheless, all studies except one small study in cervical carcinoma36 concur 
that there is no correlation between overall labelling index of the proliferation 
markers and measurements of hypoxia. However, only few studies used methods 
that enabled quantification of the cell population that is proliferating under hypoxic 
conditions.  
Two studies combined pO2 measurements by Eppendorf microelectrodes with 
flow cytometric analysis of BrdUrd or IdUrd labelling.39,40 This combination of 
methods does not allow a spatial correlation at the micro regional level and thus 
only global associations can be investigated.  
Two other studies analyzed immunolabelling with BrdUrd and nitroimidazole 
hypoxia markers by flow cytometry.41,42 Although with this approach information 
about the architectural context is lost, it did provide quantitative data on the 
amount of dual labelled cells. This was less than 2% of the total tumour cell 
population in the xenografted human cervix cancer line SiHa42 and 3.6% in the 
murine sarcoma SaF.41  There are three reports that used a combination of 
nitroimidazole markers (pimonidazole, EF-5 or CCI-103F) and endogenous 
proliferation markers (Ki-67, MIB-1, or PCNA), analyzed by semi-quantitative 
immunohistochemistry.35,36,43 A limitation of these studies was that the staining for 
the hypoxia markers and proliferation markers was done in separate albeit 
consecutive tissue sections. This allows a qualitatitive assessment of the 
histological patterns of hypoxia and proliferation and areas of co-localization of the 
markers but no quantitative analysis. Two of these investigations were on human 
tumours and reported that proliferation was only rarely seen in hypoxic tumour 
areas.35,36 The study by Zeman et al.43 in canine tumours described overlap to 
varying extents. Quantitation of dual labelling in immunohistochemical assays 
requires staining of both markers in the same tissue section and computerized 
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image analysis. To our knowledge only the current study and the studies by 
Hoogsteen et al.45 and by van Laarhoven et al.38 which are also from our group, 
used this technology. Our results have shown that in human head and neck 
cancers, active DNA synthesis as measured by IdUrd labelling occurs only 
sporadically under hypoxic conditions. The proportion of cells labelled by both 
IdUrd and pimonidazole (FId[pimo]) was 2.4% of all IdUrd positive cells and this was 
only 0.09% of the total tumour cell population. The same technique was applied to 
liver metastases of colorectal cancer and yielded a significantly higher FId[pimo] 
value of 7.9%.38 Also, the histological patterns of hypoxia and proliferation differed 
from those generally found in head and neck cancers. This clearly illustrates the 
differences in micro regional organization and kinetics between tumours of 
different origin and histology. 
 
Characteristics of markers 
A diversity of immunohistochemical markers with different characteristics is being 
used for assessment of hypoxia and proliferation. Intracellular binding of 
pimonidazole requires pO2 levels below 10 mmHg. The tumour-associated 
transmembrane enzyme carbonic anhydrase IX (CA-IX) is used as an 
endogenous hypoxia-related marker and is upregulated under pO2 levels from 20 
mmHg downward. Both hypoxia markers demonstrate concordant staining 
patterns but because expression of CA-IX occurs at higher pO2 levels than 
pimonidazole binding, CA-IX is often seen at shorter distance from blood vessels. 
This explains why we found a much higher proportion of IdUrd labelled cells in 
CA-IX positive tumour areas (11%) in a previous study, also in head and neck 
cancers45, as compared to the current study with pimonidazole (2.4%). 
Also the proliferation markers identify different cell populations. IdUrd and BrdUrd 
are thymidine analogues and label only those cells that are actively synthesizing 
DNA. Flow cytometric analysis of murine tumours revealed the presence of viable 
cells in necrotic tumour areas with S-phase DNA content but which had not 
incorporated BrdUrd.46 One of the reasons proposed for the existence of these 
cells has been that they were hypoxic and had arrested in S-phase. This suggests 
that thymidine analogues might underestimate the proportion of S-phase cells 
under hypoxic conditions. Experiments using two hypoxic markers (pimonidazole 
and CCI-103F) together with BrdUrd in a murine tumour model possibly indicate 
that this can be a temporary arrest.47 These experiments showed that at 28 h after 
a single dose of irradiation the overall cell density in the tumour had decreased to 
55% of the initial value and cells that were hypoxic (stained by first hypoxic 
marker) at the time of irradiation had been reoxygenated (not stained by second 
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hypoxic marker). A significant proportion of these previously hypoxic cells had 
resumed proliferation as identified by BrdUrd labelling. 
The endogenous proliferation markers are expressed during different phases of 
the cell cycle. Ki-67 is expressed in all cycling cells whereas PCNA shows highest 
expression during S-phase. PCNA however has a long half-life and can also be 
found in other phases and even in a certain fraction of non-cycling cells.48 Cyclins 
are regulatory subunits of kinases that regulate the cell cycle. The pattern of cyclin 
expression varies with a cell’s progression through the cell cycle, and this specific 
cyclin expression pattern defines the relative position of the cell within the cell 
cycle. 
It is thus clear that combinations of different hypoxic and proliferation markers will 
yield different results. The question that remains to be answered is which set of 
markers is best at identifying the subpopulation of cells that is clinically most 
relevant. 
 
Clinical relevance 
In the current study, the proportion of cells proliferating under hypoxic conditions 
was small, especially if this was related to the total viable tumour cell population 
(0.09%). This does not necessarily mean that it is also an insignificant population. 
If these cells are resistant to treatment and represent tumour aggressiveness they 
can be responsible for recurrence formation even if low in number. In the current 
material there was no association between the magnitude of this cell population 
and treatment outcome. However, a possible relation cannot be fully excluded 
because a limitation of this study is the relatively small sample size and the 
heterogeneity of the patient selection with regard to tumour site, stage and 
treatment. This precludes definite conclusions and verification of the results is 
needed in a larger patient cohort. Hoogsteen et al.45 observed that a high fraction 
of IdUrd-labelled cells positive for CA-IX was significantly correlated with worse 
disease-free survival rates in head and neck cancer. This suggests that the 
population of cells under intermediate hypoxic conditions may be more relevant 
for tumour behavior and treatment outcome than cells that are already severely 
hypoxic.  
 
 
Conclusion 
 
Using an immunohistochemical triple staining technique combined with a 
computerized simultaneous analysis of multiple parameters we were able to 
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assess co-localization between proliferating cells and hypoxia in head and neck 
carcinomas. In the current analysis, the proportion of proliferating cells in hypoxia 
was small and showed no relation with treatment outcome. Which combination of 
immunohistochemical markers is most useful to identify a clinically relevant cell 
population is currently under investigation in a larger patient material. 
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Abstract 
 
Purpose  
Hypoxia is detected in most solid tumours and is associated with malignant 
progression and adverse treatment outcome. However, the oxygenation status of 
malignant salivary gland tumours has not previously been studied. The aim of this 
study was to investigate the potential clinical relevance of hypoxia in this tumour 
type. 
 
Methods and materials 
Twelve patients planned for surgical resection of a salivary gland tumour were 
preoperatively injected with the hypoxia marker pimonidazole and the proliferation 
marker iododeoxyuridine (IdUrd). Tissue samples of the dissected tumour were 
immunohistochemically stained for blood vessels, pimonidazole, carbonic 
anhydrase-IX (CA-IX), the glucose transporters-1 and -3 (Glut-1, Glut-3), hypoxia-
inducible factor-1α (HIF-1α), IdUrd and for the epidermal growth factor receptor 
(EGFR). The tissue sections were quantitatively assessed by computerized image 
analysis. 
 
Results 
Tissue material from 8 patients was of sufficient quality for quantitative analysis. 
All tumours were negative for pimonidazole binding as well as for CA-IX, Glut-1, 
Glut-3 and HIF-1α. Vascular density was high with a median value of 285 mm-2 
(range 209 – 546 mm-2). IdUrd labelling index varied from <0.1% to 12.2% with a 
median of 2.2%. EGFR expression levels were mostly moderate to high. In half of 
the cases nuclear expression of EGFR was observed. 
 
Conclusion 
The absence of detectable pimonidazole binding as well as the lack of expression 
of hypoxia-associated proteins in all tumours indicates that malignant salivary 
gland tumours are generally well oxygenated. It is unlikely that hypoxia is a 
relevant factor for their clinical behavior and treatment responsiveness. 
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Introduction 
 
Hypoxia has been recognized as an important factor determining the 
aggressiveness of tumours and their responsiveness to treatment. Tumour 
hypoxia plays a role in promoting genetic instability, tumour cell invasiveness, 
metastasis and overall adverse clinical outcome.1,2 It may serve as a physiological 
selection pressure in tumours by promoting apoptosis in some cells but survival of 
those cells that have lost their apoptotic potential.3 The causes of hypoxia are 
multifactorial and include factors such as abnormal tumour vasculature, impaired 
blood perfusion, rate of oxygen consumption and anemia. Several techniques 
have become available for measurement of tumour oxygenation including invasive 
techniques like polarographic needle electrodes and minimal invasive methods 
such as exogenous hypoxia markers, endogenous molecular markers and 
functional imaging with positron emission tomography (PET) and dynamic 
contrast-enhanced magnetic resonance imaging.4 Clinically relevant hypoxia is 
detected in approximately 50% of all solid tumours irrespective of their size and 
histological features.5 It has been shown to decrease the therapeutic efficacy of 
radiation treatment, surgery and some forms of chemotherapy. 
One tumour type where hypoxia is strongly related to treatment responsiveness 
and outcome is squamous cell carcinoma of the head and neck. A number of 
clinical studies using various methods for assessment of hypoxia have 
demonstrated that hypoxia is a strong predictor for locoregional tumour control 
and survival.4,6 Treatment strategies that counteract hypoxic resistance have been 
most successful in head and neck squamous cell carcinomas.7 A less common 
category of head and neck cancers are the salivary gland tumours. These 
tumours are generally considered less sensitive to radiotherapy and chemo-
therapy. To what extent hypoxia plays a role in these tumours is unknown and has 
not previously been investigated in clinical studies. 
The aim of this study was to assess the oxygenation status of salivary gland 
tumours using the exogenous nitroimidazole marker pimonidazole and a panel of 
vascular and endogenous hypoxia-related immunohistochemical markers 
including carbonic anhydrase IX (CA-IX), the glucose transporters-1 and -3 (Glut-1 
and Glut-3) and hypoxia-inducible factor-1α (HIF-1α). An additional aim was to 
study the proliferative activity and epidermal growth factor receptor (EGFR) 
expression patterns in relation to the oxygenation status in these tumours. 
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Materials and methods 
 
Patients 
In the period from 1999 to 2004 tumour tissue was collected from 12 patients who 
underwent resection of a salivary gland carcinoma after administration of immuno-
histochemical markers for hypoxia and proliferation. The diagnostic workup 
included physical examination, biopsies, chest X-ray, CT-scan and/or MRI-scan of 
the head and neck area. 
Approximately 2 h before tumour resection the patients received a 20 min 
intravenous infusion of 500 mg/m2 of the hypoxia marker pimonidazole ((1-((2-
hydroxy-3-piperidinyl)propyl)-2-nitroimidazole hydrochloride, Hypoxyprobe-1; 
Natural Pharmacia International, Belmont, MA) dissolved in 100 ml NaCl 0.9%. 
Pimonidazole is a bioreductive chemical probe with an immunorecognizable side 
chain. Necrotic areas are not stained by pimonidazole because the probe binds 
only in viable cells as a result of hypoxia-dependent bioreduction by cellular 
nitroreductases. The S-phase marker 2’-deoxy-5-iodouridine (IdUrd; Centre 
Hospitalier Universitaire Vaudois, Lausanne, Switzerland) was injected 
intravenously in 5 min in a dose of 200 mg, 20 min before tumour resection. IdUrd 
is a thymidine analogue with a short half-life and is rapidly incorporated into the 
DNA of S-phase cells. The tumours were removed under general anesthesia and 
the specimen were transported to the pathology department were representative 
samples were taken. These tissue samples were snap frozen and stored in liquid 
nitrogen until immunohistochemical processing. 
Approval for this study was obtained from the Institutional Review Board of the 
Radboud University Medical Centre Nijmegen and all patients gave written 
informed consent. 
 
Immunohistochemistry 
Six staining procedures were performed with different marker combinations: 1) 
staining for hypoxia using antibodies against CA-IX and pimonidazole and for 
blood vessels using PAL-E, a monoclonal antibody for human endothelium 
especially useful in frozen tissue sections8; 2) staining for hypoxia by 
pimonidazole, proliferation by IdUrd and vasculature by PAL-E; 3) Glut-1 and 
vasculature (PAL-E); 4) Glut-3 and vasculature (PAL-E); 5) HIF-1α and 
vasculature (PAL-E); 6) staining combination for EGFR, pimonidazole and PAL-E. 
In all staining procedures negative and positive control sections were included. As 
positive controls, tumours were used with significant amounts of hypoxia that in 
previous studies have consistently demonstrated positivity for the respective 
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markers. These were included in each staining procedure to assure that the 
antibodies were working properly. Three different tumour tissues were used for 
this: biopsy material from a T3N2cM0 squamous cell carcinoma of the larynx, a 
resected liver metastasis from a colon carcinoma and the FaDu tumour line which 
is a human head and neck squamous cell carcinoma transplanted in nude mice. 
Timing and mode of administration of pimonidazole and IdUrd were similar as for 
the salivary gland tumours except for the administration of pimonidazole in the 
metastatic colon carcinoma patient which was done 12 h prior to surgery. The 
positive controls were not intended to be used for comparison of staining levels. 
From the tissue samples, sections of 5 μm were cut and mounted on poly-l-lysine 
coated slides and stored at -80oC. Prior to staining the sections were fixed in 
acetone of 4oC for 10 min and rehydrated in phosphate buffered saline (PBS) 
twice for 2 min. Between all consecutive steps of the staining procedure, sections 
were rinsed in PBS three times for 5 min. The staining combination of CA-IX, 
pimonidazole and vessels was performed on two different sections whereas the 
other stainings were done on a single section from each of the tumour samples. 
 
1) CA-IX, pimonidazole and vessels 
During 30 min an incubation was done at 37 oC with mouse-anti-CA-IX (E. Ooster-
wijk, Dept. of urology UMCN, Nijmegen, the Netherlands) 1:100 in PAD ((primary 
antibody diluent) Genetex, Cambridge, UK). A second incubation was done with 
goat-anti-mouse Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PA, 
USA) 1:600, 30 min at 37 oC, followed by donkey-anti-goat Cy3 (Jackson 
ImmunoResearch Laboratories) during 30 min at 37 oC. Next the sections were 
incubated with rabbit-anti-pimonidazole (J.A. Raleigh, Dept. of Radiation Oncology 
and Toxicology, University of North Carolina, Chapel Hill, North Carolina, USA) 
1:1000 in PAD during 30 min at 37 oC. Then the sections were incubated with 
donkey-anti-rabbit Alexa 488 (Molecular Probes, Leiden, The Netherlands) 1:400, 
30 min at 37 oC. Finally, the vessels were stained by PAL-E (Euro Diagnostica 
BV, Arnhem, the Netherlands) 1:10 during 30 min at 37 oC, followed by goat-anti-
mouse Cy5 (Jackson ImmunoResearch Laboratories) 1:200 in PBS during 60 min 
at 37 oC. After the staining procedure, the sections were mounted in fluorostab 
(Euro Diagnostica BV).  
 
2) Pimonidazole, IdUrd and vessels 
For this combination we started with the PAL-E staining as described above 
followed by the pimonidazole staining. Both the vascular signal and the hypoxia 
signal were then scanned under the microscope. Next, the sections were taken 
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back to the lab and DNA was denaturated during 10 min with 2N HCL, followed by 
10 min in 0.1 M Borax to neutralize the pH. Then the sections were incubated 
overnight with mouse-anti-IdUrd (Caltag laboratories, Burlingame, CA, USA) 
1:1000 in PAD at 4 oC, followed by goat-anti-mouse Cy3 (Jackson Immuno-
Research Laboratories) 1:600 in PBS for 30 min at 37oC. Finally, all nuclei were 
stained by Hoechst 33342 (Sigma, St. Louis, MO, USA) 0.5 µg/ml in PBS during 2 
min. 
 
3,4,5) Glut-1, Glut-3, HIF-1α and vessels 
These stainings were done at an overnight incubation with either rabbit-anti-Glut-1 
(Chemicon international, Temecula, CA, USA) 1:50 in PAD at 4 oC, rabbit-anti-
Glut-3 (Chemicon international) 1:100, or with rabbit-anti-HIF-1α (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) 1:50. The first step was followed by 30 min 
incubation at 37 oC with goat-anti-rabbit Cy3 (Jackson ImmunoResearch 
Laboratories) 1:600 in PBS and a third incubation of 30 min at 37 oC with donkey-
anti-goat Cy3 1:600. Finally, vasculature was stained by PAL-E, but this time the 
second antibody was chicken-anti-mouse-Alexa 647 (Molecular Probes) 1:100 in 
PBS for 30 min. 
 
6) EGFR, pimonidazole and vessels 
The final staining was done by an overnight incubation with goat-anti-EGFR 
(Santa Cruz Biotechnology) 1:50 in PAD at 4 oC, followed by donkey-anti-goat Cy3 
1:600 in PBS during 30 min at 37 oC. Pimonidazole was stained as previously 
described. For the vessels we used again Pal-E 1:10 followed by chicken-anti-
mouse-Alexa 647 1:100 in PBS for 30 min. 
 
Image acquisition 
The sections were scanned at 100x magnification using a high-resolution 
intensified solid-state camera on a fluorescence microscope (Axioskop, Zeiss, 
Göttingen, Germany). Each tumour section was scanned for each immuno-
histochemical signal separately yielding gray scale images of the corresponding 
signal. From these images, a composite binary image was created using an 
interactive threshold operation. Signal intensity levels were graphically displayed 
on a linear scale and the threshold was set at values twice the intensity level of 
the background where the signal started to show a steep increase. After 
completion of the scanning procedure the composite images showing the various 
combinations of markers were superimposed as previously described by Rijken et 
al.9 The scanning procedure was followed by a delineation of the tumour area 
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excluding necrosis, artifacts, and non-tumour tissue. This delineation was done 
with use of a haematoxylin-eosin staining of a consecutive tumour section and 
was supervised by a pathologist. 
 
Image analysis 
Computerized image analysis was performed for the entire delineated tumour 
section. The vascular density was defined as the number of vascular structures 
per mm2 of tumour surface. Hereto, the number of objects in the binary image 
containing the vascular structures was divided by the total tumour area (converted 
to mm2) in the binary image containing the delineated tumour area. The IdUrd 
labelling index was determined as the area of IdUrd positively stained nuclei 
relative to the total area of nuclei (Hoechst). To quantify EGFR expression we 
estimated the percentage of positively labelled cells relative to the total tumour 
area and categorized the tumours into 4 groups: ≤10%, 10 - 30%, 30 - 50% and 
≥50%. 
 
Statistics 
Correlations between marker expression were assessed by the Spearman test 
(two-tailed) using the SPSS 12.0.1 software package. 
 
 
Results 
 
Patients 
Tumour material was collected from 12 patients. Samples from two patients 
contained no viable tumour tissue and one tumour was too small to properly be 
examined. One tumour was contaminated by an infection and therefore the 
tumour was not easily recognizable. All patients underwent primary surgery and 
were not previously treated for this tumour. Except for one they all received 
postoperative radiotherapy. Patient and tumour characteristics are shown in table 
1. The mean follow-up was 27 months with a range from 6 to 60 months. 
 
Immunohistochemical stainings 
The positive controls stained strongly for pimonidazole, partially co-localizing with 
CA-IX (Figure 1). However, none of the salivary gland tumours showed detectable 
staining of pimonidazole or CA-IX (Figures 1 and 2). Because this was somewhat 
unexpected, the combined staining for CA-IX, pimonidazole and vessels was 
repeated on different tumour sections with the same result. Also, Glut-1, Glut-3, 
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and HIF-1α expression could not be demonstrated in any of the salivary gland 
tumours while the metastatic colon carcinoma showed strong positivity for both 
glucose transporters and the FaDu tumour line demonstrated extensive nuclear 
expression of HIF-1α. 
 
 
Table 1. Patient and tumour characteristics 
 
Number Age Localisation Histology Clinical follow up Duration of 
follow up 
1 66 oral cavity mucoepidermoid 
carcinoma, low 
grade 
alive, no 
evidence of 
disease 
60 months 
2 81 parotid gland oncocytic 
carcinoma 
dead, no 
evidence of 
disease 
6 months 
3 83 parotid gland adenocarcinoma died with local 
relapse 
9 months 
4 28 parotid gland oncocytic 
carcinoma 
alive with distant 
metastases 
40 months 
5 52 parotid gland adenosquamous 
carcinoma 
dead with distant 
metastases 
6 months 
6 72 parotid gland mucoepidermoid 
carcinoma, high 
grade 
dead with distant 
metastases 
32 months 
7 43 parotid gland adenoidcystic 
carcinoma 
alive, no 
evidence of 
disease 
42 months 
8 65 parotid gland acinic cell 
carcinoma 
alive, no 
evidence of 
disease 
24 months 
 
 
The IdUrd staining was bright and reproducible as shown in figures 1 and 2. The 
proliferative activity varied widely between the tumours with an IdUrd labelling 
index ranging from <0.1% to 12.2% with a median of 2.2% (Table 2). Whereas 
squamous cell carcinomas often show active proliferation in close proximity to the 
blood vessels, the salivary gland tumours mostly showed a more random pattern 
of proliferation. 
All salivary gland tumours exhibited a dense vascular network. Vascular densities 
ranged from 209 mm-2 to 546 mm-2 with a median value of 285 mm-2 (Table 2). In 
some of the tumours, areas with lower vascular density were observed which 
contained mainly stromal elements (Figure 1D-F). There were hardly any necrotic 
parts. 
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EGFR expression was found in all tumours but in only four this was a typical 
membranous staining pattern. The other tumours showed predominantly nuclear 
expression (Figure 3). In one tumour to a lesser extent both expression patterns 
were found. EGFR positivity varied from <10% of viable tumour area involved to 
>50% (Table 2). There was no correlation between IdUrd labelling index and 
EGFR expression (p = 0.32). 
 
 
Table 2. EGFR expression, vascular density and IdUrd labelling index. 
 
Number EGFR 
expression 
pattern 
EGFR 
relative area 
positive (%) 
Vascular density
(mm-2) 
IdUrd labelling 
index (%) 
1 membranous 30-50 283 2.1 
2 nuclear 10-30 298 5.9 
3 nuclear 30-50 275 12.2 
4 nuclear 30-50 546 0.1  
5 membranous <10 232 10.5  
6 nuclear and 
membranous 
30-50 308 --* 
7 membranous <10 209 2.2 
8 membranous >50 288 <0.1 
* No IdUrd administered 
 
Discussion 
 
Salivary gland tumours are generally considered to be of low radiosensitivity. 
However, the basis for this assumption goes back to few, mainly older studies.10 It 
has been suggested that hypoxia might be a causative factor related to this 
alleged radiotherapy resistance.11 In this context it is of interest to note that for 
inoperable, incompletely resected or recurrent salivary gland tumours, a 
significant advantage for radiotherapy with fast neutrons was recognized relative 
to conventional radiotherapy with high energy photons with 10-year locoregional 
control rates of 56% and 17%, respectively.12 Fast neutrons were the first of the 
non-conventional radiation qualities used in clinical radiation therapy. Neutrons 
are of high Linear Energy Transfer (LET) quality, characterized by dense energy 
deposits along the radiation track whereas photons (low LET) produce smaller 
and more variable energy deposits. High LET radiation is less dependent on 
tissue oxygenation and thus more effective in hypoxic tumours as compared to 
low LET photon irradiation. The success of neutrons in salivary gland tumours 
supported the suggestion of clinically relevant hypoxia in these tumours.13 With 
the re-introduction of high LET particle radiotherapy in several centers around the 
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world it is likely that the argument of hypoxia will be used again for selection of 
patients with salivary gland tumours. 
 
 
 
 
Figure 1. Microscopic images of salivary gland carcinoma (#5) (upper panels) and 
squamous cell carcinoma of the head and neck (lower panels). A and D: hematoxylin and 
eosin staining. B and E: immunofluorescent images showing blood vessels (blue), 
pimonidazole (green) and CA-IX (red). Co-localization of pimonidazole and CA-IX shows 
as yellow. Note absence of pimonidazole and CA-IX in salivary gland carcinoma but 
higher vascular density compared to squamous cell carcinoma. C and F: immuno-
fluorescent images showing blood vessels (blue), pimonidazole (green) and 
iododeoxyuridine (red). Active proliferation in both tumours. 
A B C
D E F
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Figure 2. Composite binary images of complete tumour samples showing blood vessels 
(blue), pimonidazole (green), iododeoxyuridine (red), A: salivary gland carcinoma (#5). B: 
head and neck squamous cell carcinoma. High vascular density and absence of 
detectable hypoxia in salivary gland tumour. Active proliferation in both tumours. Scale 
bars represent 1 mm. 
 
 
  
Figure 3. Immunofluorescent images of different salivary gland carcinomas showing blood 
vessels (blue) and EGFR (red). A: tumour #1 showing membranous EGFR expression 
pattern. B: tumour #4 showing nuclear EGFR expression. Scale bars represent 100 μm. 
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However, to our knowledge, the oxygenation status of human salivary gland 
tumours has not been previously investigated. The current study is the first to 
provide actual data on oxygenation status and fails to demonstrate any significant 
hypoxia in salivary gland tumours. The number of tumours examined in this study 
is relatively small but given the fact that none of them demonstrated detectable 
levels of pimonidazole binding, it is unlikely that hypoxia is a relevant factor in this 
tumour type. The pimonidazole binding assay is a robust and widely used method 
for assessment of tissue hypoxia.14 In a previous study we analyzed 43 head and 
neck squamous carcinomas all of which showed some degree of pimonidazole 
binding with hypoxic fractions varying from 0.3% to 17.2% and a mean of 6.0%.15 
High pimonidazole binding levels were associated with poor locoregional control 
and disease-free survival. It can be argued that the pimonidazole binding assay 
can yield false negative results if a tumour does not express sufficient levels of the 
nitroreductase enzymes that are required for binding of pimonidazole under 
hypoxic conditions. On the other hand, in all tumour types that have been 
investigated for hypoxia by this method thus far, pimonidazole binding was 
observed in a significant proportion of the tumours. This includes a wide range of 
histologies such as squamous cell carcinomas (head and neck, uterine cervix), 
adenocarcinomas (colorectal, breast, prostate), urothelial cell carcinomas 
(bladder), gliomas and sarcomas.16-19 This might indicate that nitroreductase 
deficiency, if it is a relevant limitation of the pimonidazole assay, is probably not so 
much linked to a specific histological tumour type. 
The observation that pimonidazole negativity is accompanied by absence of CA-
IX, glucose transporters and HIF-1α supports the conclusion that hypoxia is an 
uncommon phenomenon in salivary gland tumours. As a survival response to 
hypoxia, tumour cells up-regulate CA-IX and glucose transporters.20,21 The switch 
from oxidative phosphorylation to anaerobic glycolysis in hypoxic tumour cells is 
accompanied by an increase in glucose requirements and transport which is 
mediated by the glucose transporters. CA-IX protects cells from intracellular 
acidification, thereby producing an acidic extracellular environment which is 
known to be associated with tissue hypoxia.22 The glucose transporters and CA-IX 
are under transcriptional control of HIF-1α. It should be noted however, that they 
are not very specific markers of hypoxia because they also can be up-regulated 
by non-hypoxic stimuli. Also, tumours may lack the capacity for upregulation of 
these hypoxia-related proteins. 
In vitro studies using salivary gland carcinoma cell lines have demonstrated that 
incubation under hypoxic conditions enhances the expression of HIF-1α and 
VEGF in these cell lines.11,23 Consequently, it was suggested that hypoxia is a 
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driving force for angiogenesis and metastasis formation in salivary gland tumours. 
Our observations of absence of HIF-1α in clinical tumour material, however, 
dispute the role of hypoxia as an important factor in the malignant progression of 
these tumours. 
Salivary gland tumours are relatively rare and there exist many histological 
subtypes with different clinical behavior. Before strong and general conclusions 
can be drawn a larger series will need to be investigated. Nevertheless, the 
absence of detectable levels of both exogenous and endogenous hypoxia 
markers in all the tumours examined in the current study does not support the 
generic presence of hypoxia as observed in several other tumour types. 
One possible explanation for the good oxygenation status might be the relatively 
slow growth rate that is characteristic not only for the low grade tumours but also 
for some of the high grade types. Under these circumstances angiogenesis can 
keep up with tumour expansion and the tumour is less likely to outgrow its 
vasculature. This is consistent with our observation of a much higher vascular 
density in the salivary gland tumours (median 285 mm-2, range 209-546 mm-2) as 
compared to our measurements in squamous cell carcinomas (median 55 mm-2, 
range 19-89 mm-2).24 As a likely consequence, salivary gland tumours rarely 
exhibit necrosis. 
An additional aim of this study was to investigate the relation between the 
proliferative activity of tumour cells and their oxygenation status. In previous work 
we have demonstrated that in squamous cell carcinomas of the head and neck a 
critical subpopulation of cells exists with clonogenic capacity under conditions of 
intermediate hypoxia.25 These therapy resistant cells can be responsible for 
tumour regrowth and treatment failure. We questioned whether such a population 
of cells could be found in salivary gland tumours as well. Intermediate hypoxia is 
characterized by CA-IX positivity and pimonidazole negativity as pimonidazole 
binding occurs at pO2 levels below 10 mmHg26 whereas up-regulation of CA-IX 
may occur already at pO2 levels from 20 mmHg and downward.27 To identify 
proliferating cells we used the S-phase marker IdUrd. In addition we stained for 
EGFR because this membrane receptor has been linked to several critical 
components of mitogenic signalling pathways and has been demonstrated to be of 
prognostic significance in head and neck cancers.28 We found varying levels of 
IdUrd labelling between the tumours and mostly moderate to high EGFR 
expression in absence of detectable levels of hypoxia. An interesting observation 
was the nuclear expression of EGFR in half of the tumour samples. Larger studies 
confirm the high rate of EGFR expression in malignant salivary gland tumours but 
have not described this nuclear expression pattern.29,30 Nuclear EGFR is 
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associated with increased treatment resistance and poor prognosis in 
oropharyngeal squamous cell carcinoma and breast cancer.31,32 It has been 
demonstrated that nuclear EGFR may function as a transcription factor activating 
genes required for cell proliferation and as a regulator of proliferating cell nuclear 
antigen (PCNA), an essential protein for DNA replication and damage repair.33,34 
Furthermore, nuclear EGFR transport was linked with DNA-dependent protein 
kinase (DNA-PK) complex formation and activation, thus stimulating DNA damage 
repair after ionizing irradiation.35 These observations might open a new field of 
research into the radiosensitivity properties of salivary gland tumours. 
 
 
Conclusion 
 
This is the first report in the literature on the oxygenation status of human salivary 
gland tumours. Absence of detectable pimonidazole binding, a robust and widely 
used method for assessment of tissue hypoxia, indicates that these tumours are 
generally well oxygenated. This is supported by lack of expression of the hypoxia-
related proteins CA-IX, Glut-1, Glut-3 and HIF-1α. Given these observations, it is 
unlikely that hypoxia is a clinically relevant factor in the aggressive behaviour and 
treatment resistance of malignant salivary gland tumours. 
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The aim of this study was to visualize and quantify biologic tumour characteristics 
relevant for radiation therapy resistance in head and neck cancer. We performed 
immunohistochemical staining of multiple endogenous and exogenous markers in 
a same tissue section. Visualization of these marker with preservation of the 
tissue architecture has improved our understanding of some of the patho-
physiological aspects of the microenvironment of these tumours.1-3 
The method of computerized image analysis of immunohistochemical stainings 
provides an objective and quantitative assessment of marker expression and also 
allows quantitation of co-expression of multiple markers. This is an important step 
forward compared to the semiquantitative visual scoring that is most often used in 
this type of studies and which is subjective and prone to inter- and intra-observer 
variations. In addition, advanced quantitative analysis provides much more 
information than the mere expression level of markers. 
We correlated these characteristics with patient outcome after radiation with the 
aim to explore their predictive potential. Predictive assays need to be 
distinguished conceptually from “prognostic factors”. The latter have been 
determined empirically and although they can be powerful predictors of treatment 
outcome, they simply indicate favorable or unfavorable response but they offer no 
basis for selecting possibly superior alternative treatments. A predictive assay on 
the other hand is mechanistically based, thereby offering the possibility of rational 
early interventions to improve therapeutic outcome. We demonstrated proof of 
principle of this in a pilot series of head and neck cancer patients.  
 
Markers of hypoxia 
As markers of hypoxia we used the exogenous marker pimonidazole and various 
endogenous markers such as CA-IX, HIF-1, Glut-1 and Glut-3. These markers 
demonstrated different expression patterns and also different associations with 
outcome. There are several reasons for this. 
Pimonidazole hydrochloride was the only exogenous hypoxia marker used, it has 
a high water solubility and can be easily administered intravenously. It distributes 
rapidly into the tissues and the intracellular binding properties rise steeply at pO2 < 
10 mm Hg. The pimonidazole binding assay is a robust and widely used method 
for assessment of tissue hypoxia.4 These properties and the absence of any 
adverse effect make this agent attractive for clinical use.5-7 Pimonidazole binding 
was demonstrated in clinical tumours of various histologies such as squamous cell 
carcinomas (head and neck, uterine cervix), adenocarcinomas (colorectal, breast, 
prostate), urothelial cell carcinomas (bladder), gliomas and sarcomas.8-11 
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The intravenous administration, the inability to investigate archived material and 
the cost of exogenous hypoxia markers are, however, limiting factors for their 
widespread application in the clinic. Attractive alternatives are therefore hypoxia-
related proteins as potential endogenous markers. HIF-1 is the key regulator of 
oxygen homeostasis and in response to low oxygen conditions, it is known to 
transactivate more than 70 genes whose protein products function either to 
increase O2 availability or to mediate metabolic adaptation to O2 deprivation.12 
Some studies demonstrated strong induction of HIF-1α by hypoxia, but HIF-1α 
induction is also shown to be dependent on other microenvironmental conditions 
such as glucose availability.13,14 Studies using immunohistochemistry and flow 
cytometry to compare HIF-1α expression to pimonidazole binding in head and 
neck squamous cell carcinomas demonstrated no correlation between HIF-1α 
expression and pimonidazole positive cells.14,15  Given the association between 
HIF-1α expression and outcome, it is likely that HIF-1α indicates tumour 
aggressiveness.16,17 It is however debatable whether it is also a reliable marker of 
tumour hypoxia. 
Experiments with graded hypoxia in one cell line demonstrated CA-IX induction 
from pO2 levels of approximately 20 mmHg and downward.18 Relative to 
pimonidazole binding, CA-IX expression was often observed at shorter distances 
from the vessels suggesting that CA-IX upregulation occurs at pO2 levels higher 
than required for pimonidazole binding. This indicates that CA-IX expression 
identifies low tissue oxygenation levels as well as intermediate levels. 
Furthermore, the duration of hypoxia plays a role with the use of the various 
markers. The presence of pimonidazole for a period of 30 min is sufficient to stain 
all hypoxic areas19 whereas the upregulation of CA-IX requires at least several 
hours.20 CA-IX is involved in intra- and extracellular pH homeostasis of tumour 
cells and thus, changes in the acid/base balance may provide additional stimuli for 
CA-IX expression.21  
Also the glucose transporters are under transcriptional control of HIF-1. Their 
expression pattern is often described as “perinecrotic” indicating that they are 
associated with chronic hypoxia.22,23 However, expression of Glut-1 and Glut-3 not 
related to tissue hypoxia can also be observed as we demonstrated in Chapter 4. 
Up-regulation of glucose transporters is not specifically under hypoxic conditions 
and can also be the consequence of glucose starvation and reflecting the high, 
though inefficient, glucose metabolism in malignant tumours,  
Because they are not exclusively regulated by hypoxia, these endogenous 
proteins are better called “hypoxia-associated” markers. We and others found 
different associations between these hypoxia-associated proteins and treatment 
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outcome and most probably their potential usefulness will be as prognosticators of 
tumour aggressiveness and less as predictors for response to oxygenation 
modifying treatments such as ARCON.   
Clearly, pimonidazole is a more specific and robust marker of hypoxia and for that 
reason more likely to be an indicator of hypoxic radioresistance. This is supported 
by our observation that the pimonidazole assay was able to identify the patients 
that are most likely to profit from ARCON. If confirmed in a larger clinical study this 
would be an important step forward towards treatment customization.  
The presence of hypoxia has been demonstrated in a variety of tumour types and 
all the squamous cell head and neck carcinomas investigated in this study 
showed at least some degree of pimonidazole binding indicating hypoxia. 
Interestingly, no hypoxia could be demonstrated in a less frequent type of head 
and neck cancers, i.e. salivary gland tumours. This information may be of 
relevance for the selection of future treatment strategies for this entity. 
 
Vasculature 
With our automated image processing system we analyzed complete tissue 
sections and the average number of vascular structures was calculated per mm2 
tumour area. This is different from “hot spot counting” where vessel counting is 
restricted to selected areas of high vascularity yielding what is general referred to 
as “microvascular density” (MVD). Measures of vascular density have been 
suggested as surrogate markers for tumour blood flow and/or oxygenation. 
Obviously there are important limitations to this because the organisation of the 
tumour vasculature is usually chaotic and functionally deficient.24 This implicates 
that not all tumour blood vessels visualized by immunohistochemical endothelial 
markers are perfused. In addition, if the vessels are perfused oxygen exchange is 
not always optimal. This may explain why we found no correlations between the 
hypoxic fraction based on pimonidazole binding and vascular density (Chapter 3). 
Nevertheless we did find correlations with outcome and, as for hypoxic fraction, 
there was an indication that vascular density can predict response to ARCON. 
The underlying mechanism of this phenomenon remains to be elucidated. 
 
Proliferation 
Tumour cell proliferation is another important mechanism of radiotherapy 
resistance in head and neck cancer. Measurements of proliferative activity in 
tumours by single proliferation markers, endogenous (Ki-67, PCNA) or exogenous 
(iododeoxyuridine, bromodeoxyuridine), however, do not demonstrate consistent 
correlations with outcome.25 Also here it is important to notice that markers have 
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different characteristics. We used the exogenous marker Iododeoxyuridine and 
the endogenous marker Ki-67. Iododeoxyuridine is a thymidine analogue and 
label only those cells that are actively synthesizing DNA. Ki-67, a nuclear antigen 
is expressed in all phases of the cell cycle except Go.26 A study by Wilson et al. 
demonstrated that not so much the proliferation index but the proliferative 
organization might be relevant for tumour behaviour and response to treatment.27 
They found the best local tumour control with proliferation patterns of the marginal 
type (proliferation in close relation with the vessels) while the outcome was 
progressively worse for the intermediate, mixed and random patterns. They gave 
as explanation that this might be due to differences in growth fraction, cell cycle 
time and cell loss rate. We were able to categorize a series of 50 head and neck 
tumours before and after transplantation in nude mice according to these 
proliferation patterns. An important observation was that the probability of growth 
after xenotransplantation was higher for tumours with high proliferative activity and 
high vascularity. Half of the tumours retained their proliferation patterns after 
transplantation. This clearly demonstrates that selection occurs when human 
tumours are xenotransplanted for preclinical research. It is likely that further 
selection will occur with subsequent passages. This raises concerns about the 
widely used experimental tumour lines that are often cultured in labs over many 
years. It can be questioned to what extend they are still representative for the 
clinical situation. In addition, if only one or few tumour lines are used in preclinical 
research this may not represent the variety of tumour characteristics encountered 
in the clinic. These considerations are of particular importance in settings of 
translational research where results from preclinical research should be 
transportable to clinical studies.   
 
Co-registration of hypoxia and proliferative activity may identify an important 
subpopulation of tumour cells that is resistant to therapy while retaining 
clonogenic potential. These cells can escape cytotoxic treatment and give rise to 
tumour recurrence. In chapter 6 we therefore investigated the magnitude and 
clinical relevance of this population in a cohort of patients with head and neck 
carcinomas. Quantitative analysis of dual labelling by IdUrd and pimonidazole 
revealed that active DNA synthesis as measured by IdUrd labelling occurs only 
sporadically under hypoxic conditions. Also, no association was observed 
between the magnitude of this small cell population and outcome. However, 
Hoogsteen et al.28 found that when dual staining with CA-IX and IdUrd was 
performed a larger population of cells could be identified which did show a 
significant correlation with the disease-free survival rate. This indicates that 
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indeed a critical subpopulation of cells may exist under conditions of intermediate 
hypoxia. 
 
Future considerations 
We demonstrated that our system of multiparameter analysis of tumour 
microenvironmental characteristics has potential as a predictive tool for the 
selection of patients for customized treatment. This must now be confirmed in a 
larger prospective clinical study. Not only single marker expression should be 
subject of investigation but especially marker combinations to provide a better 
understanding of interactions between treatment resistance mechanisms. This 
work is now ongoing at the department of Radiotherapy of the Radboud University 
Nijmegen Medical Centre using biopsy material from larynx cancer patients that 
have been treated in a randomized trial comparing ARCON against radiotherapy 
alone. 
A limitation of this methodology is that it requires an advanced system for image 
processing and a certain level of expertise that is not available in all routine 
pathology labs. Another disadvantage is that only biopsies are examined, and not 
the complete tumour. Non-invasive techniques with repetitive capacity that image 
the whole tumour like PET scan or MRI are therefore very attractive. A limitation of 
these methods is that they are not able to show the relations between different 
biological features at the microregional level. Also, before they are introduced into 
clinical routine proper validation of these methods is required. In a collaboration 
between the departments of Radiotherapy and Nuclear Medicine preclinical and 
clinical studies are ongoing to validate PET tracers for hypoxia (18F-fluoro-
misonidazole) and proliferation (18F-fluorothymidine) against histopathology using 
the immunohistochemical markers pimonidazole and iododeoxyuridine.29-31 It can 
be expected that the role of these imaging techniques will increase in future 
clinical studies.  
Another field of research that is rapidly developing is gene expression profiling. 
This is another approach that may facilitate early detection of aggressive tumours 
and customization of therapeutic interventions.32,33 An important future direction of 
research will be to correlate gene expression patterns with the micro-
environmental phenotypic features of tumours. 
The more we learn about the diversity of tumours the more obvious it becomes 
that there is much to gain if we can categorize patients based on biological tumour 
characteristics to choose the appropriate treatment for them. Treatments for 
malignant diseases are continuously improving leading to higher cure rates and 
longer survival of cancer patients. However, these new approaches are often 
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accompanied by increased short- and long-term side effects. To provide the best 
attainable quality of life for individual patients and the cancer patient population as 
a whole, it is of increasing importance that tools be developed that allow a better 
selection of patients for these intensified treatments. 
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Summary 
 
Many efforts have been made to improve treatment outcome of patients with head 
and neck carcinomas. Important factors determining treatment response after 
radiation are hypoxia and proliferation.  
Chapter 1 is an introductory chapter and briefly describes the history of the 
oxygen effect and the pathophysiology of tumour hypoxia. Two different types of 
hypoxia (perfusion-limited and diffusion-limited) are recognized. Endogenous and 
exogenous immunohistochemical hypoxia markers are discussed as well as non-
invasive techniques to visualize and quantify hypoxia. Next, the relevance of 
tumour cell proliferation and immunohistochemical markers of proliferation are 
discussed. An outline of the thesis is provided, describing the general aims and 
outlines of the subsequent chapters. 
Chapter 2 describes our first experience with the hypoxia marker pimonidazole in 
human tumour material. Twenty-one head and neck cancer patients were injected 
with pimonidazole. Frozen sections of twenty-two biopsies were stained for 
vessels and hypoxia and subsequently scanned and analyzed. The hypoxic 
fractions varied from 0.02-0.29 and were independent from other patient and 
tumour characteristics. Three different hypoxia patterns were described. The first 
type contained large viable hypoxic areas at large (> 200 µm) distance from the 
vessels. The second category showed a band-like distribution of hypoxia at an 
intermediate distance 50-200 µm. The third category showed hypoxia within 50 
µm from the vessels, indicating acute hypoxia. We demonstrated the clinical 
feasibility of this quantitative method for multiparameter analysis of vascularity and 
hypoxia in head and neck tumours. 
In chapter 3 we analyzed forty-three tumour biopsies from patients with head and 
neck tumours. All patients were potential candidates for a phase II trial with 
accelerated radiotherapy combined with carbogen and nicotinamide (ARCON). 
Tissues were stained for blood vessels, pimonidazole and CA-IX. The distribution 
patterns of both hypoxia markers were similar, although the CA-IX signal was 
generally observed at shorter distance from the vessels. There was a weak but 
significant correlation between the relative tumour areas positive for pimonidazole 
binding and areas with CA-IX expression. The 2-year locoregional control rates 
were 48 versus 87% for tumours with high and low pimonidazole binding levels 
(p=0.01) and 48 and 88% for tumours with low and high vascular density (p=0.01). 
These associations disappeared in the subgroup of patients treated with ARCON. 
The level of CA-IX expression had no relationship with treatment outcome. We 
concluded that pimonidazole binding and vascular density are predictors of 
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treatment outcome in head and neck carcinomas. Pimonidazole and CA-IX 
demonstrate concordant staining patterns, however, CA-IX is less specific for 
hypoxia.  
Chapter 4 describes the prognostic value of different endogenous hypoxia-related 
markers CA-IX, Glut-1 and Glut-3 in patients treated with ARCON. We examined 
tumour biopsies of 58 patients with head and neck carcinomas treated with 
ARCON. All sections were stained for CA-IX, Glut-1 and Glut-3. CD-34 was used 
as an endothelial marker to assess microvascular density. Sections were scored 
for relative tumour area stained by the markers (CA-IX and Glut-3) and for the 
intensity of the staining (Glut-1 and Glut-3). Both CA-IX and Glut-3 were observed 
at some distance from vessels and adjacent to necrosis. Glut-1 staining was more 
diffuse. Patients with a high CA-IX positivity (>25% of tumour area) had a 
significantly better locoregional control (p=0.04) and freedom of distant 
metastases (p=0.02). High Glut-3 expression was associated with a better 
locoregional control (p=0.04). Higher Glut-1 intensity was associated with an 
increased rate of distant metastases (p=0.0005) and a worse overall survival 
(p=0.001). We concluded that the inconsistent associations with outcome of CA-IX 
and the glucose transporters indicates that different factors play a role in up-
regulation of these markers.  
Chapter 5 describes different proliferation patterns in human tumour samples and 
quantitative categorization based on these patterns. Also, it was examined 
whether these characteristics were retained after xeno-transplantation. Fifty 
tumour samples from head and neck cancer patients were immunohistochemically 
stained for Ki-67 and vessels. Also, parts of the samples were transplanted into 
nude mice. Vascular and proliferation patterns were analyzed using an image 
processing system. The 50 tumours were categorized into four patterns of 
proliferation by visual assessment: marginal (6), intermediate (10), random (21) 
and mixed (12). One tumour could not be classified. These patterns were 
quantified by calculating the Ki-67 labelling index in distinct zones at increasing 
distance from vessels yielding good discrimination and significant differences 
between patterns. We found that the probability of growth after xeno-
transplantation was significantly higher for tumours with a labelling index and 
vascular density above the median value compared to tumours with both 
parameters below the median (82% vs. 35%). Fifty percent of the tumours 
retained their proliferation patterns after xeno-transplantation. We concluded that 
the combination of quantitative and architectural information of multiple 
microenvironmental parameters adds a new dimension to the study of treatment 
resistance mechanisms. Tumour models representative of the various patterns 
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can therefore be used to further investigate the relevance of these architectural 
patterns. 
In chapter 6 we examined a subpopulation of tumour cells in human head and 
neck cancers that retain clonogenic potential under hypoxic conditions. The 
markers iododeoxyuridine and pimonidazole were administered intravenously 
prior to biopsy taking in patients with stage II-IV squamous cell carcinoma of the 
head and neck. Triple immunohistochemical staining of blood vessels, IdUrd and 
pimonidazole was performed and co-localization of IdUrd and pimonidazole was 
quantitatively assessed by computerized image analysis. The results were related 
with treatment outcome. Thirty-nine biopsies were analyzed. Tumours exhibited 
different patterns of proliferation and hypoxia but generally the IdUrd signal was 
found in proximity to blood vessels whereas pimonidazole binding was 
predominantly at a distance from vessels. Overall, no correlations were found 
between proliferative activity and oxygenation status. The fraction of IdUrd-
labelled cells positive for pimonidazole ranged from 0% to 16.7% with a mean of 
2.4% indicating that proliferative activity was low in hypoxic areas and occurring 
mainly in the well-oxygenated tumour compartments. IdUrd positive cells in 
hypoxic areas made up only 0.09% of the total viable tumour cell mass. There 
were no associations between the magnitude of this cell population and local 
tumour control or survival.  
Chapter 7 deals with salivary gland tumours. Twelve patients planned for surgical 
resection of a salivary gland tumour were preoperatively injected with 
pimonidazole and iododeoxyuridine. Tissue samples of the dissected tumour were 
immunohistochemically stained for blood vessels, pimonidazole, carbonic 
anhydrase-IX, the glucose transporters-1 and -3, hypoxia-inducible factor-1α, 
IdUrd and for the epidermal growth factor receptor. Tissue material from 8 patients 
was of sufficient quality for quantitative analysis. All tumours were negative for 
pimonidazole binding as well as for CA-IX, Glut-1, Glut-3 and HIF-1α. Vascular 
density was high with a median value of 285 mm-2 (range 209 – 546 mm-2). IdUrd 
labelling index varied from <0.1% to 12.2% with a median of 2.2%. EGFR 
expression levels were mostly moderate to high. In half of the cases nuclear 
expression of EGFR was observed. We concluded that the absence of detectable 
pimonidazole binding, as well as the lack of expression of hypoxia-associated 
proteins in all analyzed tumours indicates that malignant salivary gland tumours 
are generally well oxygenated. It is therefore unlikely that hypoxia is a relevant 
factor for their clinical behavior and treatment responsiveness.  
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Samenvatting 
  
De laatste jaren is veel moeite gedaan om de behandelingsuitkomst van patiënten 
met een hoofd-hals tumor te verbeteren. Belangrijke factoren die het resultaat van 
een bestraling beïnvloeden zijn een tekort aan zuurstof (hypoxie) en de mate van 
celdeling (proliferatie). 
Hoofdstuk 1 is een inleidend hoofdstuk, en geeft een beknopte beschrijving van 
het zuurstof effect en de pathofysiologie van tumor hypoxie. Twee verschillende 
soorten van hypoxie (perfusie-gelimiteerd en diffusie-gelimiteerd) worden onder-
scheiden. Endogene en exogene immunohistochemische hypoxiemarkers worden 
besproken, evenals de verschillende niet-invasieve methoden om hypoxie aan te 
tonen en te kwantificeren. Vervolgens wordt de relevantie van tumor cel 
proliferatie en immunohistochemische proliferatie markers besproken. Hierna 
wordt kort het doel en de studie opzet per hoofdstuk vermeld. 
Hoofdstuk 2 beschrijft de eerste studie die we hebben verricht met de hypoxie 
marker pimonidazol in humaan tumor weefsel. Eenentwintig patiënten met een 
hoofd-hals tumor werden geïnjecteerd met pimonidazol. Vriescoupes van 
tweeëntwintig biopten werden gekleurd voor vaten en hypoxie en vervolgens 
gescand en geanalyseerd. De hypoxische fracties varieerden van 0.02-0.29 en 
waren onafhankelijk van andere patiënt- en tumor karakteristieken. Drie 
verschillende patronen van hypoxie werden beschreven. Het eerste type bevatte 
grote vitale hypoxische gebieden op ruime afstand van de vaten (>200 µm). De 
tweede categorie toonde een lijnvormige verdeling van hypoxie op een 
middelgrote afstand van de vaten (50-200 µm). De laatste categorie toonde 
hypoxie binnen 50 µm van de vaten, duidend op acute hypoxie. We toonden de 
klinische toepasbaarheid van deze kwantitatieve methode aan voor multi-
parameter analyse van vasculariteit en hypoxie in hoofd-hals tumoren. 
In hoofdstuk 3 hebben we 43 tumor biopten van patiënten met een hoofd-hals 
tumor onderzocht. Alle patiënten waren potentiële kandidaten voor een fase 2 
onderzoek waarbij versnelde bestraling met carbogeen en nicotinamide werd 
gecombineerd (ARCON). De biopten werden gekleurd voor vaten, pimonidazol en 
CA-IX. De verdelingspatronen van beide hypoxische markers was vergelijkbaar, 
hoewel het CA-IX signaal meestal dichter bij de vaten lag. Er was een kleine, 
maar significante correlatie tussen de relatieve tumor oppervlakten positief voor 
pimonidazol en de gebieden met CA-IX aankleuring. De locoregionale tumor vrije 
controle na 2 jaar bedroeg 48 versus 87% voor tumoren met een hoge danwel 
lage pimonidazol aankleuring (p=0.01) en 48 en 88% voor tumoren met een lage 
en hoge vaatdichtheid (p=0.01). Deze verschillen verdwenen in de groep 
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patiënten die behandeld was met ARCON. De mate van de CA-IX kleuring had 
geen relatie met de behandelingsuitkomst. We concludeerden dat pimonidazol 
binding en vaatdichtheid een voorspellende waarde hebben in de behandelings-
uitkomst bij patiënten met een hoofd-hals tumor. Pimonidazol en CA-IX tonen 
vergelijkbare kleuringspatronen, hoewel CA-IX minder specifiek hypoxie 
aankleurt. 
Hoofdstuk 4 beschrijft de voorspellende waarde van verschillende endogene 
hypoxie gerelateerde markers CA-IX, Glut-1 en Glut-3 in met ARCON behandelde 
patiënten. We onderzochten 58 tumorbiopten van patiënten met hoofd-hals 
tumoren die met ARCON behandeld waren. Alle coupes werden gekleurd met CA-
IX, Glut-1 en Glut-3. Voor de vaatdichtheid werd CD-34 als endotheelmarker 
gebruikt. Tevens werd gekeken naar het door de markers aangekleurde relatieve 
tumor oppervlakte (CA-IX en Glut-3) en naar de intensiteit van de kleuring (Glut-1 
en Glut-3). Zowel CA-IX als Glut-3 werden voornamelijk gezien op grote afstand 
van de vaten en dicht bij necrose. De Glut-1 kleuring was meer diffuus verspreid. 
Patiënten met meer CA-IX aankleuring (> 25% van de tumoroppervlakte) hadden 
een significant betere locoregionale controle (p=0.04) en afwezigheid van 
afstandsmetastasen (p=0.02). Een hogere expressie van Glut-3 was eveneens 
geassocieerd met een betere locoregionale controle (p=0.04). Een sterke Glut-1 
intensiteit was geassocieerd met toename van afstandsmetastasen (p=0.0005) en 
een slechte overleving (p=0.001). We concludeerden dat de verschillende 
uitkomsten voor CA-IX en glucose transporters in relatie met tumor controle 
impliceren dat er meerdere factoren een rol spelen in de op-regulatie van deze 
markers. 
Hoofdstuk 5 beschrijft verschillende proliferatiepatronen in humane tumoren, 
alsmede de kwantitatieve categorisatie gebaseerd op deze patronen. We onder-
zochten in hoeverre deze karakteristieken bewaard bleven na xeno-transplantatie. 
Vijftig tumor biopten van patiënten met een hoofd-hals tumor werden immuno-
histochemisch gekleurd voor Ki-67 en vaten. Van de biopten werd een deel in 
naakte muizen geïmplanteerd. Tumoren werden gecategoriseerd in 4 proliferatie-
patronen. De verschillende vaat- en proliferatiepatronen werden geanalyseerd 
gebruik makend van een beeldverwerkingsysteem. De vier verschillende 
proliferatiepatronen waren: marginaal (6), intermediair (10), diffuus (21) en 
gemengd (12). Eén tumor kon niet worden geclassificeerd. Deze patronen werden 
gekwantificeerd door de Ki-67 labeling index te berekenen per zone op 
toenemende afstand van de vaten. Hierbij vonden we een goed onderscheid en 
significante verschillen tussen de patronen. De kans op groei na implantatie in de 
muis was significant hoger voor tumoren met een labeling index en vaatdichtheid 
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boven de mediaan in vergelijking met tumoren waarbij deze waarden onder de 
mediaan lagen (82-35%). Vijftig procent van de tumoren behield het proliferatie-
patroon na xeno-transplantatie. We concludeerden dat de combinatie van 
kwantitatieve en architectonische informatie over vaten en proliferatie een bijdrage 
kan leveren in het onderzoek naar bestralingsreacties. Het belang van de 
verschillende patronen moet nog nader onderzocht worden. 
Hoofdstuk 6 beschrijft een studie naar een subpopulatie van tumor cellen in 
hoofd-hals kanker, die de mogelijkheid tot celdeling onder hypoxische omstandig-
heden behouden. Hiervoor werden bij patiënten met een stadium II-IV hoofd-hals 
plaveiselcelcarcinoom de markers iododeoxyuridine en pimonidazol intraveneus 
toegediend. Negenendertig biopten werden gekleurd op vaten, IdUrd en 
pimonidazol. Vervolgens werd co-lokalisatie van IdUrd en pimonidazole met 
behulp van de computer gekwantificeerd. Het resultaat hiervan werd aan de 
behandeluitkomst gerelateerd. De tumoren toonden verschillende patronen van 
proliferatie en hypoxie, maar IdUrd labeling werd vooral gevonden in de buurt van 
de vaten, terwijl pimonidazol binding zich voornamelijk op afstand van de vaten 
bevond. Over het algemeen was er geen correlatie tussen proliferatieve activiteit 
en de oxygenatie-toestand van een tumor. De fractie IdUrd gelabelde cellen 
positief voor pimonidazol varieerde van 0% tot 16.7% met een gemiddelde van 
2.4%. De proliferatieve activiteit was laag in hypoxische gebieden en kwam 
voornamelijk voor in de goed geoxigeneerde tumor velden. IdUrd positieve cellen 
in hypoxische gebieden bedroegen slechts 0.09% van het totale aantal vitale 
tumorcellen. Er was geen verband tussen de hoogte van deze celpopulatie en 
lokale tumor controle of overleving.  
Hoofdstuk 7 beschrijft een studie bij speekselkliertumoren. Twaalf patiënten met 
een geplande resectie van een speekselkliertumor werden preoperatief 
geïnjecteerd met pimonidazol en iododeoxyuridine. Weefselstukjes van de 
verwijderde tumor werden immunohistochemisch gekleurd op bloedvaten, 
pimonidazol, carbon anhydrase-IX, glucose transporters-1 en -3, hypoxia-
inducible factor-1α, IdUrd en voor epidermale groei factor receptor. Weefsel van 8 
patiënten was van voldoende kwaliteit voor verdere analyse. Geen van de 
tumoren toonde aankleuring voor pimonidazol, CA-IX, Glut-1, Glut-3 en HIF-1α. 
De vaatdichtheid was hoog met een mediaan van 285 mm-2 (spreiding 209-546 
mm-2). IdUrd labeling index varieerde van <0.1% tot 12.2% met een mediaan van 
2.2%. De EGFR expressie was voornamelijk gemiddeld tot hoog. In de helft van 
de gevallen werd een kernkleuring waargenomen. We concludeerden dat de 
afwezigheid van aantoonbare pimonidazol binding, evenals het ontbreken van aan 
hypoxie gerelateerde eiwitten in alle onderzochte tumoren, aantoont dat maligne 
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speekselkliertumoren over het algemeen goed geoxygeneerd zijn. Het is daarom 
onwaarschijnlijk dat hypoxie bij speekselkliertumoren een relevante rol speelt in 
het klinisch gedrag en behandeluitkomst. 
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